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ABSTRACT OF THE DISSERTATION 
 
The Role of Notch Signaling in the Pathogenesis of Acute Promyelocytic Leukemia 
 
by 
 
Nicole Renée Grieselhuber 
 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Immunology) 
 
Washington University in St. Louis, 2012 
 
Professor Timothy Ley, Chairperson 
 
 
The t(15;17) translocation is found in nearly 98% of acute promyelocytic 
leukemia (APL, FAB subtype M3) cases and results in the fusion of the promyelocytic 
leukemia (PML) gene with the retinoic acid receptor alpha (RARA) gene.  The fusion 
product, PML-RARA, encodes a functionally altered transcription factor that is the 
initiating event in APL.  To better understand the transcriptional changes associated with 
APL pathogenesis, we compared the gene expression profiles of APL samples to those of 
other acute myeloid leukemia FAB subtypes and of enriched normal human 
promyelocytes.  We identified a signature of genes that are specifically dysregulated in 
APL relative to other AML subtypes and normal promyelocytes.  We found that most 
dysregulated genes are not direct targets of PML-RARA, but are rather distal events in 
pathogenesis.  In contrast, the APL signature was enriched in leukemia cells derived from 
a mouse model of APL, demonstrating that common leukemogenic pathways exist in 
mouse and human cells.     
We then observed that human APL overexpresses the Notch ligand Jagged-1 
(JAG1) compared to other AML and normal promyelocytes.  Unlike many APL signature 
 iii 
genes, overexpression of JAG1 is also found in human APL cell lines and in murine APL.  
We hypothesized that Notch signaling, which has known roles in proliferation and 
survival, may be important in leukemogenesis.  Inhibition of Notch signaling by 
pharmacological and genetic approaches resulted in a loss of serial replating by marrow 
cells from young non-leukemic mCG-PML-RARA animals.  In contrast, colony 
formation by wildtype marrow is unaffected by Notch inhibition, suggesting that PML-
RARA expressing cells are uniquely dependent upon Notch signaling for increased self 
renewal.  Growth of primary murine APL cells in vitro was variably reduced by 
pharmacological inhibition of Notch signaling (6/9 samples), demonstrating that while 
Notch signaling is required for early events in leukemogenesis, in some cases it is 
dispensible for the fully transformed tumor.  However, inhibition of Notch signaling in 
four tumor samples tested did not result in reduced tumor burdens in vivo.  In conclusion, 
we have demonstrated a previously unappreciated role for the Notch signaling pathway in 
the development of acute promyelocytic leukemia.   
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"A disease that, starting from an insignificant injury, can attack a person in perfect health, 
in the full vigor of early maturity, and in some insidious, mysterious way, within a few 
months, destroy life, is surely a subject important enough to demand our best thought and 
continued study." – Dr. William Coley, from an address to the New York Academy of 
Medicine on April 27, 1891 
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1.1.  Acute Myeloid Lekemia and Acute Promyelocytic Leukemia 
Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by a 
block in the differentiation of progenitor cells and an accumulation of immature cells in 
the bone marrow and blood (1).  Rather than a single disorder, AML represents a 
collection of related malignancies.  The French-American-British (FAB) classification 
recognizes 8 major subtypes of AML, based on cellular morphology and cytochemical 
staining (2).  Approximately 10,000 new cases of AML are diagnosed in the United 
States each year (3).  However, a substantial minority of patients, approximately 25 
percent, carry recurrent chromosomal translocations that result in the fusions of the 
coding regions of specific genes (4).  One such example is the t(15;17) (q21;q22) 
translocation found in over 98% of acute promyelocytic leukemia (APL, FAB subtype 
M3) cases (3).  The translocation results in the fusion of the promyelocytic leukemia 
(PML) gene on chromosome 15 with the retinoic acid receptor alpha (RARA) gene on 
chromosome 17 (5-7).  The fusion product, PML-RARA, encodes a functionally altered 
transcription factor that is the initiating event in APL leukemogenesis.  As such, it 
represents a unique opportunity for modeling the development of leukemia. 
 
1.2.  Identification of the t(15;17) translocation and the PML-RARA fusion protein 
Hillestad first identified APL as a distinct subtype of AML in 1957, based upon 
its distinct morphology, the accumulation of promyelocytes, the associated syndrome of 
disseminated intravascular coagulation (DIC) and a poor clinical course that progressed 
to lethal disease within a few weeks of presentation (8).  Twenty years later, Rowley et al 
described three APL patients with the t(15;17)  in their blasts (9).  Subsequent reports 
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showed that the translocation is present in nearly all APL cases (10, 11).  The RARA 
gene maps to 17q21, close to the breakpoint in the t(15;17) translocation.  At the time, it 
was known that retinoic acid could induce differentiation of APL cells and some 
leukemic cell lines (12, 13).  Based on these observations, several groups investigated the 
role of the RARA gene in the t(15;17) translocation (14-16) and simultaneously reported 
in 1991 that RARA was fused to an unknown locus, initially named myl (6, 7, 17).  de 
The et al subsequently renamed the transcript promyelocytic leukemia (PML) and 
reported the sequences of both the native PML and PML-RARA fusion transcripts (5).    
The reported length of the PML-RARA transcript varied in early reports (5, 6, 7, 
17, 18).  An analysis of the breakpoints in a collection of APL patients demonstrated that 
while the chromosome 17 breakpoint is always found within intron 2 of the RARA gene, 
the chromosome 15 breakpoint can occur in at least 3 different locations within the PML 
gene (19).  The most common breakpoint, termed bcr1, occurs in intron 6 of PML, and 
joins PML exon 6 to RARA exon 3, resulting in the long isoform of PML-RARA.  The 
bcr 3 breakpoint occurs within PML intron 3, creating a short isoform that joins PML 
exon 3 to RARA exon 3.  Bcr2, which occurs within PML exon 6, is relatively  rare.  
Since the breakpoint invariably occurs within RARA intron 2, the bcr1, bcr2 and bcr3 
isoforms of PML-RARA all contain the same RARA domains:  the N terminal AF-1 
domain is lost but the ligand binding domain, DNA binding domain and AF-2 
transactivation domains remain intact (20).  The PML sequences that are retained in the 
fusion vary amongst the different breakpoints; however, all contain the RBCC motif (21).  
The bcr1 isoform additionally retains the NLS present in PML exon 6.  The bcr3 PML-
RARA isoform lacks the NLS, since it only preserves the first three exons of PML.  
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Together, bcr 1 and bcr3 account for 95% of APL patients (20).  The relative frequencies 
of bcr1 and bcr3 are known to vary in different ethnic groups (22-24) and in pediatric 
populations (25).  There is some evidence that patients harboring the bcr3 rearrangement 
have a worse prognosis (26), perhaps because of that isoform’s lower affinity for ATRA 
(27).  To date, the majority of studies, including our own, have focused on the bcr1 
isoform, so the differences in the functions of the isoforms is not well studied.  
Additionally, multiple isoforms of PML-RARA can occur within the same cell, due to 
alternative splicing of both the PML and RARA portion of the fusion gene (19).  Since 
the bcr1 cDNA is sufficient for leukemogenesis in multiple mouse models (28-30), the 
functional role of alternatively spliced isoforms is unclear. 
 
1.3.  Treatment of APL with all trans-retinoic acid (ATRA) 
 Prior to the development of targeted therapies, the prognosis of APL was among 
the worst of all AML subtypes, with a 5 year survival of only 25-30 percent (31).  Death 
occurred in up to 15 percent of patients undergoing induction chemotherapy, most often 
due to DIC, and those who achieved a complete remission invariably relapsed within 2 
years (32).  However, in the mid 1980s, based on the observation that retinoic acid could 
induce differentiation of APL cells in vitro, Huang et al performed a small trial of all 
trans-retinoic acid (ATRA) alone or in combination with traditional chemotherapy in 24 
APL patients (33).  The success of this study and subsequent trials (34-36) led to the 
adoption of ATRA therapy in combination with anthracycline based chemotherapy as the 
standard treatment for APL.  Currently, the 5-year disease free survival of APL patients 
treated with combination chemotherapy and ATRA is approximately 75 percent (37).  
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This development was all the more remarkable, in that ATRA was investigated before the 
realization that RARA itself is involved in APL-associated translocations.  Once the 
t(15;17) breakpoints were characterized, it was apparent that ATRA targets the very 
molecule that is mutated in nearly all APL cases. 
 Despite the success of ATRA therapy of APL, many challenges remain in the 
treatment of APL patients.  APL patients have a propensity to develop coagulation and 
bleeding disorders, and are at particular risk for early death during the initiation of 
chemotherapy due to DIC (38).  Patients commonly develop “ATRA syndrome,” 
characterized by leukocyte activation, fever, respiratory difficulties, pleural or pericardial 
effusions and renal failure (38).  ATRA syndrome can be treated successfully with 
corticosteroids, but nevertheless is a potentially life threatening complication.  In 
addition, up to 30 percent of APL patients will eventually experience a relapse of their 
leukemia despite ATRA and chemotherapy treatment (37).  Relapsed APL is frequently 
resistant to ATRA (39).  Relapsed or refractory APL may be treated with chemotherapy 
in combination with arsenic trioxide, histone deacetylase (HDAC) inhibitors, 
hematopoeitic stem cell transplantation and various experimental drugs currently in 
clinical trials (31, 35, 37).  Despite these advances, approximately 40-50 percent of 
patients will die within 2 years of relapse (40).  These facts underscore the need for a 
better understanding of PML-RARA mediated leukemogenesis. 
 
1.4.  Mouse models of APL 
 Mouse models have been critical in establishing that PML-RARA is the initiating 
event  in APL, as well as in demonstrating the importance of targeting expression to the 
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correct cellular compartment and the correct developmental stage to initiate disease.  
Several early attempts to create a transgenic mouse model of APL failed because 
transgene expression was directed to the incorrect developmental stage.  When PML-
RARA was expressed under the control of the CD11b promoter, which is activated at the 
myelocyte stage (a later stage than promyelocytes), no mice were observed to develop 
leukemia despite robust expression of the transgene (41).  Similarly, when PML-RARA 
was directed to early myeloid progenitors under the control of the c-fes promoter, no 
leukemia developed (42).  Attempts were made to create a transgenic line with a β-actin 
promoter driving PML-RARA, but no viable animals were born, suggesting that 
widespread PML-RARA expression is incompatible with life (43). 
 The Ley laboratory created the first successful transgenic APL mouse model.  
PML-RARA bcr-1 was expressed under the control of human cathepsin G regulatory 
sequences previously shown to target transgene expression to the promyelocyte 
compartment (29).  All of these hCG-PR mice exhibited myeloproliferation without a 
block in differentiation.  As the mice aged, 15 percent of the mice developed leukemia 
characterized by promyelocyte expansion, anemia, thrombocytopenia and splenomegaly, 
with an average latency of approximately 220 days.  A second group later created a 
transgenic line with the same PML-RARA isoform expressed under the control of the 
same hCG region and obtained similar results (43).  Around the same time, a third group 
published a report describing the MRP8-PML-RARA transgenic mouse, in which PML-
RARA was expressed under the control of a human MRP8 promoter fragment, which is 
activated at the promyelocyte stage, with persistent expression to mature neutrophils (28).  
These mice also developed leukemia, but a complete analysis was hampered leaky 
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expression in keratinocytes, leading to the development of fatal PML-RARA induced 
skin lesions.  Bone marrow transplants into lethally irradiated syngeneic hosts allowed 
further study of this murine APL. 
 The penetrance of APL development could be increased in transgenic PML-
RARA mice by coexpressing additional oncogenes, including bcr-3 RARA-PML (44), an 
activated FLT3 allele (45), Bcl2 (46), or activated K-ras (47), and also by crossing PML-
RARA transgenic mice with PML knockout mice (48) or PU.1 haploinsufficient animals 
(49).  However, a high penetrance model remained elusive until our laboratory developed 
a mouse in which the PML-RARA cDNA is knocked into the endogenous murine 
cathepsin G locus (mCG+/PR mice) (30).  It had been noted that transgene expression in 
hCG-PR mice was unexpectedly low, and it was initially hypothesized that the 
endogenous CG promoter might lead to increased expression and therefore increased 
penetrance.  While the mCG-PR mice did develop APL with a penetrance of greater than 
90%, PML-RARA expression was unexpectedly nearly 50 fold lower than in the hCG-PR 
mice.  These observations provided evidence for the “gain-of-function” hypothesis of 
PML-RARA function, discussed in more detail below.  In addition, because virtually all 
mice are “preleukemic,” the high penetrance model allowed for the performance of 
valuable studies of hematopoietic perterbations in preleukemic mice (58).  These studies 
would be impossible in strains in which a substantial proportion of the mice never 
develop overt leukemia.  A study published by our lab investigated the gene expression 
profiles of APL tumors derived from mCG-PR mice and of cells from wildtype and 
preleukemic mice undergoing in vitro myeloid differentiation (50).  Many of the genes 
that were dysregulated in the APL tumors were expressed normally in preleukemic 
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myeloid cells, indicating that perhaps the vast majority of dysregulated genes represent 
late events in pathogenesis.  In addition, leukemic cells isolated from APL mice have 
recurrant chromosomal abnormalities (51).  Collectively, these results suggest that 
additional ‘progression hits’ are required for the development of frank leukemia from the 
preleukemic state.   
 Recently, the Ley lab has developed a conditional PML-RARA knockin model.  
A PML-RARA cDNA preceeded by a Lox-Stop-Lox cassette was knocked into the 
5’UTR of the murine PML locus (52).  PML-RARA is only expressed upon Cre mediated 
excision of the Lox-Stop-Lox.  Importantly, PML-RARA expression is controlled by the 
native PML promoter, allowing for dose appropriate expression.  In addition, PML-
RARA expression is somatically acquired in only a few cells, which more accurately 
models the human disease than mice in which PML-RARA is expressed in all myeloid 
cells for the entire lifespan of the animal.  Unexpectedly, leukemia development in the 
conditional knockin mice is an uncommon event.  When PML-PRflox mice are crossed 
with LysM-Cre mice, only rare leukemias develop.  In a second experiment, PML-PRflox 
mice were bred to ERT2-Cre mice expressing a tamoxifen inducible Cre.  Tamoxifen 
treatment results an expansion of the floxed (PML-RARA expressing) cells, but no overt 
leukemias.  These results suggest that many cooperating downstream events are 
necessary for leukemogenesis, and that PML-RARA expression by itself is insufficient 
for development of disease. 
 
1.5.  Cellular effects of PML-RARA expression 
 10
In all mouse models of APL, leukemogenesis proceeds slowly, requiring months 
and secondary events.  In hCG-PR transgenic and mCG-PR knockin mice, young animals 
do not have overt signs of disease and have normal peripheral blood counts (29, 30).  
However, there are subtle alterations in hematopoeisis that indicate that expression of 
PML-RARA by itself alters hematopoeisis.  In hCG-PR mice, there is a small but 
significant increase in the percentage of myeloid cells in the peripheral blood, and an 
increase in promyelocytes and myelocytes in the marrow (29).  Myeloid colony forming 
units in the spleen and bone marrow are increased as well compared to wildtype animals 
(49).  In addition, an abnormal Gr-1+, c-kit+ population is found in the spleens of 
transgenic animals.  Similarly, preleukemic mCG-PR knockin mice have normal 
peripheral blood counts, but Gr-1+, CD34+ cells are significantly increased in the spleen 
(30).  When cells from the marrow of mCG-PR animals are subjected to G-CSF induced 
in vitro differentiation, they expand more rapidly and have an increased fraction of 
morphologically immature cells compared to wildtype marrow cultures (53).  In addition, 
mCG-PR marrow has increased colony formation and will serially replate in 
methylcellulose cultures for up to one month, in contrast to wildtype cells which do not 
form colonies after the second week in culture (54).  When marrow PML-PRflox x ERT2-
CRE mice is treated with tamoxifen in vitro, serial replating is similarly observed (52).  
In competitive repopulation assays with wildtype marrow, expansions of mCG-PR cells 
were observed not just in the Gr-1+ myeloid cells as expected, but also in the B220+ and 
CD3+ lymphoid lineage cells, suggesting that PML-RARA may act at a multipotent 
progenitor cell, and not at a myeloid committed stage as previously proposed (55).  
Similarly, after a single tamoxifen treatment, the percentage of floxed (PML-RARA 
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expressing) cells in the marrow of PML-PRflox x ERT2-Cre mice increases from 5% to 
over 40%, suggesting clonal expansion is occurring (52).  Collectively, these results from 
multiple mouse models suggest that PML-RARA acts in a multipotent progenitor to 
increase self renewal and partially block myeloid differentiation.  The molecular 
pathways that are activated or repressed to create these phenomena remain largely 
unknown, as are the secondary cooperating events responsible for the development of 
leukemia, but remain an area of active investigation in the Ley laboratory.   
 
1.6.  Normal RARA Functions 
1.6.1.  Protein structure of RARA 
RARA is a member of the nuclear receptor superfamily of ligand-dependent 
transcription factors.  While nuclear receptors were originally recognized for their role in 
steroid hormone signaling, it was later appreciated that other family members respond to 
fat soluble vitamins, thyroid hormone, lipids, or inflammatory mediators (56).  A large 
sub-family of orphan receptors responds to no known ligand (57).  The nuclear receptors 
share a common protein structure consisting of four major domains.  The AF-1 and AF-2 
transactivation domains are located at the N and C termini, respectively, while the zinc 
finger DNA binding domain (DBD) and ligand binding domain (LBD) are located 
centrally(56).  The LBD consists of 11 alpha helices which form a pocket that varies in 
size and shape to recognize specific ligands (58, 59).  In the absence of ligand, the LBD 
is blocked by helix 12 of the AF-2 domain.  In this conformation, helices 3 and 4 bind the 
corepressors NCOR1 (nuclear corepressor 1) and silencing mediator for retinoid and 
thyroid hormone receptor (SMRT) (60, 61).  NCOR1 and SMRT recruit  histone 
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deacetylases (HDACs), which silence genes by closing chromatin.  In the presence of 
ligand, helix 12 is repositioned so that it no longer covers the LBD pocket, but instead 
disrupts the interaction of corepressors with helices 3 and 4 (58).  At the same time, 
helices 3,4, and 12 form a new binding motif recognized by coactivators, including p300, 
histone acetyl transferases (HATs), chromatin remodeling proteins, and RNA 
polymerases (56). 
RARA recognizes both all-trans retinoic acid (ATRA) and 9-cis retinoic acid (62).  
However, the normal physiologic role of the 9-cis isomer is controversial and ATRA is 
regarded as the major native ligand.  RARA function requires heterodimerization with the 
promiscuous rexinoid X receptor (RXR) (63, 64).  RXR also partners with vitamin D 
receptors (VDRs), thyroid hormone receptor (TR), peroxisome proliferator activated 
receptors (PPAR) and various lipid responsive receptors (63).  Dimerization with RXR 
increases DNA binding efficiency, but the consensus site binding specificity is provided 
by the specific nuclear receptor (65).  RAR-RXR heterodimers recognize retinoic acid 
response elements (RAREs) consisting of direct repeats of the 6 base pair half site 
(A/G)G(G/T)TCA separated by either 2 or 5 base pairs (62, 66, 67).  These sites are 
termed DR2 and DR 5 sites respectively.  RAR-RXR heterodimers can also bind DR1 
sites, but evidence suggests that they are unable to activate transcription even in the 
presence of ligand (62).  In general, RXR binds the 5’ half site, while RARA recognizes 
the 3’ half site (68, 69, 70).  As described above, in the absence of retinoic acid, RARA 
recruits corepressors, leading to transcriptional repression.  Retinoic acid induces the 
dissociation of the corepressor complex and the formation of a coactivator complex.  
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RXR is incapable of binding corepressors and only weakly binds coactivators, so the 
switch from repression to activation of transcription is dependent upon RARA. 
 
1.6.2.  RARA and Hematopoeisis 
The in vivo role of RARA in hematopoeisis remains unclear.  RARA is not 
absolutely required for granulopoiesis, since RARA-/- animals have normal numbers of 
peripheral neutrophils and Gr-1+Mac-1+ cells in the bone marrow (71-74).  Hematopoetic 
cells also express retinoic acid receptor gamma (RARG), yet double knockout RARA-/- x 
RARG-/- mice have no detectable defects in fetal hematopoeisis (75).  The double 
knockout cells have no ability to respond to retinoids, indicating that retinoic acid 
signaling is not required for the production of mature neutrophils.  However, several lines 
of experimental evidence support RARA as a modulator of granulopoiesis.  First, 
exogenous retinoic acid enhances the formation of CFU-GM colonies in cultured 
hematopoietic precursors (76).  Secondly, mice fed a vitamin A deficient diet develop an 
expansion of mature neutrophils that reverses upon ATRA supplementation (77).  
Similarly, mice treated with a pan-RAR antagonist also exhibit myeloid expansion, but 
with an increase in immature forms (75).  Furthermore, mouse marrow cells that are 
retrovirally transduced with a dominant negative RARA containing a mutated ligand 
binding domain cannot terminally differentiate, and are blocked at the promyelocyte 
stage (78).  However, these cells are not fully transformed and cannot induce leukemia 
when transplanted to a secondary host.  It is believed that RARA promotes the terminal 
differentiation and death of granulocytes, accounting for the myeloid expansion in 
animals in which retinoic acid signaling is inhibited or deficient (76).    
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1.7.  Normal PML Functions 
  PML is a ubiquitously expressed RING finger domain protein that 
characteristically localizes to discrete sub-nuclear protein aggregates variously termed 
PML oncogenic domains (PODs), also known as nuclear bodies (NBs) (79, 80).  When 
the PML cDNA was identified, de The et al initially noted that the predicted protein 
sequence contained a proline rich N-terminus and three cysteine rich regions (5).  The 
first cysteine cluster was later shown to reside within a zinc binding domain known as a 
RING finger motif, while the others are part of two B box domains which can also bind 
zinc.  The B box domains are followed by a coiled-coil domain composed of two alpha 
helices.  Together, the RING domain, B boxes and coiled-coil domain form a RBCC 
motif, a conserved structure that defines a large family of proteins (21).  The PML RBCC 
motif serves largely to allow homo- and heterodimeric protein-protein interactions, and is 
critical in establishing sub-cellular localization to PODs (81).  While the RBCC motif is 
present in all PML isoforms, the C terminus of PML varies considerably due to 
alternative splicing (81).  Most isoforms contain a C terminal nuclear localization signal 
(NLS), but several appear to be cytoplasmic (82).  One isoform, designated PML-I, 
contains C terminal nuclear export signal (NES) in addition to the NLS, suggesting that it 
may shuttle between the cytoplasm and nucleus (83).  Additionally, the C terminal 
domains can confer isoform-specific protein interactions.  For example, the PML-IV 
isoform can interact with the tumor suppressor p53 (84) and histone deacetylases 
(HDACs) (85), properties not shared by PML-RARA or other PML isoforms. 
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 PML has known roles in cell growth, apoptosis, tumor suppression, 
transcriptional activation, and antiviral responses.  Much of this knowledge was obtained 
from studies of PML deficient mice.  Despite the ubiquitous expression of PML and its 
involvement in diverse cellular processes, PML-/- mice are viable and grossly normal in 
appearance and fertile; however, they are susceptible to fatal Botryomycosis infections 
(86).  They do not develop leukemia or any other spontaneous malignancy.  PML-/- mice 
have reduced circulating granulocytes and a decreased ability to terminally differentiate 
myeloid cells.  PML deficient mice were more susceptible to chemical carcinogen-
induced skin papillomas and lymphomas.  In addition, while overexpression of PML in 
mouse embryonic fibroblasts (MEFs) (87) can inhibit growth, PML deficient MEFs 
exhibited increased growth, as did PML negative splenic lymphocytes undergoing 
concanavalin A activation.  When PML-/- mice were crossed with hCG-PR transgenic 
mice, the incidence of disease increased and latency decreased in a dose dependent 
fashion (48).  These results support the idea that PML functions as a tumor suppressor 
with growth suppressive properties.  PML was found to be required for several apoptotic 
pathways.  Cells from PML deficient mice are resistant to irradiation, Fas, TNF, IFN, and 
ceramide-induced apoptosis, and the majority of PML -/- mice can survive γ-radiation 
doses equivalent to the LD50 for wildtype mice (88).  However, not all apoptotic 
pathways are attenuated in PML -/- mice, since complete suppression of apoptosis is 
generally incompatible with life.  PML is therefore best regarded as a modulator of 
apoptosis.  Additionally, PML has been shown to interact with several proteins involved 
in the DNA damage response, including the checkpoint kinase Chk2 and TopBP1, a 
protein involved in the repair of double strand DNA breaks (89).  PML’s tumor 
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suppressor properties likely are due to a combination of effects on both the DNA damage 
response and apoptosis. 
 
1.8.  DNA Binding Properties of PML-RARA 
1.8.1.  PML-RARA as a Dominant Negative RARA 
After demonstrating that t(15;17) results in the fusion of RARA to the previously 
unknown myl (PML) locus, de The et al speculated that such a fusion could result in a 
dominant negative RARA that inhibited the transcription of normal RARA target genes 
(6).  In a follow up study, the same group showed that PML-RARA could repress RA 
dependent luciferase expression from a reporter vector containing three tandem DR5 sites 
from the RARβ gene (5).  The same result was observed when a reporter construct with 
an optimized palindromic thyroid hormone response element (TRE) was used.  However, 
these studies were performed in HepG2 cells; other groups obtained different results 
using different cell lines.  For example, Kakizuka et al found that in CV-1 and K562 
cells, PML-RARA could constitutively activate TRE and RARβ driven reporters in the 
absence of RA (17). When RA was added, PML-RARA could enhance activation beyond 
that observed with wildtype RARA.  Oddly, they also observed PML-RARA 
superactivation in HepG2 cells, the same cell line in which de The et al saw PML-RARA 
driven repression.  In HL60 cells, PML-RARA could suppress basal transcription of 
RARA targets, but exhibited superactivation in the presence of RA.  Kastner et al also 
demonstrated that the degree of PML-RARA mediated repression or activation varied 
with different promoters, RAREs, and cell lines (18).  It was later found that PML-RARA 
could also induce transcription from promoters containing PPAR response elements 
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(PPRE) in the presence in RA, but repressed transcription in the presence of PPAR 
ligands (90).  Similarly, PML-RARA can inhibit vitamin D response elements (VDRE) 
(91).  Inhibition of PPAR and VDR mediated transcription was purported to be a result of 
PML-RARA sequestering RXR, a common heterodimerization partner for RARA, PPAR 
and VDR, as opposed to PML-RARA directly binding to the response elements.  While 
PML-RARA can bind RXR (91), definitive evidence that PML-RARA competes with 
other nuclear receptors for heterodimerization partners is still lacking.   
Many of these early studies on PML-RARA’s DNA binding and transactivation 
properties had substantial limitations.  First, as evidenced by the varied results obtained 
using different promoters, reporter constructs and cell lines, PML-RARA function is 
highly dependent upon its cellular context.  It is difficult to say what relevance 
experiments performed in non-myeloid cell lines such as Cos and HeLa cells have for 
PML-RARA functions in a promyelocyte.  Secondly, all of these studies exhibited 
intrinsic bias, in that the RAREs and other response elements were chosen by 
investigators without considerating the possibility that PML-RARA may well bind 
additional consensus sites besides canonical RAREs.  Third, many of these early studies 
relied exclusively upon luciferase or chloramphenicol acetyl-transferase reporter assays, 
and did not directly investigate whether PML-RARA physically interacted with the 
various response elements. Nevertheless, despite these limitations, PML-RARA came to 
be considered primarily a dominant negative RARA with “super-repressor” properties, a 
paradigm that would direct APL research for over a decade after the discovery of PML-
RARA.   
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1.8.2.  PML-RARA Specific Consensus Sites 
However, two studies of PML-RARA’s in vitro DNA binding specificity 
provided early evidence that PML-RARA was not merely a dominant negative RARA, 
but had its own unique binding properties.  Perez et al investigated the binding of RARA 
and PML-RARA in in vitro gel shift assays to DR1-5 elements containing either 
GGGTCA(n1-5)AGGTCA or GGTTCA(n1-5)AGTTCA half sites, termed DRnG and 
DRnT sites respectively (91).  While RARA/RXR bound equally well to DRnG and 
DRnT DR2 and DR5 probes, PML-RARA showed a marked preference for the DRnG 
probes.  However, in light of the fact that the RARβ DR5 site used as the prototypical 
PML-RARA binding site is a DRnT site, it remains unclear what effect, if any, these 
preferences would have in the proper cellular context.  Additionally, PML-RARA bound 
DR2 probes as well as DR3 probes, unlike RARA/RXR homodimers, which bind DR2 
and DR5 sites most strongly.  This study was the first evidence that PML-RARA has an 
extended binding repertoire compared to RARA.  A subsequent study by Hauksdottir and 
Privalsky examined the binding of RARA and PML-RARA to a canonical 
AGAGGTCAACGAGAGGTCA DR5 site when half site residues or preceeding 
residues were systematically mutated (92).  PML-RARA proved less sensitive than 
RARA to changes in the base immediately preceeding a half site, and to changes in the 
third residue of a half site.  The presence of RXR further enhanced PML-RARA binding 
to less favorable sites in vitro.  However, the correlation of binding with activation was 
imperfect.  While PML-RARA alone could activate mutated DR5 sites better than 
RARA/RXR in reporter assays, the presence of RXR reversed this trend.  PML-
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RARA/RXR transactivation was less than that seen with RARA/RXR, suggesting that 
repression by PML-RARA may be dependent upon RXR.   
A 2004 study by Kamashev et al provided the first unbiased screen of PML-
RARA consensus sites (93).  PML-RARA protein was incubated with 25 base pair 
random DNA duplexes, and bound sequences were selected by gel shifts and amplified.  
After six rounds of selection and amplification, the duplexes were cloned and sequenced.  
The identified binding sites contained not only canonical DR2, DR3, DR4 and DR5 
RAREs, but also widely spaced RAREs containing up to 13 base pair spacers between 
half sites.  Inverted repeats, most commonly IR0 sites, and everted repeat sites (most 
often ER8 sites) were also identified.  The addition of RXR to gel shift assays extended 
the binding of PML-RARA to RARES with up to 20 residues separating half sites (DR20 
sites).  Interestingly, transgenic mice expressing PML-RARA which cannot bind RXRA 
do not develop leukemia (94), suggesting that the role of RXR in DNA binding may also 
be relevant in vivo.  Kamashev et al demonstrated that IR0, ER8 and DR sites with more 
than 5 base pair spacers are minimally activated by RARA in the presence of RA, but are 
strongly induced by PML-RARA.  The relaxed binding specificity of PML-RARA is a 
clear gain-of-function above basal RARA functions; PML-RARA can no longer be 
considered to be solely a dominant negative RARA.  Accordingly, in other studies, when 
APL blasts or NB4 cells are treated with ATRA, many of the induced or repressed genes 
do not contain known RAREs in their promoters (95).  These relaxed binding sites 
provide a potential mechanism by which PML-RARA can alter expression of genes other 
than RARA targets. 
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However, the study by Kamashev et al did not examine whether PML-RARA 
binds altered RAREs in a chromosomal context, instead relying upon gel shift and 
luciferase reporter assays.  In recent years, several chromatin immunoprecipitation 
studies have been published which have validated non-canonical RAREs as bona fide 
PML-RARA binding sites, as well as demonstrating new motifs.  Hoemme et al reported 
a ChIP-chip study of PR9 cells, which contain a zinc inducible PML-RARA construct 
(96).  Only 40% of the identified PML-RARA targets contained classical RAREs, and 
many of the remaining genomic regions contained altered RAREs.  While this study was 
limited by the design of the arrays used, which contained only 12,000 known promoter 
regions and 12,000 CpG islands, it did demonstrate that PML-RARA had altered DNA 
properties in a chromosomal context.  Two later reports expanded upon these 
observations.  Martens et al performed chromatin precipitation coupled to high 
throughput next-generation DNA sequencing (ChIP-seq), using PR9 cells, NB4 cells and 
primary APL patient samples (97).  Nearly all possible combinations of half sites were 
found within PML-RARA binding regions, including DR elements with up to 13 
nucleotide spacers and half sites in everted or inverted orientation.  Wang et al reported a 
separate study ChIP-chip study (98) at the same time as the Martens study.  This study 
represented an improvement over the previous ChIP-chip study because of improved 
array design (probes covering over 25,500 promoters versus only 12,000 promoters) and 
advances in bioinformatic identification of binding regions and potential motif sequences.  
Consistent with previous reports, binding regions with various orientations of RARE half 
sites were identified.  However, bioinformatic motif discovery approaches demonstrated 
that RARE half sites frequently appeared near PU.1 consensus sites.  A separate ChIP-
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chip experiment demonstrated that PU.1 protein was in fact occupying the consensus 
sites near RARE half sites.  PML-RARA selectively binds RARE half sites in proximity 
to occupied PU.1 consensus sites, via both coiled-coiled domain dependent protein-
protein interactions with PU.1 and DNA binding to the half site.  Formation of this PML-
RARA-PU.1 complex leads to repression of PU.1 transcriptional targets.   
 
1.9.  Protein-protein interactions of PML-RARA 
1.9.1.  Interactions Which Produce Gene Repression  
PML-RARA has domains that allow protein-protein interactions in both the 
RARA and PML portions.  Like wildtype RARA, PML-RARA can recruit the 
NCor/SMRT/HDAC corepressor complex (99-102).  Histone deacetylation causes 
chromatin to adopt a “closed” conformation that is less accessible to the transcriptional 
machinery, therefore silencing gene expression.  In contrast to RARA, PML-RARA does 
not dissociate from the corepressor complex in the presence of physiological 
concentrations of RA, but requires pharmacological doses to relieve transcriptional 
repression.  PML-RARA, unlike RARA, can self-dimerize and form higher order 
oligomers; it has been suggested that oligomerization allows for increased corepressor 
binding (103).  Along with the data from transient transfections, this biochemical 
evidence is the primary support for the role of PML-RARA as a “super-repressor.”   
PML-RARA may alter chromatin structure through mechanisms distinct from the 
NCor/SMRT pathway shared with wild type nuclear receptors.  Wildtype PML can bind 
Daxx through its coiled-coil domain (104); this interaction is dependent upon 
sumoylation of lysine-160 (105).  PML-RARA retains the ability to recruit Daxx through 
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the same domain.  Daxx recruits DNA methyltransferase 1 (DNMT1) in a DNMT 
associated protein-1 (DMAP1) dependent manner, leading to promoter methylation 
(106).  Additionally, Daxx has also been shown to bind HDAC1 (104).  The interaction 
between PML-RARA and Daxx is essential for leukemogenesis, since transgenic mice 
expressing a PML-RARA transgene with a mutated sumoylation site do not develop 
leukemia (107).  A recent report demonstrated that PML-RARA can also recruit the 
polcomb repressor complex 2 (PRC2) to target genes (108).  PRC2 includes the proteins 
EZH2, SUZ12 and histone binding proteins.  PRC2 recruitment results in H3K27 histone 
methylation by EZH2, another epigenetic modification associated with transcriptional 
repression.  It is not yet known whether PRC2 recruitment is essential for PML-RARA 
induced leukemogenesis or immortalization.  Additionally, there is evidence that PML-
RARA can recruit histone methyltransferases directly (109).  In summary, PML-RARA 
appears to drive repression through three distinct mechanisms:  histone deacetylation, 
DNA methylation, and histone methylation. 
Accordingly, PML-RARA bound regions undergo epigenetic modification, 
including decreases in histone H3 acetylation and increases in lysine 9 and lysine 9 
trimethylation.  Upon ATRA treatment, H3 acetylation increases in most PML-RARA 
bound regions as well as globally (97).  The global DNA methylation profile of APL 
samples is also distinct from that of other AML (110).  Since PML-RARA target genes 
include chromatin modifying enzymes such as JMJD3 (H3K27 demethylation), SETDB1 
(H3K9 methylation), and DNMT3a (DNA methylation) (97, 98), it is likely that the 
global changes reflect both direct recruitment of modifying enzymes by PML-RARA and 
effects on expression of the enzymes. 
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1.9.2.  Interactions which produce gene activation 
Under certain conditions, PML-RARA can act as a transcriptional activator in the 
absence of RA.  Paradoxically, it largely associates with repressor proteins and it has 
been difficult to explain how PML-RARA could activate transcription.  Some have 
suggested that PML-RARA could indirectly deregulate gene expression by titrating 
corepressors and RXR away from sites of transcription.  However, this mechanism has 
cannot account for specificity of activation.  A report by Reineke et al investigated the 
interaction of PML-RARA with members of the co-activator complex (111).  PML-
RARA was able to bind the co-activators ACTR, SRC-1, GRIP1, and p300/CBP in a 
ligand independent manner, while RARA associates with these proteins only in the 
presence of RA.  These interactions were confirmed in both in vitro GST pull-down 
assays and in co-immunoprecipitation experiments.  Surprisingly, the hormone 
independent interactions of PML-RARA were mediated by the same domains as for 
wildtype RARA, and deletions of PML domains had no effect on PML-RARA’s ability 
to bind co-activators.  The conformational characteristics of PML-RARA that allow it to 
constituitively bind co-activators remain unknown.  The authors presented evidence that 
in transient transfection assays, the ability of PML-RARA to repress glucocorticoid 
receptor (GcR) mediated transcription is dependent upon its association with 
coactivators, suggesting that PML-RARA can indirectly inhibit gene expression by 
sequestering coactivators.  Again, this hypothesis fails to account for specificity, since the 
transcription of many genes is dependent upon co-activators.  We favor the alternative 
interpretation that PML-RARA can associate both with corepressors and coactivators, 
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and can therefore act as either a repressor or activator of transcription, depending upon 
the cellular and molecular context.         
 
1.9.3  Interactions with Transcription Factors 
In addition to its direct effects on target genes, PML-RARA may alter gene 
expression through inhibition of other transcription factors through protein-protein 
interactions.  For example, in the presence of ligand, RARA is known to inhibit activity 
of the AP-1 transcription factor composed of c-fos/c-jun heterodimers.  In contrast, PML-
RARA increases AP-1 activity in the presence of physiological concentrations of RA (1-
10nM), and this effect is believed to be dependent upon a physical interaction between c-
jun and PML-RARA (112).  Similarly, PML-RARA inhibits transcription of p53 targets 
by inducing the Mdm dependent degradation of p53 (113).  The PML-IV isoform 
normally stabilizes p53 by promoting its acetylation.  PML-RARA binds PML-IV and 
recruits HDACs to the PML-p53 complex, leading to deacetylation and destabilization of 
p53.  Similarly, while PML-RARA has long been thought to downregulate the expression 
of the transcription factor PU.1, recent evidence suggests that it may also inhibit PU.1 
protein activity (114).  PML IV promotes the formation of a PU.1/p300 complex on the 
promoter of the CEBPε gene, a transcription factor required for terminal differentiation 
of granulocytes, leading to enhanced transcription.  The CEBPε promoter contains a 
RARE and it was initially thought that PML-RARA repressed CEBPε by binding this 
consensus site and then recruiting corepressors to the locus.  However, PML-RARA 
disrupts the PML IV/PU.1/p300 complex and can repress CEBPε even when the RARE 
in the promoter has been mutated. 
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Additionally, it has become increasingly apparent that PML-RARA can alter gene 
expression via disruption of the Sp1 transcription facor.  PML-RARA induces the 
expression of the basic helix-loop-helix (bHLH) transcription factors ID1 and ID2 in the 
presence of ATRA, and represses expression in the absence of ATRA (115).  
Surprisingly, neither the ID1 nor the ID2 promoter contain RAREs.  Transactivation is 
dependent upon a CCAAT box and a GC box located within the proximal promoter.  
These sites are known motifs for the NF-Y and Sp1 transcription factors, respectively.  
PML-RARA interacts with Sp1, forming a complex with NF-Y and Sp1, and 
transforming ID1 and ID2 into ATRA responsive genes.  These interactions are 
dependent upon the coiled-coil domain of the PML moiety.  Similarly, tissue factor (TF), 
a known target gene of Sp1 and the AP-1 complex, is overexpressed in APL cells, which 
may be partly responsible for the high incidence of coagulopathy in APL patients (116).  
PML-RARA can interact with the TF promoter and induce TF expression only with an 
intact coiled-coil domain.  In contrast, mutants lacking the RARA DNA binding domain 
are unimpaired.  It is believed that through interactions with Sp1, PML-RARA 
deregulates TF.  Finally, PML-RARA, in the absence of ATRA, upregulates Hes1, 
another bHLH transcription factor and canonical target of Notch signaling (117).  Like 
ID1, ID2 and TF, the regulation of Hes1 by PML-RARA is dependent upon the coiled-
coil domain, not the DNA binding domain.  Similar to ID1 and ID2, the Hes1 promoter 
contains NF-Y and Sp1 consensus sites in close proximity.   
Collectively, these studies indicate that PML-RARA has both direct and indirect 
effects on transcription that are more complex than initially recognized.  PML-RARA can 
alter gene expression via at least 4 mechanisms:  1) direct DNA binding to motifs 
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containing RARE half sites in various orientations, 2) protein-protein interactions with 
other transcription factors, including Sp1, c-jun and PU.1, 3) simultaneously binding a 
single RARE and the PU.1 transcription factor occupying a consensus site in the same 
promoter and 4) disrupting PML-IV complexes with other transcription factors.  Notably, 
all of these mechanisms represent a gain-of-function compared to wildtype RARA.  
These results also explain the puzzling observation that transgenic mice expressing PML-
RARA lacking the DNA binding domain still develop leukemia (118).  Through protein-
protein interactions, PML-RARA can disrupt the activities of other transcription factors, 
and this disruption is sufficient to cause leukemogenesis. 
 
1.10.  Proposed mechanisms of PML-RARA induced leukemogenesis 
 The balanced t(15;17) translocation creates 4 genetic changes:  1) generation of 
the PML-RARA fusion protein 2) generation of the reciprocal RARA-PML fusion in 
~80% of cases (119) 3) PML haploinsufficiency and 4) RARA haploinsufficiency.  
However, PML-RARA was first hypothesized to act as a dominant negative inhibitor of 
RARA signaling.  At the time PML-RARA was identified, it was already known that 
differentiation of APL cells could be induced by ATRA treatment (12, 13).  Several early 
studies of PML-RARA function demonstrated that it could repress RARA target genes 
when transfected into various cell lines, and that the repression was lifted with the 
addition of pharmacological doses of ATRA to the culture medium (5, 6, 17, 18, 92).  In 
addition, vitamin A deficiency and RARA antagonists can produce myeloid expansion, 
though not frank leukemia, in mice (75-77), suggesting that inhibition of RARA function 
could alter myelopoiesis.  A retrovirus harboring a dominant negative RARA construct 
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immortalized mouse bone marrow progenitors at the promyelocyte stage; ATRA could 
induce differentiation in these cells as well (78).   
However, several lines of evidence suggest that inhibition of RARA does not 
completely explain PML-RARA’s actions.  First of all, many of the transient 
transfections performed in early studies used non-myeloid cell lines, making it difficult to 
extend the results to promyelocytes.  In some cases, PML-RARA was separately reported 
as either activating or repressing a promoter, depending in which cell line the 
experiments were performed.  Secondly, while excesses or deficiencies of vitamin A can 
alter hematopoeisis both in vitro and in vivo, neither is sufficient to cause leukemia, 
suggesting that additional pathways must be involved.  Third, PML-RARA is expressed 
at extremely low levels in patients and APL mouse models (30), so high level expression 
of a dominant negative RARA driven by a retroviral promoter may not accurately reflect 
the human disease process.  Indeed, when self-dimerizing, artificial RARA fusion 
proteins were expressed in the myeloid cells of transgenic mice, leukemia development 
was extremely rare (4/164 mice), despite the fact that these artificial fusions do repress 
RAREs in transient transfection assays (120).  Likewise, transgenic mice in which 
HDAC1 was artificially fused to RARA did not develop leukemia, demonstrating that 
enforced recruitment of corepressors onto RARA target genes is insufficient for 
leukemogenesis in vivo (121).  Recently, an APL patient was identified in which a 
frameshift mutation created a truncated PML-RARA with no RARA domains, suggesting 
that APL can develop in the absence of any RARA inhibition (122).  It should be noted 
that it is possible that the frameshift mutation occurred after PML-RARA initiated 
leukemia.  Similarly, transgenic mice expressing a PML-RARA cDNA with a mutated 
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DNA binding domain still develop leukemia (118), indicating that the ability of PML-
RARA to directly activate or repress transcription is not essential for leukemogenesis.   
 PML was an unknown locus when PML-RARA cDNA was initially cloned.  
After subsequent studies demonstrated that PML overexpression could suppress growth 
in fibroblasts (87), it was hypothesized that PML-RARA may act as a double dominant 
negative, inhibiting both PML and RARA.  PML-RARA expression disrupts PODs and 
causes PML to relocalize to hundreds of smaller nuclear foci (18).  While PML knockout 
mice do not spontaneously develop malignancies, they are at increased risk in several 
cancer models (48, 86), suggesting that PML deficiency could cooperate with other 
oncogenes to produce cancer.  PML is known to interact with several tumor suppressor 
proteins, including p53 and Rb (89), and PML deficient cells are resistant to inducers of 
apoptosis including radiation, Fas and TNF (88).  Inhibition of PML functions could alter 
cell cycle properties, priming cells for malignant transformation.  When PML +/- mice 
are crossed with hCG-PML-RARA transgenic mice, the incidence of leukemia in the first 
year of life increases from 12 to 31 percent, suggesting PML-RARA and PML 
haploinsufficiency may cooperate (48).  However, the presence of rare alternative 
translocations in APL, leading to other RARA fusions (PLZF-RARA, NPM-RARA, 
NUMA-RARA and STAT5B-RARA) suggests that PML inhibition is not necessary for 
APL pathogenesis (20).  The other RARA fusions do not disrupt PODs, demonstrating 
that intact PML function does not prevent leukemogenesis. 
 Since the evidence does not support dominant negative inhibition of PML, RARA 
or both PML and RARA as the sole mechanism of PML-RARA action, PML-RARA is 
now considered to have unique gain-of-function properties in addition to its inhibitory 
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activities.  First of all, overexpression of PML-RARA is toxic in cell lines and primary 
cells of both hematopoietic and non-hematopoietic origin (53, 123, 124).  Neither PML 
nor RARA deficiency leads to cell death, and PML deficiency has been shown to protect 
against apoptosis-inducing stimuli (88).  Secondly, higher expression of PML-RARA 
does not lead to increased penetrance in mouse models of APL (30).  In a simple 
dominant negative model, increased dose should result in an increased incidence of 
disease.  The higher incidence of leukemia in our mCGPR/+ mice, which have a 50 fold 
lower expression of PML-RARA compared to hCG-PML-RARA transgenic mice, argues 
strongly against this model, and suggests that there is an optimal PML-RARA expression 
level for disease initiation.  Even a 2 fold increase in dose in mCGPR/PR mice resulted in 
decreased penetrance, demonstrating the sensitivity of the system to dose.  Biochemical 
studies of the PML-RARA protein also support the gain-of-function hypothesis.  As 
described above, PML-RARA interacts with a variety of chromatin altering proteins, 
including some that do not bind wild type RARA (107, 108, 111).  Additionally, studies 
of PML-RARA’s DNA binding properties revealed that PML-RARA is capable of 
binding to widely spaced RAREs that RARA does not recognize (93).  It is likely that 
PML-RARA activities depends upon a combination of gain-of-function, inhibition of 
endogenous RARA and PML functions, and haploinsufficiency of wildtype RARA and 
PML. 
 
1.11.  The APL dsyregulome 
The development of microarray technology allowed for the identification of gene 
expression signatures from different leukemia subtypes.  Several reports have shown that 
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the expression profile of APL reproducibly clusters separately from other AML.  Schoch 
et al found that principal component analysis could separate t(15;17) cases from those  
AML samples carrying the t(8;21) or inv(16) rearrangements (125).  Furthermore, two 
different methodologies (weighted voting and multiple tree classification) could reliably 
predict to which karyotypic class samples belonged.  Later studies compared the 
expression profiles of larger groups of patients, including AML without recurrent 
chromosomal rearrangements.  In these reports, patients with t(15;17) clustered 
separately in unsupervised analyses (126-128).  A similar phenomenon was seen in 
pediatric APL patients (129).  When statistical methods such as Significance Analysis of 
Microarrays (SAM) were utilized to identify class discriminating genes, a number of 
genes were consistently reported as characteristically overexpressed in APL, including 
hepatocyte growth factor (HGF), macrophage stimulating growth factor 1 (MST1) and 
stabillin-1 (STAB1) (125-129).  Collectively, these studies suggest that t(15;17) positive 
AML cells have a distinct set of genes that is consistently dysregulated, termed the APL 
dysregulome.   
It was initially assumed that downstream targets of PML-RARA would be found 
within the unique signatures of genes overexpressed or underexpressed in APL.  
However, early gene expression profiling studies did not compare APL samples to 
normal myeloid cells, especially normal promyelocytes.  Many genes characteristically 
expressed in CD34+ progenitors are downregulated in promyelocytes as part of a normal 
developmental program of myelopoiesis.  The single published study which did utilize a 
normal promyelocyte comparison relied upon G-CSF in vitro differentiated CD34+ cells 
as “promyelocytes,” which may not represent the unmanipulated cells (130).  Failure to 
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compare APL expression patterns to those of normal promyelocytes leads to the 
misidentification of genes as APL specific when they have the same expression pattern in 
all promyelocytes, both normal and malignant.  We hypothesized that any bona fide 
PML-RARA transcriptional target must be uniquely expressed or repressed in APL cells 
compared both to other AML and normal promyelocytes.  Genes with similar expression 
in normal and leukemic myeloid cells, or that are repressed in both APL and normal 
promyelocytes, are unlikely to represent direct targets of PML-RARA.  In order to 
identify the true APL dysregulome, we compared gene expression profiles of APL 
samples to those of both other AML and sorted normal human myeloid cells, including 
CD34+ stem/progenitor cells, promyelocytes and neutrophils (131).  The identification of 
the human APL dysregulome is described in further detail in Chapter 2.     
We compared the set of genes dysregulated in human APL to our previously 
published murine APL dysregulome and to two cell line models of APL.  We 
hypothesized that a gene with altered expression in human APL as well as multiple model 
systems was most likely to be an important player in pathogenesis.  We found that the 
Notch ligand Jagged-1 (JAG1) is overexpressed in human APL compared to normal 
promyelocytes and other AML.  JAG1 is also highly expressed in murine APL cells and 
in NB-4 cells, an APL cell line.  Finally, in the PR-9 cell line, which contains a zinc 
inducible PML-RARA cassette, JAG1 mRNA increased upon PML-RARA induction.  
Since Notch signaling has a known role in self renewal and leukemogenesis, we then 
conducted in depth studies of the functional role of Notch signaling in APL, as discussed 
further in Chapter 3.  A detailed description of Notch signaling and its roles in normal 
and leukemic hematopoeisis follows below. 
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1.12.  Notch signaling 
Notch signaling is highly conserved pathway with critical roles in lineage 
specification, differentiation, proliferation and cellular survival.  The principle 
components of the notch pathway include the Notch receptors, ligands of 
Delta/Serrate/LAG (DSL) family, and downstream transcriptional activators such as CSL 
and Mastermind (132).  The core pathway elements are found in all metazoan animal 
species examined, including sponges, cnidarians, C. elegans, Drosophila and vertebrates, 
but are absent in plants (133).  Notch signaling does not appear to be present in fungi or 
protists, but some taxa have isolated components, such transcription factors homologous 
to CSL or genes with unknown function that contain domains homologous to Notch.  
This suggests that the individual building blocks of the Notch pathway predate the 
evolution of multicellular animals.  Mammalian genomes, including mice and humans, 
contain 4 Notch receptors, termed Notch1-4, and 5 Notch ligands, Delta-like 1, 3 and 4 
and Jagged1-2. 
 
1.12.1.  Notch receptors 
Notch receptors are synthesized as type I transmembrane proteins (134).  The 
extracellular domain contains numerous tandem EGF repeats which are important for 
interaction with DSL ligands, while the intracellular domain contains a RAM domain, 6 
ankyrin repeats, 2 nuclear location signals, a transactivation domain and a C-terminal 
PEST domain (135).  The RAM domain and ankyrin repeats are thought to mediate 
protein-protein interactions, while the PEST domain plays an important role in protein 
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turnover.  The extracellular domain is cleaved at the S1 site immediately proximal to the 
transmembrane domain by furin-like convertases residing the trans-Golgi network.  The 
two resulting fragments associate non-covalently to form the functional Notch 
heterodimer.  Importantly, the C-terminus of the N-terminal extracellular fragment 
contains a Lin12/Notch (LNR) domain which associates with and protects the 
transmembrane domain from cleavage in the absence of ligand binding (134).  The 
extracellular domain is further modified by O-linked glycosylation during its transit 
through the Golgi apparatus; these additions seem to promote proper folding and 
trafficking (136).  Some of the O-fucose residues may be extended via addition of N-
acetylglucosamine by Fringe family glycosyltransferases.  Fringe mediated glycosylation 
characteristically occurs O-fucose residues within EGF repeat 12, which is critical for 
ligand binding (135).  Several studies have demonstrated that Fringe modified Notch 
preferentially binds to Delta family ligands and interacts poorly with Jagged type ligands, 
representing a mechanism for specificity of ligand-receptor interactions (137, 138). 
 
1.12.2.  Notch Ligands 
Notch ligands are divided into two families, the Delta and Serrate/Jagged 
families, based upon structure and sequence homology.  Like Notch receptors, Notch 
ligands are type 1 cell surface proteins with many EGF repeats in the extracellular 
domain (139).  Both Delta and Jagged type ligands contain a conserved N-terminal (NT) 
and DSL domain, which are required, along with the first two EGF repeats, for 
ligand/receptor interactions.  Jagged ligands contain nearly double the number of EGF 
repeats of Delta ligands, and also possess a cysteine-rich (CR) region immediately 
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proximal to the transmembrane domain (140).  The role of the additional EGF repeats 
and CR region in the function of Jagged ligands is not yet clear.  The intracellular domain 
of Notch ligands is less well conserved, but most contain multiple lysine residues which 
can be ubiquitinated to regulate trafficking and turnover (141).  In vertebrates, Jag1, Dll1 
and Dll4 have a PDZ ligand motif within the C-terminus of the intracellular domain 
(139).  The PDZ ligand domain of Jag1 interacts with the PDZ domain of afadin-6 (AF6), 
a Ras target with roles in cellular junctions (142).  The PDZL domain has been shown to 
be required for cellular transformation of rat kidney epithelial (RKE) cells by 
overexpression of Jag1 (143).  These effects are independent of Notch signaling and 
suggest possible cell intrinsic activities of Notch ligands.  Similarly, the PDZL domain of 
Dll1 interacts with the discs large 1 (Dlg1) and membrane associated guanylate kinases 
with inverted domains (MAGI) proteins (144).  The interaction with Dlg1 seems to 
regulate cell-cell junctions and reduce cellular migration, while MAGI proteins recruit 
Dll1 to adherens junctions. 
 Computational analysis has predicted other domains within the intracellular tails 
of Notch ligands, such as SH2, SH3 and cyclin binding domains, which could potentially 
allow for diverse interactions with various signaling proteins.  In addition potential O-
linked glycosylation sites are found in some Notch ligands.  The validity of these sites 
and their roles in the function of Notch ligands has not yet been investigated. 
 
1.12.3.  Canonical Notch signaling 
Notch signaling occurs via an ordered sequence of proteolytic processing steps.  
The first cleavage (S1) occurs within the Golgi apparatus, where furin-like covertases 
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cleave the Notch precursor protein into N and C terminal fragments that associate to form 
the mature Notch heterodimeric receptor (145).  Once on the cell surface, binding of the 
DSL domain of a Notch ligand to EGF repeats 11-12 of a Notch receptor results in a 
conformational change in the LNR domain of the receptor that exposes the S2 proteolytic 
cleavage site.  Notch is cleaved at S2 by metalloproteinases of the ADAM10/TACE 
family, allowing removal of the Notch extracellular domain (146).  The membrane 
anchored Notch intracellular domain is then cleaved at the S3 site by intramembrane 
protease γ-secretase (135).  Cleavage by γ-secretase is a necessary and rate-limiting step 
in Notch signaling.  The freed intracellular Notch (ICN) fragment then translocates to the 
cell, where it associates with the CSL transcription factor (also called CBF-1 or RBP-Jκ) 
and the co-activator Mastermind-like (MAML) (132).  In the absence of Notch signaling, 
CSL functions as a transcriptional repressor through recruitment of NCoR/SMRT co-
repressors and histone deacetylases (HDACs) to target gene promoters (147, 148).  The 
formation of the ternary ICN/CSL/MAML complex displaces co-repressors and recruits 
the histone aceytlase p300 and RNA polymerase II, activating transcription (149).  
Known Notch target genes include c-myc, Hes-1, Deltex and Cyclin D1 (134).  Under 
normal physiologic conditions, Notch signaling is short-lived due to degradation of ICN.  
ICN is phosphorylated in the PEST domain by CDK8 (150).  Fbxw7 then ubiquitinates 
phospho-ICN, targeting it for degradation (150, 151). 
 
1.12.4.  Non-canonical Notch signaling 
Several non-canonical Notch signaling pathways have been described.  ICN has 
been shown to interact with IKKα and promote its activity, resulting in Ikb degradation 
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and Nf-kb activity (152).  This effect is not dependent on the presence of CSL.  The 
hypoxia activated transcription factor HIF1α can associate with ICN and potentiate 
Notch signaling (153).  This interaction may underlie the ability of hypoxia to promote an 
undifferentiated state in many stem cell populations.  Finally, ICN may have functions 
outside of transcription.  In Drosophila, ICN positively regulates axon growth via 
interactions with the cytoskeletal proteins Disabled and Trio (154).  This association has 
not yet been described in mammalian systems, although Notch signaling does play a role 
in mammalian axon growth.  A second example of non-transcriptional effects of Notch is 
seen in the interaction of ICN with mTOR and Rictor, resulting in activation of Akt; this 
mechanism is believed to be important for the anti-apoptotic effects of Notch in both 
normal tissues and various cancers (155).  However, while these CSL independent 
pathways are intriguing, they appear to be a minor component of Notch signaling.  CSL 
knockout embryos phenocopy Notch deficiency (156), suggesting that the majority of its 
cellular effects are CSL mediated.   
 
1.12.5.  The role of intracellular trafficking in Notch signaling 
A number of accessory proteins involved in trafficking of both receptors and 
ligands are required for Notch signaling.  The E3 ubiquitin ligase mindbomb (Mib) 
ubiquitinates lysine residues in the intracellular tail of Notch ligands (157).  The 
cytoplasmic protein epsin binds these tagged residues and recruits clathrin and other 
endocytic machinery, resulting in the internalization of the ligand into an endosome 
compartment (139).  This process influences Notch signaling via two distinct 
mechanisms.  First, endocytosis is required for the maintenance of active ligand at the 
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cell surface (158).  Ligands must traffic through recycling endosomes and back to the cell 
surface in order to be able to activate Notch signaling.  Presently it is unclear how ligands 
become activated, although several attractive mechanisms, including oligomerization of 
ligands, post-translational modifications and sorting of ligand into lipid rafts, have been 
proposed.  Secondly, during Notch signaling, ligand endocytosis creates a mechanical 
force on the extracellular domain of Notch, exposing the S2 site and allowing 
ADAM10/TACE mediated cleavage (159). The ligand/extracellular Notch complex are 
then endocytosed together.  Notch receptors are also thought to be endocytosed following 
S2 cleavage, and this may promote S3 cleavage (160).  The bulk of cellular γ-secretase 
resides within the endosome compartment (161), and this may provide a mechanism for 
bringing Notch into contact with high concentrations of secretase, allowing for more 
efficient generation of ICN.   
 
1.13. Notch signaling and hematopoiesis 
1.13.1. Notch  and embryonic hematopoiesis 
In the embryo, hematopoiesis occurs in two waves, termed the primitive and 
definitive phases.  The primitive phase occurs in the yolk sac in the E7.5 mouse embryo, 
and gives rise to primitive nucleated erythrocytes expressing embryonic hemoglobin and 
macrophage progenitors (162).  The yolk sac progenitor cells can form colonies in vitro 
but lack long term repopulating ability when transplanted into a whole animal.  Definitive 
hematopoiesis begins in the aorta-gonadal-mesonephros (AGM) region at E10.5, when 
clusters of hematopoietic cells appear in the ventral wall of the dorsal aorta.  It is 
currently believed that a bipotent population of hemangioblasts in this region 
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differentiates into hematopoietic lineage upon appropriate signaling, and becomes 
endothelium by default in the absence of such signals (163).  These cells later seed the 
fetal liver and bone marrow, and are capable of repopulating the marrow of lethally 
irradiated recipients.  Notch 1 and 4 are expressed in AGM cells and the ligands Jag1, 
Jag2 and Dll4 are found in the surrounding stroma (163). 
Primitive hematopoiesis in the yolk sac is not perturbed by genetic ablation of 
Notch ligands or receptors, indicating that Notch signaling is dispensable for this process.  
In contrast, AGM cells from Notch1-/- embryos cannot form colonies and lack 
expression of hematopoietic genes such as Runx1 and Gata2 (164).  Similar results are 
observed in zebrafish embryos treated with gamma secretase inhibitors (165), and in 
mindbomb1 (166) and CSL (167) deficient mouse embryos, which also lack Notch 
signaling.  However, these results are complicated by the severe vascular defects in these 
animals and disruption of arterial identity specification (156).  It is currently believed that 
arterial identity is a prerequisite for proper specification of HSCs within the dorsal aorta.  
This conundrum was solved by the observation that Jag1-/- embryos, which have a less 
severe vascular phenotype and intact arterial identity, nonetheless do not form definitive 
HSCs within the AGM (168).  AGM explants can be rescued in vitro by culture with Jag1 
expressing fibroblasts, demonstrating that the requirement for Jag1 is non-cell 
autonomous.  Notch signaling in the dorsal aorta hemangioblast induces expression of 
Gata2, an essential transcription factor in hematopoiesis (169).  In contrast, Jag2 (168) 
and Dll4 deficient animals do not have detectable defects in HSC specification, although 
the development of the T cell lineage is altered in these mice.  Therefore, there is a non-
redundant requirement for Notch1/Jag1 signaling to specify definitive hematopoiesis.   
 39
 
1.13.2. Notch and adult hematopoiesis 
 The role of Notch signaling in adult hematopoiesis is more controversial, and 
remains an active area of investigation.  Notch ligands, including Jag1, Jag2, and Dll1, 
are expressed on the non-hematopoietic stroma of the bone marrow microenvironment.  
Both murine KLS and human CD34+ cells express Notch receptors.  Furthermore, stem 
and progenitor cells cultured in the presence of Notch ligand expressing fibroblasts, 
stroma or artificial ligand monolayers expand, yet retain an immature phenotype, 
suggesting that Notch signaling promotes self renewal and inhibits differentiation (170-
174).  A criticism of such experiments is that the concentration of ligand may be higher 
than in vivo and therefore not physiologically relevant.  Conditional knockouts of Notch1 
(175), Notch2 (176) and Jag1 (175) under the control of the interferon inducible Mx-Cre 
have no detectible phenotype on HSCs.  Hypothesizing that redundancy of Notch 
receptors and ligands may explain the lack of a detectable phenotype, Maillard et al 
generated animals in which Notch signaling is totally ablated by either expression of a 
dominant negative MAML or conditional knockout of CSL (177).  These animals had no 
HSC defects at rest, and none were apparent even after stringent competitive repopulation 
assays or serial transplantation experiments, suggesting that canonical Notch signaling is 
dispensable for steady-state hematopoiesis and after myeloablative radiation.  The 
authors further demonstrated that the expression of many Notch target genes, such as 
Hes1 and Hey5 are very low in HSCs compared to early T cell progenitors in the thymus, 
even though expression of Notch receptors is comparable.  They hypothesized that Notch 
signaling is opposed in the bone marrow to prevent ectopic T cell development.  The LRF 
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proto-oncogene is known to inhibit Notch signaling through unknown mechanisms (178), 
and is strongly expressed in HSCs. 
 Nevertheless, HSCs appear poised to respond to Notch signaling.  The ability of 
HSCs to expand upon exposure to Notch ligands in vitro is well documented.  Similar 
phenomena occur in vivo in certain settings.  For example, exogenous administration of 
parathyroid hormone leads to increased Jag1 expression on osteoblasts via a cAMP 
dependent mechanism, and a concurrent expansion of the HSC population (179).  In 
addition, TNFα or LPS, which stimulates its production, can lead to increased Jag1 and 
Jag2 on marrow endothelium and a similar increase in HSCs and progenitors (180, 181).  
Osteoblasts and endothelial cells are components of the “stem cell niche,” and as such are 
capable of altering HSC activity.  Notch signaling may therefore modulate adult 
hematopoiesis in times of stress, such as infection, inflammation or bone trauma. 
 
1.13.3.  Notch signaling in the bone marrow microenvironment 
 Notch signaling may also have indirect effects on hematopoiesis through its role 
in bone biology and the bone marrow microenvironment.  Genetic ablation of Notch 
signaling in osteoblasts results in osteoporosis (182) secondary to an increase in 
osteoclasts.  In mature osteoblasts, Notch positively regulates the transcription of 
osteoprotegerin, a secreted negative regulator of osteoclastgenesis.  In contrast, 
overexpression of ICN in osteoblasts causes osteosclerosis and marrow cavities filled 
with trabecular bone (183).  In this model, the bone is poorly organized and contains 
increased immature osteoblasts, suggesting that Notch signaling prevents terminal 
differentiation into mature osteoblasts.  Similarly, conditional knockout of the 
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presenillins (part of the γ-secretase complex) in mesenychmal stem cells produces 
animals with increased bone density, due to increased differentiation of MSCs into 
osteoblasts (182).  Confusingly, in certain settings, Notch signaling may also promote 
differentiation.  Activation of bone morphogenic protein (BMP) signaling concordantly 
with Notch signaling promotes MSC commitment to the osteoblastic lineage (184, 185).  
Notch signaling therefore appears to have a dual role in bone biology:  it both maintains 
MSCs and immature osteoblasts in an undifferentiated state and drives them to adopt an 
osteoblastic fate.  In addition, Notch signaling in marrow osteoclast precursors inhibits 
osteoclastgenesis and bone resorption (186).  Collectively, these results suggest that 
caution should be used in interpreting experiments that do not control for the effect of the 
microenvironment.   
Indeed, several mouse models have demonstrated that altered Notch signaling in 
the non-hematopoietic components of the bone marrow environment can have a profound 
effect on hematopoietic cells.  The conditional deletion of mindbomb-1 (Mib1) results in 
myeloproliferation dependent on defective Notch signaling in the stroma (187).  Mib1 -/- 
cells transplanted into a wildtype recipient do not produce MPD, while wildtype cells 
transplanted into a Mib1-/- animal produce highly proliferative granulocytes and 
granulocytic progenitors.  This effect is reversible if a second transplant into a wildtype 
recipient is performed.  Notch signaling within the hematopoietic compartment was 
intact, but was defective within the stroma.  Similarly, presenilin-1 haploinsufficient, 
presenilin-2 knockout (PS1+/- PS2-/-) animals have reduced Notch signaling and develop 
a non-transplantable MPD (188), suggesting that a defective microenvironment is also 
responsible. 
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1.14.  Notch Signaling in Leukemia 
1.14.1.  Notch Signaling in T-ALL 
The human Notch1 gene was originally identified through analysis of the t(7;9) 
translocation found in a minority of T cell acute lymphoblastic leukemia (T-ALL) 
patients (189).  The breakpoint of this translocation invariably occurs within intron 24 of 
the Notch1 gene and places exons 24-30 under the control of the TCRβ locus.  The 
resulting truncated transcript, termed TAN1 (truncated activated Notch1), encodes a 
mutant Notch1 protein which lacks the extracellular EGF repeats and LNR domains, but 
retains the transmembrane and intracellular domains.  TAN1 is constitutively active and 
causes T-ALL in mice transplanted with retrovirally transduced TAN1 marrow (190).  
However, t(7;9) is present in only 1-2% of T-ALL cases.  Sequencing of the Notch1 gene 
in human T-ALL cases revealed that 50-60% of cases have mutations in either the 
heterodimerization domain, the C-terminal PEST domain or both (191).  HD domain 
mutations make the Notch receptor more susceptible to gamma secretase cleavage, while 
PEST domain mutations prevent ubiquitination of cleaved Notch1 by Fbxw7, and 
subsequent degradation by the proteosome (192).  Interestingly, 10% of T-ALL cases 
lack Notch mutations or translocations but have inactivating mutations of Fbxw7, which 
also lead to an inability to degrade cleaved Notch (192).  
The mechanism of Notch induced leukemogenesis appears to involve activation 
of multiple downstream target genes and cross talk with many signaling pathways.  In 
mouse models, Notch1 mutations cooperate with overexpression of c-myc and Pbx3, both 
of which cause T-ALL with long latency, as well as loss of p53, Ikaros and p27 (134).  A 
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genomic approach comparing Notch ChIP-on-chip and microarray expression analysis of 
GSI treated T-ALL cell lines identified several upregulated transcriptional targets of 
activated Notch1 (193), including the pro-proliferative oncogene c-myc, Taspase-1, 
which promotes cell cycle progression (194, 195), cyclin D3, which promotes G1/S 
progression (196) and the cold shock domain protein CSDA, which has anti-senescent 
activities (197).  T-ALL associated Notch mutants also appear to activate the PI3K/Akt 
survival pathway, either directly (155) or through its downstream transcriptional target, 
Hes1, which represses PTEN expression (198).  In addition, Notch signaling induces 
transcription of Skp2, which has anti-senescent activities via its role in the degradation of 
the cyclin dependent kinase inhibitor p27 (199).  T-ALL associated Notch mutants also 
activate pro-survival NF-κB signaling both via inducing transcription of RelB and 
NFKB2 and by direct activation of the IκB kinase complex (200). In summary, the 
overall effect of Notch signaling in T-ALL seems to be promotion of cellular survival and 
proliferation. 
 
1.14.2.  Notch signaling in myeloid leukemias 
Notch mutations are only rarely found in acute myeloid leukemia (AML).  These 
cases belong to the primitive M0 subtype and are characterized by expression of T-cell 
markers, a mixed lineage immunophenotype and high expression of the Notch target gene 
TRIB2 (201).  However, Notch signaling may still be altered in AML in the absence of 
Notch mutations.  Data from the Ley laboratory shows that Notch receptors are expressed 
in human AML (131).  Gene expression profiling of a large set of AML patients (FAB 
subtypes M0-M7) revealed that NOTCH1 and NOTCH2 are highly expressed in nearly 
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all samples.  The delta-like ligands are typically either not expressed or expressed at low 
levels.  In contrast, JAG2 expression is detectable across a wide range of FAB subtypes.  
JAG1 is characteristically overexpressed in APL (see Chapter 3), but is also highly 
expressed in occasional non-M3 cases.  In addition, the components of the gamma 
secretase complex and the mastermind-like coactivators are robustly expressed in nearly 
all AML, suggesting that AML cells are capable of transducing Notch signals.    
Several AML associated fusion proteins ectopically activate Notch signaling in 
the absence of ligand.  Notch signaling is required for the differentiation of 
megakaryocytes, as demonstrated by the reduction in both mature megakaryocytes and 
megakaryocyte progenitors in mice transplanted with dominant negative MAML 
transduced marrow (202).  Acute megakaryoblastic leukemia (AMKL, FAB M7) is 
characterized by a recurrent t(1;22) translocation which results in the fusion protein OTT-
MAL.  Wildtype OTT binds CSL and causes repression of its transcriptional targets, 
while wild type MAL functions as a transcriptional activator.  The OTT-MAL fusion 
binds CSL and leads to inappropriate activation of CSL target genes in the absence of 
Notch signaling (203).  In addition, t (1;22) AMKL have increased expression of 
Notch/CSL target genes such as Hes1 and Hey1 compared to AMKL with GATA1 
mutations.  A knock-in mouse model of OTT-MAL resulted in hematopoietic 
abnormalities and frank megakaryoblastic leukemia in 10-15% of the animals.  Similarly, 
the AML-ETO fusion protein produced by the t(8;21) translocation found in M2 AML 
can cause Notch independent transcription of CSL target genes (204).  Wild type ETO is 
part of the corepressor complex recruited by CSL in the absence of Notch signaling.  
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Expression of AML-ETO inhibits corepressor recruitment, causing activation of Notch 
target genes. 
PML-RARA appears to alter Notch signaling through at least three possible 
mechanisms.  When PML-RARA expression is induced in the PR-9 cell line, both JAG1 
protein and mRNA increase (131, 205).  Cotransfection of PML-RARA and a Hes1 
promoter reporter construct results in increased luciferase expression, suggesting that 
PML-RARA expression leads to downstream activation of Notch signaling (205).  APL 
samples characteristically overexpress JAG1 relative to other AML, promyelocytes and 
CD34+ stem and progenitor cells (128, 130, 131, 205), suggesting that PML-RARA 
increases JAG1 in primary cells as well as cell lines.  It is currently unclear how PML-
RARA upregulates JAG1 expression; three genome wide ChIP studies failed to find 
evidence of PML-RARA binding in the JAG1 promoter, suggesting that the mechanism 
is not direct transcriptional regulation (96, 97, 98).  Concordant with its upregulation of 
JAG1, PML-RARA may also negatively regulate the glycosyltransferase Lunatic Fringe 
(LFNG).  LFNG mRNA decreases upon PML-RARA induction in PR9 cells (205) and is 
decreased in APL relative to other AML (128, 131).  A genome wide ChIP-seq study of 
PML-RARA transcriptional targets identified multiple peaks in the LFNG promoter, 
suggesting that regulation of LFNG by PML-RARA may be direct (97).  LFNG modified 
Notch molecules preferentially signal through Delta-like family ligands and have 
impaired interactions with Jagged family ligands (137, 138).  Therefore, PML-RARA 
both increases JAG1 and promotes Jagged/Notch signaling via downregulation of LFNG.  
Finally, the Notch target gene Hes1 may be a transcriptional target of PML-RARA 
through its interactions with Sp1 and NF-Y (117).  Despite these data implicating Notch 
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signaling in APL, its role in APL pathogenesis is still not defined; this will be addressed 
further in Chapter 3. 
Expression of Notch ligands and target genes may be altered in myeloid 
malignancies in the absence of the fusion proteins described above.  For example, 
expression of the Notch target gene Hes1 has been noted to increase in the accelerated 
and blast crisis phases of chronic myeloid leukemia (CML) as compared to the chronic 
phase (206).  Retroviral overexpression of Hes1 immortalizes committed myeloid 
progenitors, and cooperates with BCR-ABL to cause leukemia, suggesting a role for 
Notch signaling in leukemic transformation (206).  A study of expression profiling in 
human leukemic stem cells by Gal et al. found that JAG2 expression is increased in the 
CD34+ CD38- putative LSC population as compared to the more mature CD34+ CD38+ 
population (207).  Treatment of primary AML samples with the gamma secretase 
inhibitor DAPT lead to decreased colony formation and colony size in methylcellulose, 
suggesting that Notch signaling contributes to self-renewal and proliferation in AML.  
Collectively these studies indicate that Notch signaling may play a wider role in myeloid 
malignancies than is commonly recognized. 
Inhibition of Notch signaling may also be associated with myeloid malignancies.  
Recently, an inversion on chromosome 11 which fuses the mixed-lineage leukemia 
(MLL) gene to the Notch associated coactivator Mastermind-like 2 (MAML2) has been 
identified in rare cases of myelodysplastic syndrome (MDS), secondary AML and 
secondary T-ALL (208).  The MLL-MAML2 fusion protein lacks the domains necessary 
for interaction with cleaved Notch and seems to act in a dominant negative fashion to 
prevent transcription of Notch target genes.  Because of the contributions of the N-
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terminal MLL domain of the fusion protein, it is difficult to assess the contributions of 
inhibited Notch signaling to the overall leukemogenic process.  In addition, several 
studies have reported that Delta-like (Dlk1) is overexpressed in myelodysplastic 
syndrome (MDS) marrow samples and MDS CD34+ cells compared to normal CD34+ 
cells (209-211).  Dlk1 is a secreted homologue of the Dll family Notch ligands that is 
believed to inhibit Notch signaling.  Ectopic expression of Dlk1 results in reduced 
proliferation and impaired differentiation and colony formation (209).  In the setting of 
MDS, Dlk1 mediated Notch inhibition may be more responsible for the cytopenias 
associated with the disease than promoting leukemic transformation. 
 
1.15.  Summary 
In this thesis, we will study the downstream pathways altered in the setting of 
PML-RARA expression in myeloid cells and how those alterations produce the 
development of promyelocytic leukemia.  We address broad two questions: 
 
(1)  How is gene expression altered in primary human APL compared to other forms of 
AML and normal myeloid cells, and how well do current cell line and animal model 
systems reflect the gene expression changes associated with the human disease? 
(2) What is the role of Jagged/Notch signaling in the pathogenesis of APL, and is that 
role is the same or different in the pre-leukemic phase versus the fully transformed 
tumor? 
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In Chapter 2, we will describe the identification of the human APL dysregulome, its 
validation by high throughput digital mRNA quantification and the comparison between 
gene expression changes in human APL and those observed in various model systems.  
Chapter 3 examines the role of the overexpression of the Notch ligand Jagged-1 (JAG1) 
in the pathogenesis of APL, especially in the hematopoietic alterations found in young, 
preleukemic mCG-PR mice.  Finally, in Chapter 4, we will discuss our cumulative 
results and investigate future lines of inquiry that could be employed to continue the 
study of the role of Notch in APL pathogenesis. 
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2.1.  Abstract 
Acute promyelocytic leukemia (APL) is characterized by the t(15;17) chromosomal 
translocation, which results in fusion of the retinoic acid receptor α (RARA) gene to 
another gene, most commonly promyelocytic leukemia (PML).  The resulting fusion 
protein, PML-RARA, initiates APL, which is a subtype (M3) of acute myeloid leukemia 
(AML). In this report, we identify a gene expression signature that is specific to M3 
samples; it was not found in other AML subtypes and did not simply represent the normal 
gene expression pattern of primary promyelocytes. To validate this signature for a large 
number of genes, we tested a recently developed high throughput digital technology 
(NanoString nCounter). Nearly all of the genes tested demonstrated highly significant 
concordance with our microarray data (P < 0.05). The validated gene signature reliably 
identified M3 samples in 2 other AML datasets, and the validated genes were 
substantially enriched in our mouse model of APL, but not in a cell line that inducibly 
expressed PML-RARA. These results demonstrate that nCounter is a highly reproducible, 
customizable system for mRNA quantification using limited amounts of clinical material, 
which provides a valuable tool for biomarker measurement in low-abundance patient 
samples. 
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2.2.  Introduction 
Here we describe what is, to our knowledge, the first use of a high-throughput 
digital system to assay the expression of a large number of genes in primary clinical 
samples from patients with acute myeloid leukemia (AML).  This technology captures 
and counts individual mRNA transcripts without enzymatic reactions or bias and is 
notable for its high levels of sensitivity, linearity, multiplex capability, and digital readout 
(1). The nCounter system (NanoString) is capable of detecting as little as 0.5 fM of a 
specific mRNA, making it a valuable tool for expression signature validation, diagnostic 
testing, and large translational studies, all of which often are limited by the very small 
amounts of clinical material available.  
In this study, our primary clinical focus is on acute promyelocytic leukemia 
(APL), a subtype (M3) of AML that is unique in its morphology and its defining 
molecular initiating event. (Throughout this manuscript, we refer to human APL as M3 
AML and the mouse models as murine APL.) Morphologically, the leukemic cells are 
abnormal promyelocytes, which nevertheless retain many of the structural and 
immunophenotypic characteristics of normal promyelocytes. M3 AML is further 
characterized by fusion of the retinoic acid receptor α (RARA) gene to another gene, most 
commonly the promyelocytic leukemia (PML) gene, through a balanced translocation of 
chromosomes 17 and 15, respectively. The resulting fusion protein, PML-RARA, has 
been shown to initiate APL in several mouse models (2–5). Unlike most other AML 
subtypes, the initiating event of M3 AML is known, making it an attractive model for the 
study of mechanisms of pathogenesis and progression.  
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Several recent gene expression profiling studies used microarray technologies to 
compare subclasses of AML and have reported specific expression signatures for 
individual morphologic or molecular subtypes (6–18). Although a subset of these studies 
included normal whole bone marrow or purified myeloid precursor CD34+ cells, none of 
them included fractionated primary hematopoietic cells from multiple discrete stages of 
myeloid differentiation (6, 7, 9, 11, 13–15, 17, 18). Because different subtypes of AML 
represent various arrested developmental stages of hematopoiesis (e.g., M3 versus normal 
promyelocytes), differences in expression may result from these developmental stages 
rather than a fundamental difference in pathogenesis or progression. The inclusion of 
normal, primary fractionated myeloid precursors, including promyelocytes, could 
mitigate this potential pitfall.  
Another shortcoming of many gene expression profiling studies, including the 
AML studies above, is that only a small number of genes have been validated in a small 
number of samples, due to limiting amounts of clinical material available and the labor-
intensive and costly nature of quantitative RT-PCR–based (qRT-PCR–based) validation. 
In this study, we have overcome these limitations with a digital RNA quantitation system, 
which allowed triplicate measurements of the expression levels of 46 genes, using only 
100 ng of total RNA (the amount obtained from approximately 40,000 myeloid cells) in a 
multiplex reaction. Thus, the confidence of our M3-specific signature is substantially 
increased by such extensive validation. 
In the current study, we compare M3 cell expression patterns with those of other 
AML subtypes and to normal CD34+ cells, promyelocytes, and neutrophils purified from 
independent healthy human bone marrow samples using high-speed flow cytometry. 
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Using these data, we define a unique expression signature of M3 malignant 
promyelocytes, which is distinct both from other subtypes of AML and from normal 
promyelocytes. A subset of the most highly dysregulated genes in this signature were 
extensively validated using both conventional (qRT-PCR) and innovative (NanoString 
nCounter system; ref. 1) methodologies.  
We further used gene set enrichment analysis (GSEA) (19, 20) to evaluate our 
validated gene set in 3 other datasets: a published set of 325 human AML samples (18), a 
mouse model of APL (5), and the PR-9 cell line (21), which is commonly used in studies 
of PML-RARA activity. Both the human M3 AML and murine APL samples 
demonstrated significant enrichment of the validated gene set. However, the PR-9 cells 
failed to show significant enrichment of this gene set after induction of the PML-RARA 
transgene.  
Importantly, the validated genes reliably identified bona fide M3 samples (PML-
RARA fusion gene positive), separating them from other FAB subtypes in 3 independent 
AML datasets. 
 
2.3.  Results 
In order to identify genes that are specifically dysregulated in M3 AML cells, we 
compared the gene expression patterns of M3 samples to those of normal myeloid cells at 
various stages of differentiation. We collected bone marrow from healthy donors and 
immediately fractionated it into CD34+ cells, promyelocytes, or neutrophils. CD34+ cells 
were isolated after incubation with an anti-CD34 antibody and separation on a Miltenyi 
Biotec MACS column, resulting in greater than 90% purity, as validated by flow 
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cytometry (data not shown).  To ensure a high-quality expression analysis of normal 
promyelocytes, we refined a previously described flow cytometry–based methodology 
(22) to obtain a large number of highly enriched cells. After red cell lysis, whole bone 
marrow was incubated with antibodies to CD9, CD14, CD15, and CD16. Washed cells 
were sorted and collected on a Dako MoFlo flow cytometer as follows: CD9–, CD14–, 
CD15+, and CD16lo (for promyelocytes) and CD9–, CD14–, CD15+ and CD16hi for 
neutrophils. (See Methods for details; Figure 2-1A for flow cytometric plots; and Figure 
2-1B for photomicrographs of sorted cells.)  Cell purity for all myeloid cell fractions was 
high: the average promyelocyte purity exceeded 80%, and neutrophil and band purity was 
greater than 95%, as determined by manual differentials performed on cytospin samples. 
RNA isolated from purified cells was analyzed on Affymetrix U133+2 microarrays.  
To confirm that each myeloid cell fraction contained cells with gene expression 
patterns consistent with the predominant cell type, we compared the RNA expression 
levels of several developmentally regulated myeloid genes (Figure 2-1C).  The “early” 
hematopoietic genes (associated with primitive myeloid precursor cells) CD34, FLT3, 
and KIT demonstrated much higher expression in the CD34+ cell fraction than in the 
other 2 fractions. Conversely, the “late” genes (associated with neutrophils) CTSS, FPR1, 
IL8RB, and NCF2 were most highly expressed in the neutrophil fraction. Most 
importantly for this study, the “mid-myeloid,” promyelocyte-specific azurophil granule 
genes CTSG, ELA2, MPO, and PRTN3 displayed very high expression in the 
promyelocyte fraction, which decreased by an order of magnitude or more in neutrophils. 
Further analysis identified genes specifically expressed in each of the 3 fractions. The 
heat map in Figure 2-1D illustrates a progression of gene expression from less 
 73
differentiated to terminally differentiated myeloid cells.  The patterns of expression 
described above support the flow cytometric and morphologic data, demonstrating that 
each fraction is highly enriched for the target population. Collection of these fractions 
was essential for a robust comparison of malignant promyelocytes with normal myeloid 
cells at different stages of differentiation.  
For this study, we analyzed 77 de novo AML bone marrow samples obtained at 
diagnosis. The characteristics of the patients from which these samples were obtained are 
summarized in Table 2-1 and have previously been described (Discovery set, FAB 
subtypes M0–M4; ref. 23).  Of these samples, 15 were diagnosed as M3; only samples 
with t(15;17) confirmed by cytogenetics and/or FISH were included in the M3 analysis 
set (24).  The remaining 62 samples consisted of FAB subtypes M0, M1, M2, and M4 
with 2 or fewer cytogenetic abnormalities (these FAB subtypes were chosen because they 
represent the most common AML subtypes and because there were insufficient numbers 
of M5, M6, or M7 patient samples available for analysis). RNA was prepared from snap-
frozen cell pellets of the bone marrow cells and analyzed on Affymetrix U133+2 
expression microarrays. We did not fractionate the AML samples for the following 
reasons: (a) the bone marrow blast percentage for all samples, including M3 abnormal 
promyelocytes, was high (median >70%), (b) we have previously observed that AML 
bone marrow aspirates subjected to Ficoll separation of mononuclear cells, compared 
with unfractionated snap-frozen cell pellets, demonstrated no significant differences in 
expression by microarray analysis (our unpublished observations), and (c) as of yet, there 
is no standard cell surface marker that can reliably separate malignant AML cells from 
normal human hematopoietic cells.  
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2.3.1.  Defining the M3-specific dysregulome.  
To identify genes specific to M3 AML, we compared M3 samples to other FAB 
subtypes and to normal myeloid cells at various stages of differentiation. We established 
a series of criteria for M3-specific genes: significant differences in expression when 
compared with non-M3 AML or normal promyelocytes, including up- or downregulation, 
high expression similar to that of CD34+ myeloid precursor cells, and/or high expression 
of genes that are not expressed in any of the normal myeloid cells tested. We first 
performed significance analysis of microarrays (25), using a false discovery rate (FDR) 
cutoff of 0.05. This analysis identified 2,023 annotated genes (3,787 probe sets) whose 
expression was significantly up- or downregulated in M3 compared with other AML 
subtypes, as demonstrated by the clear separation of the two groups in the expression heat 
map (Figure 2-2A).  We observed that some of the genes were expressed at similar levels 
in both normal and transformed (M3) promyelocytes. Therefore, to exclude genes that are 
simply markers of the normal promyelocyte developmental stage, and conversely to 
retain genes that represent aberrant expression of developmentally regulated genes, we 
filtered these genes based on a comparison with the specific expression signatures 
identified for normal myeloid cells at 3 stages of differentiation (see Methods and Figure 
2-3).  In addition to showing significant (FDR < 0.05) differences in expression 
compared with other AML subtypes, these genes, which we call the M3-specific 
dysregulome, fulfilled one or more of the following criteria: (a) were CD34+ precursor 
stage specific but persistently expressed at similar levels in M3 cells (M3: CD34+ 
precursor fraction ratio, ≥1:1), (b) showed significantly different expression (FDR < 0.05) 
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from that of normal promyelocytes, and/or (c) showed significantly upregulated M3 
expression (FDR <0.05; M3/normal cell fraction ratio, >2:1) and were not expressed in 
any of the normal myeloid cells tested (greater than 75% absent calls, determined by the 
MAS 5 algorithm in Affymetrix expression analysis software). The normal promyelocyte 
filter removed approximately 1,800 probe sets, and the remaining criteria each removed 
approximately equal numbers of probe sets. The heat map in Figure 2-2B demonstrates 
clear separation of these 510 up- or downregulated genes in malignant versus normal 
promyelocytes (listed in Table 2-2).  
Many of the genes in the M3-specific signature exhibited dramatic differences in 
expression level when compared with other AML subtypes or normal promyelocytes. A 
subset of genes with the greatest level of differential expression is shown in Table 2-3.  
To investigate genes that may be activated or repressed in M3 AML, equal numbers of 
up- and downregulated genes were selected for further study and validation.  Some of 
these highly dysregulated genes (such as HGF, FGF13, and PPARG) have been 
documented in previous reports (6–8, 12, 14). There are also many genes in this list that 
have not been previously reported to be dysregulated in M3, including BCL2A1, TWIST1, 
and TNFRSF1B. Of the 40 genes selected for further study, 17 have not previously been 
reported in other M3 AML expression studies (6–8, 12, 14). 
 
2.3.2.  Validation of M3-specific dysregulome.  
To validate the findings of the microarray analysis, we selected the 40 genes with 
the largest average fold changes (both up and down) between M3 and the other AML 
subtypes. Due to limited sample abundance, we used a high-throughput methodology for 
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gene validation that allowed us to perform triplicate measurements of expression of 46 
genes (the 40 with the highest fold changes, plus 6 developmentally regulated myeloid 
genes for calibration) with only 100 ng of RNA per replicate. Based on an average RNA 
yield of 25 µg per 107 cells from the bone marrow aspirate samples used in this study, we 
estimated that 100 ng corresponded to approximately 40,000 cells. The NanoString 
nCounter Analysis System uses digital technology based on direct multiplexed 
measurement of gene expression and offers high levels of sensitivity (500 attomolar, i.e., 
<1 copy per cell), precision, and reproducibility (1). The technology uses molecular 
barcodes and single-molecule imaging to detect and count hundreds of unique mRNAs in 
a single reaction (See Methods) (1). In this study the full capacity of the nCounter system 
was not utilized; up to 500 genes can be assayed in 1 multiplex reaction (1). To confirm 
the performance of this technology, we selected 6 “calibration” genes known to be 
differentially expressed in each myeloid cell fraction and in M3 samples. A total of 28 
AML (11 M3 and 17 other AML subtypes), 2 CD34+, 5 promyelocyte, and 2 neutrophil 
samples were analyzed. The NanoString results showed the expected pattern of 
expression for all 6 calibration genes (compare Figure 2-4, A–C with Figure 2-1C).  As 
shown in Table 2-4, 37 of the 40 M3-specific dysregulome genes were also assayed.  The 
remaining 3 genes, SYNE1, FUT4, and PGDB5, could not be analyzed due to either 
inaccurate (SYNE1 and FUT4) or ambiguous (PGDB5) mapping of Affymetrix probe set 
target sequences to the human genome (See footnote in Table 2-3).  Data from both 
methods are plotted for 2 examples each of up- or downregulated genes (HGF and 
FAM19A5, NRIP1 and TNFRSF1B, respectively) in Figure 2-5.  Data from nCounter and 
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microarray analyses demonstrate similar patterns of expression in M3 samples relative to 
other AML subtypes and normal promyelocytes (See Table 2-4 and 2-5).  
To more directly compare the nCounter and microarray methods, which have 
different units of measurement, we transformed each AML data point as a proportion of 
maximum signal for each probe set (microarray) or probe (nCounter) for all samples. 
These proportions were then plotted on a graph. As depicted in Figure 2-6, A and B, and 
Table 2-4, the correlation coefficients between the results of the 2 methods were r > 0.7 
and statistically significant (P < 0.05) for all but 1 gene, CD300A, which may be due to 
differential targeting of the microarray and nCounter probes (middle and 5′, respectively) 
to an mRNA with 3 isoforms.  Three other genes (AMICA1, SLC15A3, and HK3) 
demonstrated similar fold change values and high correlation coefficients compared with 
the microarray data but did not achieve significance when comparing expression in M3 
with other AML subtypes in the nCounter assay.  This result may be due to the low 
overall expression signals shown by both methods (Table 2-5).  We also compared fold 
change ratio measurements (M3/other FAB subtypes) of all genes assayed by both 
microarray and NanoString. As demonstrated in Figure 2-6C, the correlation between the 
2 platforms was very high (r = 0.963, P < 0.05).  Based on the stringent criteria of a 
significantly high correlation coefficient, similar fold change values, and significant 
difference in expression (M3 vs. other subtypes and promyelocytes), 33 genes were 
validated by the nCounter system. 
We also performed qRT-PCR for 9 of the 40 M3-specific dysregulome genes in 
parallel with the nCounter method. For 7 of the 9 genes, qRT-PCR confirmed the 
significant fold change expression differences among M3, other FAB subtypes, and 
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normal promyelocytes, as determined by the NanoString and microarray datasets (Table 
2-4).  Due to the limited abundance of many of our samples, we were unable to perform 
qRT-PCR assays on all 40 M3-specific dysregulome genes.  However, the nCounter 
method has previously demonstrated strong correlation with qRT-PCR for 21 genes 
whose expression was measured in quadruplicate at 7 time points (1).  
To determine whether the 33 validated genes are similarly dysregulated in AML 
samples from other studies, we used GSEA (19, 20) to evaluate a published dataset (18) 
(GSE6891). Expression in this set of 325 primary AML samples demonstrated a highly 
significant enrichment of the validated 33-gene set (FDR q value = 0.0; Figure 2-7A).  In 
addition, GSEA analysis of expression in one of our mouse models of APL (5) 
demonstrated significant enrichment (FDR q value = 0.034; Figure 2-7B) of the murine 
orthologs of the validated genes.  Finally, we tested expression of these validated genes in 
the PR-9 cell line (21), a commonly-used model of M3 AML.  Zn2+ treatment massively 
increased expression of the PML-RARA fusion gene (see Figure 2-8).  GSEA analysis 
failed to demonstrate significant enrichment of the validated gene set in PR-9 cells 
expressing high levels of PML-RARA (FDR q value = 0.956; Figure 2-7C). 
 
2.3.3.  Classification of M3 samples using the NanoString-validated gene set.  
We next tested the ability of the 33 validated genes to identify M3 samples using 
unsupervised principle component analysis (PCA; ref. 26). In our dataset, all M3 samples 
positive for the PML-RARA rearrangement separated from the other samples (Figure 2-
9).  Notably, 1 sample diagnosed morphologically as M3 AML, but with normal 
cytogenetics and negative FISH, did not cluster with those positive for the PML-RARA 
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fusion gene (Figure 2-9A).  The patient from whom this sample was taken also failed all-
trans retinoic acid (ATRA) therapy and died 2 months after induction.  PCA of the 
primary NanoString expression data also clearly separated 11/11 M3 t(15;17)-positive 
samples from other FAB subtypes, as expected (Figure 2-9B).  We next tested the 
validated gene set on a set of 325 M0–M4 AML samples (18) that contained several 
potentially ambiguous diagnoses. The PCA plot from this analysis shows that all 20 M3 
t(15;17)-positive samples clustered separately from the other FAB subtypes, as expected 
(Figure 2-9C).  In addition, 4 morphologically diagnosed M3 samples, in which the 
t(15;17) was missed by routine cytogenetics, clustered appropriately.  Another sample in 
which morphological diagnosis (M2) conflicted with routine cytogenetics [t(15;17)] was 
also appropriately identified.  Figure 2-9D demonstrates the ability of the validated gene 
set to separate all but 1 of the M3 t(15;17)-positive samples from other FAB subtypes; 19 
of 20 M3 samples were appropriately identified in a dataset of 93 AML M0–M4 samples 
obtained from CALGB and analyzed in our microarray facility (see Methods).  
 
2.4.  Discussion 
We have demonstrated the use of an innovative high-throughput methodology, the 
NanoString nCounter Analysis System, to quantify the mRNA abundance of a large 
number of genes from an expression signature using very small amounts of clinical 
material. Through the use of a large number of clinical samples and normal, primary 
myeloid cells, we defined the unique expression signature of M3 AML, which is distinct 
from other subtypes of AML and from normal promyelocytes. We then validated the M3-
specific signature using the NanoString nCounter Analysis System, which enabled us to 
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quantitate the relative expression of 46 genes with only 300 ng of total RNA, using 
multiplexed reactions. We determined that the validated genes were also significantly 
dysregulated in M3 AML samples from another large clinical study and from a mouse 
model of APL, but not from a commonly used tissue culture model of PML-RARA 
function. Finally, the validated genes reliably identify bona fide t(15;17)-positive M3 
samples, separating them from other FAB subtypes in 3 independent AML datasets. 
The findings presented here demonstrate the power of including a large number of 
de novo AML samples and normal human myeloid samples to define malignancy-
specific expression signatures. Comparison of 14 M3 samples with 62 samples of other 
AML subtypes and 15 samples of normal primary myeloid cells allowed us to identify 
expression patterns that were both unique and highly reproducible for M3 AML. 
Comparison with normal enriched promyelocyte samples enabled us to filter out genes 
that were simply markers of the promyelocyte stage of myeloid development. Although a 
previous study (7) compared M3 and promyelocyte expression patterns, these were 
derived from CD34+ PBMCs cultured for 7 days with G-CSF, IL-3, and GM-CSF. Our 
analysis showed that the majority of the genes reported in that study (7) were filtered out 
by our comparison of M3 with CD34+ cells, primary promyelocytes, neutrophils, and 
other AML subtypes.  
The NanoString nCounter system allowed us to quantify and validate (in 
triplicate) the expression of 42 of 46 genes in 28 AML and 11 normal myeloid samples, 
using approximately 1/10th of the RNA that qRT-PCR would have required. The 
nCounter system performed with a high level of precision and reproducibility, using only 
100 ng of RNA (the RNA content of ~40,000 AML cells) per replicate. Expression signal 
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values demonstrated significant correlation with microarray expression data. The 
coefficient of variation, a ratio of the standard deviation to the mean and a measure of 
reproducibility, was consistent with that of conventional qRT-PCR (data not shown). 
We have shown that the validated M3 gene set was significantly enriched in M3 
samples in another large clinical study. Experimental and in silico validation of the 
signature allowed us to examine 2 models of APL, one a knockin mouse model of the 
disease, the other a myeloid cell line with inducible expression of PML-RARA. Analysis 
of expression in APL cells derived from mCG-PML-RARA mice (27) demonstrated that 
the validated gene set was significantly dysregulated when compared with wild-type 
promyelocytes. Our previous work with this mouse model demonstrated that only 3 of 
116 genes in the murine APL dysregulome were dysregulated in PML-RARA–expressing 
preleukemic promyelocytes, suggesting that in mice the genes that are dysregulated in 
APL are not downstream targets of the transgene (27). Similarly, the validated gene set 
identified in the current study was not altered in PR-9 cells, suggesting that many of the 
dysregulated genes in primary M3 AML samples are not direct targets of PML-RARA.  
We have further demonstrated that the validated 33-gene set identifies M3 
samples from within AML microarray expression datasets from other large studies, 
reliably separating those with t(15;17) and/or the PML-RARA fusion gene from those 
that were morphologically ambiguous.  Only 1 of 60 M3 samples analyzed by PCA failed 
to segregate with the other M3s. Unsupervised hierarchical clustering of global 
expression analysis using the CALGB samples demonstrated that this outlier M3 sample 
segregated with a large mixed group of FAB subtypes and not with the other M3s (data 
not shown). There was no difference between the survival of the patient from whom this 
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sample was taken and the survival of other M3 patients in the CALGB group. This 
evidence suggests that in a small number of patients there may be secondary mutations 
that can modify expression phenotypes without altering response to ATRA. 
Importantly, the NanoString dataset itself was sufficient in reliably identifying all 
M3 samples in an unsupervised PCA of the 33-gene validated set. In both our study and 
one other that we analyzed (18), the results of routine cytogenetics conflicted with the 
morphologic diagnosis in several samples, but all PML-RARA+ samples were 
appropriately clustered by PCA.  This conflict is important since ATRA is critical for the 
proper treatment of M3 AML patients. When treated with ATRA, patients with M3 AML 
have a significantly higher survival rate than those with other FAB subtypes (28). 
Moreover, due to the risk of disseminated intravascular coagulation in M3 AML, rapid, 
highly accurate diagnosis and initiation of therapy are crucial for optimal patient 
outcomes. Although most cases of M3 AML can be diagnosed using routine methods, a 
substantial number present atypically (i.e., without evidence for the reciprocal 
translocation [ref. 29], with atypical morphology, or with normal cytogenetics [ref. 18]).  
The findings of this study may have implications for other types of cancer as well. 
For example, the diagnosis of solid tumors is often made from fine needle biopsies, 
which retrieve a small amount of tissue containing relatively few tumor cells. Depending 
upon the type of needle used and the ratio of tumor cells to stroma, a few hundred 
thousand to one million cells are typically extracted (30). Given the typical RNA yield of 
a metabolically active tumor cell, fine needle biopsies from solid tumors would likely 
provide sufficient RNA for nCounter assays of hundreds of genes.  
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In summary, we have identified and validated a set of genes that is significantly 
and specifically dysregulated in M3 relative to other subtypes of AML and normal 
myeloid cells, including promyelocytes. The nCounter method used to validate this 
signature is precise, sensitive, and automated and requires only 300 ng of RNA to assay 
up to several hundred genes in triplicate. The manufacturer provides custom probes, and 
the assay can be performed on site in a research or clinical lab. With the advent of this 
innovative technology, a more extensive validation of microarray-based signatures in 
precious clinical samples is now attainable. Extensive validation of dysregulated genes 
from clinical samples will allow us to more confidently assess the gene expression 
profiles of parallel studies performed in different laboratories and to more precisely 
evaluate model systems for human cancers. Furthermore, use of the nCounter method to 
assay the M3-specific signature provides a valuable diagnostic tool and offers the 
potential to assay the expression of hundreds of genes in very small clinical samples. 
 
2.5.  Methods 
2.5.1.  Human AML and normal sorted bone marrow samples.  
Seventy-seven de novo adult AML bone marrow aspirates, including 14 M3 
samples, were analyzed. Patient selection has been described previously (23); patient 
characteristics are summarized in Table 2-1.  Bone marrow aspirates were also obtained 
from healthy adult donors. This study was approved by the Human Research Protection 
Office at Washington University School of Medicine after patients and donors provided 
informed consent in accordance with the Declaration of Helsinki. Isolation of normal 
promyelocytes and neutrophils was performed as described previously (22). Briefly, 
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high-speed cell sorting isolated CD9–, CD14–, CD15hi, and CD16lo promyelocytes and 
CD9–, CD14–, CD15hi, and CD16hi neutrophils (Figure 1, A and B).  MACS sorting 
was performed to isolate normal CD34+ cells according to the manufacturer’s 
instructions (Miltenyi Biotec).  For all samples, sufficient cells were collected to perform 
the standard 1-cycle in vitro transcription protocol; this strategy avoids the bias 
introduced by linear amplification (2-cycle) required for small amounts of RNA. Sorted 
cells were lysed in Trizol reagent (Invitrogen) and stored at –80°C until RNA 
purification. RNA from AML bone marrow aspirates was prepared from unfractionated 
snap-frozen cell pellets using Trizol reagent. RNA from all samples was quantified using 
UV spectroscopy (Nanodrop Technologies) and qualitatively assessed using a 
BioAnalyzer 2100 and RNA NanoChip assay (Agilent Technologies). An additional 93 
de novo AML bone marrow samples, described previously (23), were obtained from C. 
Bloomfield and M. Caligiuri, both of The Ohio State University Comprehensive Cancer 
Center and James Cancer Hospital & Solove Research Institute, Columbus, Ohio, USA; 
J. Vardiman of the University of Chicago, Chicago, Illinois, USA; and the Cancer and 
Leukemia Group B Tumor Bank, Chicago, Illinois and processed using the same methods 
as the samples from Washington University School of Medicine. Samples were labeled 
and hybridized to Affymetrix Human Genome U133 Plus 2.0 Array GeneChip 
microarrays (Affymetrix) using standard protocols from the Laboratory for Clinical 
Genomics (http://www.pathology.wustl.edu/research/lcgoverview.php; ref. 27).  Profiling 
data for all samples have been deposited on the Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/; accession no. GSE12662).  
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2.5.2.  Analysis of AML and normal myeloid datasets.  
To find genes that are differentially expressed in M3 in comparison with M0, M1, 
M2, and M4 subtypes, all probe sets with fewer than 10% present calls in both groups 
and less than 0.5 coefficient of variation across all samples were eliminated from further 
analysis. The remaining probe sets were analyzed using significance analysis of 
microarrays, 2-class analysis; 3,787 probe sets were significant at an FDR of 0.05. The 
normal myeloid developmental signature was defined by probe sets that were 
significantly different among CD34+, promyelocytes, and neutrophils at an ANOVA-
adjusted P < 0.05 after multiple test correction. Probe sets specific to each developmental 
class were defined as having a significantly higher average expression in one class 
relative to both other classes (adjusted P < 0.05), yielding 2,622 CD34+-specific, 371 
promyelocyte-specific, and 601 neutrophil-specific probe sets.  
 
2.5.3.  Cell lines 
NB-4 cells were obtained from ATCC.  PR-9 cells were a gift of P. Pelicci of the 
European Institute of Oncology, Milan, Italy (21). All cell lines were maintained in RPMI 
1640 with 10% fetal calf serum. PR-9 cells were induced in 100 µM ZnSO4 diluted in 
medium. Cell lysates were collected at 0, 2, 4, 8, 16, and 24 hours after induction. RNA 
was isolated, quantified, and hybridized to microarrays as described above.  
 
2.5.4.  Western blots 
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Prior to lysis, 2 × 106 cells were incubated in the presence of 100 µM diisopropyl-
fluorophosphate (Sigma-Aldrich), then lysed in 100 µl 2% SDS/PBS. Total protein (20 
µg) was electrophoresed and Western blotting performed as previously described (5).  
 
2.5.5.  NanoString nCounter assay 
Details of the nCounter Analysis System (NanoString Technologies) were 
reported previously (1). In brief, 2 sequence-specific probes were constructed for each 
gene of interest (Table 2-6).  The probes were complementary to a 100-base region of the 
target mRNA. One probe was covalently linked to an oligonucleotide containing biotin 
(the capture probe), and the other was linked to a color-coded molecular tag that provided 
the signal (the reporter probe; see ref. 1). The nCounter CodeSet for these studies 
contained probe pairs for 73 test and control genes. Forty-six probe pairs were specific 
for Homo sapiens genes, and 28 corresponded to various nCounter system controls, 
including a standard curve. Detailed sequence information for the capture probes and 
reporter probes is listed in Table 2-6.  Each sample was hybridized in triplicate with 100 
ng of total RNA in each reaction.  All 46 genes and controls were assayed simultaneously 
in multiplexed reactions (for details, see ref. 1).  To account for slight differences in 
hybridization and purification efficiency, the raw data were normalized to the standard 
curve generated via the nCounter system spike-in controls present in all reactions.  
 
2.5.6.  qRT-PCR 
One-step qRT-PCR was performed on 20 ng total RNA using the QuantiTect 
SYBR Green RT-PCR kit and QuantiTect Primer assays (Qiagen) on a Prism 7300 real-
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time PCR system (Applied Biosystems) according to the manufacturer’s instructions. All 
reactions were performed in triplicate. Expression was normalized to GAPDH using the 
∆Ct method. 
 
2.5.7.  Analysis software 
For a significance analysis of microarrays, depending on the sample set, 2-class or 
multi-class analysis was performed. An FDR cutoff of 0.05 was used (http://www-
stat.stanford.edu/~tibs/SAM/) (25). For GSEA, depending on the sample size, phenotype 
or gene set permutation analysis with ratio-of-classes or signal-to-noise gene ranking 
were performed using GSEA (http://www.broad.mit.edu/gsea) (19, 20). Spotfire 
DecisionSite 8.2 software (TIBCO) was used in PCA and Wards hierarchical clustering.  
 
2.5.8.  Statistics  
P values for NanoString nCounter and qRT-PCR data were calculated using a 
Student’s 2-tailed t test and were considered significant when P < 0.05. Correlation 
coefficients for comparison of nCounter and microarray data were calculated as follows: 
each patient data point was transformed to a percentile of the maximum value for that 
particular probe set (microarray) or probe (nCounter). Microarray and nCounter 
percentiles were plotted against each other (see Figure 5) and the Pearson’s correlation 
coefficient R calculated. Correlation coefficients were considered significant if greater 
than 0.374, which corresponds to P < 0.05.  
Note that the T statistic for R is calculated by the formula T = R√(n – 2) / √(1 – 
R2).  T = 2.056 when P = 0.05 with a 2-tailed distribution. Using T = 2.056 and n = 28 
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(the total number of AML samples assayed by both Affymetrix microarrays and 
nCounter), the equation was solved for R (R = 0.374), meaning that any R value greater 
than 0.374 was statistically significant (P < 0.05). 
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2.8.  Figure Legends 
 
Figure 2-1.  Isolation and expression profiling of myeloid cells.  
(A) High-speed cell sorting of bone marrow aspirates from healthy donors. FSC, forward 
scatter; PMNs, polymorphonuclear cells; Pros, promyelocytes; SSC, side scatter.  (B) 
May Grunwald/Giemsa–stained cytospins of sorted promyelocytes (left; average purity, 
80% promyelocytes, 11% myelocytes) and neutrophils (right; average purity, 74% mature 
granulocytes with segmented nuclei, 21% bands [immediate precursor stage prior to the 
mature granulocyte, characterized by horseshoe-shaped nuclei]). Original magnification, 
×100.  (C) Microarray signal intensity data demonstrate the expected stage-specific 
expression of early, middle, and late developmental myeloid genes in each fraction, with 
minimal expression in other fractions.  Data are mean ± SD. (D) Heat map of microarray 
data demonstrates a progression of expression from less differentiated to terminally 
differentiated myeloid cells.  Red indicates relatively upregulated expression. Green 
indicates relatively downregulated expression.  
 
Figure 2-2.  Identification of the M3-specific dysregulome:  genes with significantly 
different expression in M3 compared with other AML subtypes and normal 
promyelocytes.  
(A) Heat map of microarray data demonstrates clear separation of 2,023 significantly up- 
or downregulated genes in M3 samples compared with other AML subtypes, although 
some genes were expressed at similar levels in normal and malignant (M3) 
promyelocytes (markers of promyelocyte differentiation).  (B) The genes from A were 
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filtered, by comparison with normal myeloid cells (including normal promyelocytes), to 
retain only those genes with M3-specific expression (510 genes).  
 
Figure 2-3.  Identification of genes with significantly different expression in M3 
compared to normal myeloid cell fractions.  
(A) Heatmap of microarray data shows genes that are normally expressed only in CD34+ 
cells, but are aberrantly expressed in M3 cells.  (B) Heatmap of microarray data shows 
genes that are normally expressed in promyelocytes, but not expressed in M3 AML cells.  
(C) Heatmap of microarray data shows genes with very high expression levels in M3 
cells, but little or no expression in any normal myeloid fraction. 
 
Figure 2-4.  Validation of NanoString nCounter system performance by comparison 
with microarray results for calibration genes.  
A total of 28 AML (11 M3, 17 other AML subtypes), 2 CD34+, 5 promyelocyte, 
and 2 neutrophil samples were analyzed.  Expression is plotted as a percentage ([sample 
signal/signal of index group] × 100) because the microarray and nCounter system data 
were expressed in different units. Asterisks indicate the signal index group for each 
graph.  The NanoString results showed the expected pattern of expression for all 6 genes.  
(A) Expression of early myeloid-specific hematopoietic genes in CD34+ cells, 
promyelocytes, neutrophils, M3 AML, and other FAB subtypes (oAML) as measured by 
the Affymetrix microarray (red) and NanoString nCounter system (green).  (B) 
Promyelocyte-specific genes.  (C) Late myeloid–specific genes.  
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Figure 2-5.  Validation of the M3-specific signature by the NanoString nCounter 
system.  
(A–D) Expression of (A) HGF, (B) FAM19A5, (C) NRIP1, and (D) TNFRSF1B as 
measured by the Affymetrix Hu133+2 microarray (left panels) and the nCounter system 
(right panels). The same samples are plotted as in Figure 3.  Each data point represents 1 
patient sample. The horizontal line indicates the mean of each group.  For microarray 
plots, each data point represents 1 sample (either patient or sorted normal cells) and 
indicates signal intensity for a single probe set on 1 microarray.  For nCounter plots, each 
data point represents the mean normalized counts for 3 technical replicate measurements 
of 1 sample (either patient or sorted normal cells).  
 
Figure 2-6.  Comparison plots of NanoString nCounter with Affymetrix GeneChip 
data for M3-specific genes.  
(A and B) Scatter plots show the percentage of maximum expression per probe/probe set 
in all samples for microarray data versus that for nCounter data. Correlation coefficients 
demonstrate significant correlation between the microarray and nCounter data. (A) 
Upregulated genes (HGF and FAM19A5), (B) downregulated genes (NRIP1 and 
TNFRSF1B), and (C) log2 (M3/other AML) fold change ratios as measured by 
Affymetrix arrays (x axis) and NanoString assay (y axis) for 37 highly dysregulated 
genes.  The linear fit of the ratios in both assays yielded a correlation coefficient of 0.963.   
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Figure 2-7.  The validated 33-gene M3-specific signature is consistently dysregulated 
in other AML datasets and a mouse model of APL, but not in a PML-RARA+ cell 
line.  
The top portion of each GSEA plot shows the running enrichment score for the validated 
M3-specific genes as the analysis moves down the ranked list.  The peak score for each 
plot is the enrichment score for the gene set.  The bottom portion of each plot shows the 
value of the ranking metric as it moves down the list of ranked genes.  The FDR is an 
expression of the significance level of the enrichment, after multiple test correction.  (A) 
GSEA plot of 325 M0–M4 AML samples (GSE6891), comparing M3 with other FAB 
subtypes, demonstrates significant enrichment.  (B) GSEA plot of mCG-PML-RARA 
murine APL cells (20, 24) compared with day 2 wild-type murine myeloid cells (mostly 
promyelocytes) demonstrates significant enrichment.  (C) GSEA plot of uninduced 
versus PML-RARA–induced PR-9 cells demonstrates no enrichment of the M3-specific 
genes at any time point.  
 
Figure 2-8.  Zn2+ treatment induces PML-RARA expression and up-regulation of 
known downstream targets in PR-9 cells.  
(A) Western blot showing PML-RARA and actin protein levels at 0, 2, 4, 8, 16 and 24 
hours post Zn2+-induction.  NB4 cells, which express PML-RARA, serve as a positive 
control in lane 1.  (B) Expression of PML, RARA, PU.1 and CCNA1 in other AML 
(oAML) subtypes, M3, and PR-9 cells 0-24 hours post Zn2+-induction.  All are 
upregulated after PML-RARA induction, as expected.  Inset: MTX1, a known Zn-
responsive gene, is also upregulated after Zn2+ treatment. 
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Figure 2-9.  The NanoString-validated, 33-gene M3-specific signature reliably 
identifies M3 samples, including those with normal cytogenetics and/or ambiguous 
morphology.  
PCA plots of the validated gene expression data demonstrate a clear separation of M3 
t(15;17)-positive samples (red) from other FAB subtypes (gray).  (A) Data from the 
Washington University AML discovery set, including 15 M3 and 62 M0, M1, M2, and 
M4 AML samples (1).  The PCA plot shows clustering of all M3 samples with the PML-
RARA rearrangement, but not of 1 sample with an M3 morphological diagnosis, normal 
cytogenetics, and negative FISH that did not respond to ATRA therapy (blue).  (B) 
NanoString nCounter expression data were sufficiently robust to separate 11/11 of M3 
t(15;17)-positive samples from other FAB subtypes.  (C) M3 samples from a published 
dataset (GSE6891) formed a distinct cluster separate from other FAB subtypes (total of 
325).  M3s with t(15;17) that were missed by routine cytogenetics (yellow) and a 
t(15;17)-positive sample morphologically classified as M2 (green) were also assigned 
appropriately to the M3 cluster.  (D) A total of 19/20 M3s with t(15;17) from a CALGB 
sample set clustered separately from 73 other FAB subtypes.  
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Table 2-1:  Clinical characteristics of patients and de novo AML samples 
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Table 2-2.  The M3 specific dysregulome 
Figure 2-2B 
Probeset Gene Symbol 
215409_at AGPAT7
228264_at ACCS
200862_at DHCR24
218043_s_at AZI2
218051_s_at NT5DC2
201790_s_at DHCR7
215483_at AKAP9
225098_at ABI2
49452_at ACACB
200974_at ACTA2
208002_s_at ACOT7
204497_at ADCY9
225342_at AK3L1
226718_at AMIGO1
228094_at AMICA1
209122_at ADFP
201792_at AEBP1
212285_s_at AGRN
232810_at AIG1
223092_at ANKH
213035_at ANKRD28
201590_x_at ANXA2
203074_at ANXA8 /// ANXA8L1 /// ANXA8L2
219366_at AVEN
39248_at AQP3
207076_s_at ASS1
218694_at ARMCX1
230244_at UNQ830
205047_s_at ASNS
210192_at ATP8A1
219660_s_at ATP8A2
201242_s_at ATP1B1
203505_at ABCA1
1554918_a_at ABCC4
212599_at AUTS2
214575_s_at AZU1
218792_s_at BSPRY
205681_at BCL2A1
205839_s_at BZRAP1
207693_at CACNB4
221042_s_at CLMN
221879_at CALML4
212586_at CAST
200935_at CALR
211031_s_at CLIP2
201850_at CAPG
227522_at CMBL
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205624_at CPA3
209790_s_at CASP6
205653_at CTSG
214450_at CTSW
203323_at CAV2
214523_at CEBPE
217078_s_at CD300A
218529_at CD320
213539_at CD3D
200663_at CD63
201005_at CD9
206761_at CD96
221556_at CDC14B /// CDC14C
217849_s_at CDC42BPB
232355_at ---
233422_at ---
236787_at ---
243937_x_at BMS1P5 /// CTGLF1 /// CTGLF6 /// CTGLF7
223513_at CENPJ
224794_s_at CERCAM
229958_at CLN8
213385_at CHN2
226473_at CBX2
218829_s_at CHD7
205944_s_at CLTCL1
208792_s_at CLU
205229_s_at COCH
204363_at F3
201161_s_at CSDA
229168_at COL23A1
205382_s_at CFD
213800_at CFH
225129_at CPNE2
202119_s_at CPNE3
211709_s_at CLEC11A
232466_at CUL4A
205899_at CCNA1
200953_s_at CCND2
224851_at CDK6
213348_at CDKN1C
209644_x_at CDKN2A
205518_s_at CMAH
217889_s_at CYBRD1
209975_at CYP2E1
223377_x_at CISH
219837_s_at CYTL1
222101_s_at DCHS1
239648_at DCUN1D3
224215_s_at DLL1
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228293_at DEPDC7
218854_at DSE
226817_at DSC2
201681_s_at DLG5
215102_at DPY19L1P1
238784_at DPY19L2
215116_s_at DNM1
212838_at DNMBP
233850_s_at EBF4
201693_s_at EGR1
204160_s_at ENPP4
206580_s_at EFEMP2
206871_at ELA2
204163_at EMILIN1
213779_at EMID1
204503_at EVPL
223253_at EPDR1
231944_at ERO1LB
236700_at EIF3C
209365_s_at ECM1
231846_at FOXRED2
229459_at FAM19A5
1568865_at FNTB
210933_s_at FSCN1
216080_s_at FADS3
227222_at FBXO10
224162_s_at FBXO31
1560031_at FRMD4A
205110_s_at FGF13
211535_s_at FGFR1
204379_s_at FGFR3
223321_s_at FGFRL1
218618_s_at FNDC3B
202995_s_at FBLN1
210220_at FZD2
202862_at FAH
234192_s_at GKAP1
228770_at GPR146
64942_at GPR153
204537_s_at GABRE
208438_s_at FGR
215659_at GSDML
223319_at GPHN
224839_s_at GPT2
205164_at GCAT
208798_x_at GOLGA8A
210425_x_at GOLGA8A /// GOLGA8B
238002_at GOLIM4
217771_at GOLM1
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31874_at GAS2L1
216860_s_at GDF11
215248_at GRB10
229377_at GRTP1
219777_at GIMAP6
213766_x_at GNA11
207124_s_at GNB5
226840_at H2AFY
211936_at HSPA5
227361_at HS3ST3B1
201655_s_at HSPG2
203821_at HBEGF
209960_at HGF
235500_at HNRNPC
235468_at HRNBP3 /// LOC100130312 
205936_s_at HK3
225601_at HMGB3
222126_at HRBL
226651_at HOMER1
231050_at HRASLS5
211728_s_at HYAL3 /// NAT6
200825_s_at HYOU1
1554452_a_at HIG2
202660_at ITPR2
202718_at IGFBP2
211959_at IGFBP5
201163_s_at IGFBP7
202746_at ITM2A
1555349_a_at ITGB2
226535_at ITGB6
224514_x_at IL17RC
212195_at IL6ST
213392_at IQCK
230472_at IRX1
229638_at IRX3
210239_at IRX5
209099_x_at JAG1
211202_s_at JARID1B
201466_s_at JUN
212813_at JAM3 /// LOC100133502
220010_at KCNE1L
243428_at KCNQ1OT1
212236_x_at KRT17
201596_x_at KRT18
234307_s_at KIF26A
216264_s_at LAMB2
200771_at LAMC1
244881_at LMLN
205381_at LRRC17
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206076_at LRRC23
1559502_s_at LRRC25
239471_at LRRC28
235359_at LRRC33
210784_x_at LILRA6 /// LILRB3
207106_s_at LTK
208771_s_at LTA4H
206480_at LTC4S
218656_s_at LHFP
212658_at LHFPL2
204381_at LRP3
209468_at LRP5
207734_at LAX1
206960_at LPAR4
227145_at LOXL4
216320_x_at MST1
213380_x_at MSTP9
209823_x_at HLA-DQB1
206111_at hCG_1998957 /// HLA-DQB1
204059_s_at ME1
37408_at MRC2
221713_s_at MAP6D1
210794_s_at MEG3
201069_at MMP2
212509_s_at MXRA7
235409_at MGA
35147_at MCF2L
210254_at MS4A3
224356_x_at MS4A6A
211456_x_at MT1P2
213629_x_at MT1F
208581_x_at MT1X
212185_x_at MT2A
226852_at MTA3
1554127_s_at MSRB3
201761_at MTHFD2
224918_x_at MGST1
203151_at MAP1A
203208_s_at MTFR1
35617_at MAPK7
205447_s_at MAP3K12
225997_at MOBKL1A
226844_at MOBKL2B
221636_s_at MOSC2
234224_at ---
225185_at MRAS
207895_at NAALADL1
228523_at NANOS1
220429_at NDST3
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224802_at NDFIP2
227870_at NOPE
223638_at NBPF3
218888_s_at NETO2
209949_at NCF2
212803_at NAB2
202237_at NNMT
1552553_a_at NLRC4
231798_at NOG
227556_at NME7
202599_s_at NRIP1
219557_s_at NRIP3
203920_at NR1H3
207202_s_at NR1I2
1559139_at NOC2L
212775_at OBSL1
213125_at OLFML2B
213825_at OLIG2
228170_at OLIG1
225105_at OCC-1
223464_at OSBPL5
226435_at PAPLN
227204_at PARD6G
209815_at PTCH1
210139_s_at PMP22
212012_at PXDN
208510_s_at PPARG
204604_at PFTK1
226150_at PPAPDC1B
207621_s_at PEMT
208591_s_at PDE3B
201481_s_at PYGB
222688_at PHCA
235411_at PGBD1
219225_at LOC100134440 /// PGBD5
220798_x_at PRG2
205463_s_at PDGFA
220952_s_at PLEKHA5
228171_s_at PLEKHG4
1553139_s_at PLXNA3
241742_at PRAM1
212662_at PVR
203688_at PKD2
226245_at KCTD1
212192_at KCTD12
222668_at KCTD15
239763_at LOC100129965 /// PRDM11
226065_at PRICKLE1
200656_s_at P4HB
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226423_at PAQR8
214203_s_at PRODH
205618_at PRRG1
211748_x_at PTGDS
207650_x_at PTGER1
213933_at PTGER3
231323_at PSMB2
208658_at PDIA4
226101_at PRKCE
225203_at PPP1R16A
204944_at PTPRG
1555579_s_at PTPRM
219654_at PTPLA
232473_at PRPF18
220005_at P2RY13
206277_at P2RY2
235634_at PURG
222087_at PVT1
201251_at PKM2
201482_at QSOX1
202252_at RAB13
219412_at RAB38
230266_at RAB7B
222810_s_at RASAL2
215620_at RREB1
219167_at RASL12
226597_at REEP6
212589_at RRAS2
220570_at RETN
228550_at RTN4R
226638_at ARHGAP23
202975_s_at RHOBTB3
212912_at RPS6KA2
205228_at RBMS2
228802_at RBPMS2
218394_at ROGDI
213939_s_at RUFY3
202917_s_at S100A8
203535_at S100A9
209686_at S100B
201825_s_at SCCPDH
206671_at SAG
215641_at SEC24D
209875_s_at SPP1
203021_at SLPI
219689_at SEMA3G
221696_s_at STYK1
202628_s_at SERPINE1
200986_at SERPING1
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207714_s_at SERPINH1
212921_at SMYD2
224817_at SH3PXD2A
1554343_a_at STAP1
244889_at LOC388210
204900_x_at SAP30
203787_at SSBP2
221562_s_at SIRT3
206634_at SIX3
232636_at SLITRK4
232020_at SMURF2
219480_at SNAI1
219593_at SLC15A3
207057_at SLC16A7
204430_s_at SLC2A5
219090_at SLC24A3
232280_at SLC25A29
205097_at SLC26A2
220475_at SLC28A3
238418_at SLC35B4
234976_x_at SLC4A5
201195_s_at SLC7A5
228654_at SPIN4
224995_at SPIRE1
218638_s_at SPON2
225639_at SKAP2
210942_s_at ST3GAL6
204150_at STAB1
231891_at STAMBPL1
204548_at STAR
201061_s_at STOM
202260_s_at STXBP1
214708_at SNTB1
233719_s_at TASP1
222116_s_at TBC1D16
227632_at TBC1D24
206301_at TEC
218872_at TESC
220623_s_at TSGA10
219587_at TTC12
219838_at TTC23
215146_s_at TTC28
225308_s_at TANC1
203313_s_at TGIF1
229253_at THEM4
220384_at TXNDC3
201666_at TIMP1
204043_at TCN2
226197_at ---
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230408_at ---
230684_at ---
237945_at ---
238024_at ---
244352_at ---
1555348_at TFAP2E
238520_at TRERF1
228284_at TLE1
244716_x_at TMIGD2
1554077_a_at TMEM53
235245_at TMEM92
203476_at TPBG
209344_at TPM4
239742_at TULP4
209191_at TUBB6
228285_at TDRD9
207113_s_at TNF
203508_at TNFRSF1B
214228_x_at TNFRSF4
202286_s_at TACSTD2
213943_at TWIST1
206828_at TXK
238057_at USP45
232621_at USP48
236597_at UGT3A1
203188_at B3GNT1
205844_at VNN1
235818_at VSTM1
219251_s_at WDR60
243526_at WDR86
206067_s_at WT1
218775_s_at WWC2
228788_at YPEL1
226137_at ZFHX3
205739_x_at ZNF107
234394_at ZNF124
235728_at ZFP3
222016_s_at ZNF323
205514_at ZNF415
205964_at ZNF426
1555793_a_at ZNF545
223680_at ZNF607
228864_at ZNF653
227080_at ZNF697
228988_at ZNF711
206059_at ZNF91
1562303_at ZKSCAN3
219247_s_at ZDHHC14
219628_at ZMAT3
210282_at ZMYM2
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Table 2-3:  M3-specific signature’s most dysregulated genes:  average microarray 
expression, fold change and FDR 
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Table 2-4:  M3-specific signature’s most dysregulated genes:  comparison of 
microarray and nCounter fold changes and nCounter average signal, and qRT-PCR 
validation. 
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Table 2-5:  Data from nCounter assays of AML samples and normal myeloid cells 
M0 M0 M0 M0 M0 M0 M0 M0 M0 M0 M0 M0 M1 M1 M1
Accession No. Gene Name/Sample ID 4528 4528 4528 4532 4532 4532 6742 6742 6742 17366 17366 17366 4534 4534 4534
NM_002841.2 PTPRG 5 2 4 0 1 0 2 2 0 3 0 3 1 0 2
NM_145256.2 LRRC25 176 175 165 2 1 3 3 3 2 9 10 8 23 22 21
NM_001972.2 ELA2 5 2 2 0 4 0 2 2 1 24 23 22 174 188 150
NM_000597.2 IGFBP2 25 12 23 0 1 0 9 5 6 8 1 5 90 79 66
NM_005413.1 SIX3 5 17 0 7 1 1 2 1 1 8 4 3 3 0 2
NM_006272.1 S100B 7 3 8 1 0 6 6 4 6 14 20 11 3 4 3
NM_003327.2 TNFRSF4 5 3 0 0 1 1 0 3 1 3 0 4 1 2 3
NM_004049.2 BCL2A1 356 363 334 17 15 10 86 76 75 42 44 35 69 61 57
NM_001911.2 CTSG 7 5 4 1 0 3 0 1 1 45 30 42 456 481 469
NM_001557.2 IL8RB 36 47 36 6 1 1 3 1 4 9 10 11 15 9 14
NM_001066.2 TNFRSF1B 845 862 760 9 5 7 19 11 11 35 49 43 115 139 101
NM_002046.3 GAPDH 3533 3587 3208 1929 1762 1790 4100 3649 3447 2494 2367 2687 4885 5088 4813
NM_006169.2 NNMT 2 2 4 0 2 3 2 2 1 3 6 5 6 3 1
NM_015381.3 FAM19A5 2 0 0 4 0 1 1 1 1 1 0 1 2 0 0
NM_015136.2 STAB1 194 195 178 7 7 8 156 112 114 14 19 26 151 115 123
NM_002029.3 FPR1 282 255 283 4 1 3 5 8 5 10 19 15 38 29 19
NM_003930.3 SCAP2 52 45 32 21 19 25 12 15 15 14 10 14 19 32 21
NM_006486.2 FBLN1 2 2 0 0 0 1 0 0 0 1 1 0 0 0 1
NM_153206.1 AMICA1 2 5 2 0 0 0 1 1 0 3 0 1 1 1 0
NM_002965.2 S100A9 6135 6132 5334 11 6 3 290 231 214 873 809 849 895 792 794
NM_021209.3 CARD12/NLRC4 56 33 38 2 1 10 2 2 4 13 9 12 13 9 9
NM_000433.2 NCF2 933 1005 861 4 2 6 13 9 9 90 104 103 105 128 102
NM_003489.2 NRIP1 74 65 56 54 56 51 1 3 2 36 30 26 33 17 19
NM_001040084.1 LOC653107/ANXA8 2 2 4 0 1 0 2 1 1 3 0 1 2 0 0
NM_016582.1 SLC15A3 83 83 114 0 1 6 1 3 1 19 9 14 8 9 8
NM_000211.2 ITGB2 1710 1648 1340 109 85 117 147 134 129 196 151 174 418 427 382
NM_000601.4 HGF 56 35 53 31 29 32 31 41 30 9 13 15 2 2 4
NM_182961.1 SYNE1 41 35 11 17 13 13 12 19 18 33 36 37 17 12 8
NM_001042729.1 FGR 1649 1506 1370 9 1 8 90 86 67 101 87 124 339 306 270
NM_001614.2 ACTG1 4209 4072 3381 2051 1782 1754 2154 1778 1840 2854 2726 2720 4114 3423 3280
NM_138444.2 KCTD12 264 260 221 1 1 4 2 8 7 17 14 14 36 34 30
NM_002964.3 S100A8 9494 9373 8823 21 23 19 637 531 509 2010 2096 1911 1532 1347 1274
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 18 17 11 131 123 128 159 151 116 22 20 20 2 2 1
NM_000474.3 TWIST1 2 3 6 1 0 0 2 0 1 0 3 3 3 4 2
NM_015869.3 PPARG 7 8 9 0 1 0 2 0 1 1 1 3 4 5 2
NM_004666.1 VNN1 9 12 11 4 2 4 3 1 3 1 3 0 17 12 21
NM_005874.1 LILRB2 509 516 490 39 44 39 37 34 27 32 49 37 98 77 86
NM_001005463.1 EBF3 2 5 4 6 2 1 5 3 2 0 3 3 3 5 2
NM_152852.1 MS4A6A 79 68 53 1 4 0 2 1 1 15 9 18 8 8 6
NM_000954.5 PTGDS 0 0 0 2 0 0 0 0 1 0 3 0 1 0 0
NM_000222.1 KIT 5 12 2 66 67 60 24 24 22 4 6 9 38 52 57
NM_004961.3 GABRE 0 2 2 2 0 3 2 1 0 1 0 1 3 2 1
NM_007261.2 CD300A 11 17 9 6 10 6 9 3 8 56 53 57 9 8 11
NM_002115.1 HK3 99 75 64 1 1 0 2 1 1 8 4 9 10 9 12
NM_023914.2 P2RY13 340 316 291 17 11 10 6 16 8 18 11 11 55 52 44
NM_033642.1 FGF13 0 2 0 1 1 1 1 1 1 1 1 0 1 1 0
AF324996.2 Athal_Spike_S23 1829 1841 1822 1853 1765 1800 1846 1855 1837 1832 1873 1858 1806 1871 1823
AF325027.2 Athal_Spike_S14 692 759 762 726 775 755 730 728 715 746 759 738 731 729 716
AF325042.2 Athal_Spike_S19 527 479 505 518 546 533 532 518 519 497 493 502 548 504 569
AY058560.1 DrosSpike8 194 158 189 179 158 202 171 165 184 195 181 180 181 183 175
AF325027.2 Athal_Spike_S13 95 72 58 79 94 68 69 87 78 82 64 78 66 80 71
AF324998.2 Athal_Spike_S22 81 98 96 77 100 88 84 83 91 88 67 73 87 72 76
AY058658.1 DrosSpike7 32 37 23 33 27 14 31 27 36 21 24 30 42 23 28
AF325032.2 Athal_Spike_S17 34 40 28 25 23 24 26 23 27 24 27 28 26 26 31
DQ412624 SarsSpike3 7 15 13 5 7 11 7 6 6 8 3 7 10 8 6
AY058658.1 DrosSpike6 9 0 4 4 4 6 2 6 6 5 7 4 1 3 3
AY058560.1 DrosSpike10 2 2 2 0 2 0 2 0 1 4 0 1 2 0 1
AY058658.1 DrosSpike11 2 0 2 1 5 0 0 2 0 0 0 3 2 3 0
AF325014.2 Athal_Spike_S12 2 3 0 4 6 3 3 2 5 4 1 9 5 3 3
AF325016.2 Athal_Spike_S15 5 2 0 6 1 8 4 2 3 3 3 3 3 2 3
AF325016.2 Athal_Spike_S16 2 5 8 2 1 3 2 2 1 5 1 0 3 4 3
AF325032.2 Athal_Spike_S18 7 5 2 2 1 0 3 2 0 3 1 1 2 2 2
AF324998.2 Athal_Spike_S20 2 2 2 0 4 6 0 2 3 9 1 3 4 2 2
AF324998.2 Athal_Spike_S21 0 5 0 2 2 4 3 3 3 8 6 1 4 2 2
AF324998.2 Athal_Spike_S24 0 10 6 2 2 6 0 1 1 4 4 3 4 2 5
DQ412624 SarsSpike4 5 3 0 2 0 1 7 1 4 5 6 1 3 2 6
AY058560.1 DrosSpike9 5 2 0 2 2 1 2 1 1 0 0 0 3 1 0
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M1 M1 M1 M1 M1 M1 M1 M1 M1 M1 M1 M1 M2 M2 M2
Accession No. Gene Name/Sample ID 6747 6747 6747 15599 15599 15599 16066 16066 16066 20900 20900 20900 4530 4530 4530
NM_002841.2 PTPRG 2 0 2 1 0 0 0 2 3 0 0 1 1 1 3
NM_145256.2 LRRC25 8 3 0 63 29 38 5 3 4 2 3 2 4 5 7
NM_001972.2 ELA2 38 33 40 25 15 7 3 2 2 3 1 3 49 58 64
NM_000597.2 IGFBP2 131 98 125 39 18 22 11 3 11 11 30 18 2 2 7
NM_005413.1 SIX3 2 0 0 0 0 4 1 0 2 0 5 2 2 1 2
NM_006272.1 S100B 2 0 0 7 3 4 7 2 1 0 2 5 5 6 4
NM_003327.2 TNFRSF4 2 5 0 0 2 0 2 0 1 1 2 1 2 0 2
NM_004049.2 BCL2A1 17 20 35 14 21 18 8 12 5 9 13 8 26 46 19
NM_001911.2 CTSG 29 45 38 524 549 469 408 414 363 54 22 37 10 14 16
NM_001557.2 IL8RB 0 3 5 10 11 5 1 2 0 1 0 1 7 6 3
NM_001066.2 TNFRSF1B 38 30 24 310 252 264 111 101 92 29 40 35 28 29 35
NM_002046.3 GAPDH 5798 5066 6083 5419 5985 4994 4404 4284 4310 3726 3595 3359 3401 3593 3512
NM_006169.2 NNMT 12 10 12 1 2 2 1 2 2 7 3 2 1 1 2
NM_015381.3 FAM19A5 0 0 0 1 0 2 1 0 0 0 0 1 0 0 0
NM_015136.2 STAB1 21 18 24 34 30 25 9 3 4 3 1 1 35 39 22
NM_002029.3 FPR1 27 8 12 1 15 9 4 3 3 3 2 3 10 19 16
NM_003930.3 SCAP2 33 25 40 22 33 24 31 26 15 20 23 22 19 11 14
NM_006486.2 FBLN1 0 0 0 1 2 2 0 0 1 0 0 0 2 0 0
NM_153206.1 AMICA1 0 0 0 1 6 2 0 0 0 0 0 0 1 0 0
NM_002965.2 S100A9 602 684 654 654 665 529 140 120 108 2 2 3 319 365 375
NM_021209.3 CARD12/NLRC4 4 5 2 35 41 36 10 9 11 5 5 2 9 5 7
NM_000433.2 NCF2 27 20 19 353 309 306 118 122 115 3 4 5 50 59 51
NM_003489.2 NRIP1 35 28 59 21 20 29 57 56 54 59 52 50 26 41 36
NM_001040084.1 LOC653107/ANXA8 4 0 5 1 8 2 4 5 6 2 3 2 3 10 6
NM_016582.1 SLC15A3 8 5 0 18 12 13 2 0 1 3 2 3 4 5 7
NM_000211.2 ITGB2 346 298 391 1030 1175 900 666 585 660 132 135 123 90 106 94
NM_000601.4 HGF 62 78 75 186 154 186 9 16 11 56 59 49 203 214 233
NM_182961.1 SYNE1 2 8 5 25 21 14 21 17 11 8 18 22 3 4 10
NM_001042729.1 FGR 44 35 38 601 616 561 47 40 63 11 6 5 63 78 83
NM_001614.2 ACTG1 2949 3035 3403 5348 4840 4460 5820 5376 5246 3142 3097 3123 2513 2689 2595
NM_138444.2 KCTD12 8 13 9 34 23 9 4 7 2 3 9 7 22 17 22
NM_002964.3 S100A8 1121 1165 1426 1091 916 934 246 310 272 4 2 1 645 670 656
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 17 13 31 7 9 2 21 10 13 3 5 2 125 128 134
NM_000474.3 TWIST1 2 5 0 4 0 2 0 3 4 4 2 4 3 3 5
NM_015869.3 PPARG 0 10 0 1 14 13 2 0 1 1 1 1 1 2 0
NM_004666.1 VNN1 2 8 2 13 11 9 5 9 10 2 0 1 23 20 22
NM_005874.1 LILRB2 12 15 16 159 142 165 142 125 139 46 55 55 57 56 52
NM_001005463.1 EBF3 8 0 5 9 2 4 3 3 3 3 5 3 5 0 5
NM_152852.1 MS4A6A 0 0 2 73 78 63 5 9 2 1 6 3 12 17 20
NM_000954.5 PTGDS 2 8 2 0 0 0 0 0 0 1 0 1 0 0 0
NM_000222.1 KIT 60 83 99 22 18 11 15 12 5 59 74 71 41 54 40
NM_004961.3 GABRE 2 0 7 3 2 0 2 0 1 2 3 3 0 1 0
NM_007261.2 CD300A 4 8 7 10 14 11 13 12 8 0 7 9 4 4 1
NM_002115.1 HK3 2 3 5 24 14 36 4 2 5 1 1 1 5 8 2
NM_023914.2 P2RY13 40 35 40 148 121 100 42 47 29 5 3 1 28 28 20
NM_033642.1 FGF13 2 5 2 1 0 2 0 0 4 0 1 0 0 0 1
AF324996.2 Athal_Spike_S23 1924 1796 1859 1856 1870 1841 1840 1893 1875 1850 1803 1804 1824 1862 1825
AF325027.2 Athal_Spike_S14 667 739 772 727 738 746 678 675 727 752 752 775 740 693 746
AF325042.2 Athal_Spike_S19 506 510 482 500 523 527 566 501 512 496 519 505 528 506 525
AY058560.1 DrosSpike8 175 219 174 185 155 183 198 188 180 173 204 188 180 185 163
AF325027.2 Athal_Spike_S13 92 78 85 66 63 67 72 77 67 70 60 71 79 73 73
AF324998.2 Athal_Spike_S22 79 91 71 97 72 80 88 108 64 91 94 82 83 97 102
AY058658.1 DrosSpike7 29 33 24 29 36 22 28 23 32 32 21 29 35 38 30
AF325032.2 Athal_Spike_S17 21 25 21 29 29 25 20 26 31 25 27 28 20 27 27
DQ412624 SarsSpike3 4 5 7 9 9 7 7 5 9 5 13 10 7 14 6
AY058658.1 DrosSpike6 2 3 5 1 3 2 3 3 2 3 6 5 2 5 4
AY058560.1 DrosSpike10 4 3 2 1 3 0 1 0 3 2 1 1 2 3 1
AY058658.1 DrosSpike11 2 0 2 0 0 0 3 2 0 0 3 1 0 1 1
AF325014.2 Athal_Spike_S12 2 0 0 1 5 2 6 5 4 2 6 6 5 3 1
AF325016.2 Athal_Spike_S15 2 5 2 7 5 2 3 2 10 5 5 4 4 5 7
AF325016.2 Athal_Spike_S16 0 0 0 1 2 5 4 2 1 0 1 3 4 2 2
AF325032.2 Athal_Spike_S18 2 0 0 0 2 0 1 2 4 1 3 2 2 3 3
AF324998.2 Athal_Spike_S20 8 5 2 3 5 2 2 2 3 3 3 3 2 3 6
AF324998.2 Athal_Spike_S21 2 3 0 5 5 4 5 2 1 2 2 4 0 2 2
AF324998.2 Athal_Spike_S24 6 3 2 1 3 0 5 2 4 0 2 5 0 3 2
DQ412624 SarsSpike4 0 0 2 3 0 2 5 2 1 6 4 5 2 6 3
AY058560.1 DrosSpike9 2 3 0 3 2 7 1 0 1 0 0 0 0 4 1
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M2 M2 M2 M2 M2 M2 M2 M2 M2 M3 M3 M3 M3 M3 M3
Accession No. Gene Name/Sample ID 4983 4983 4983 6744 6744 6744 6746 6746 6746 3038 3038 3038 4537 4537 4537
NM_002841.2 PTPRG 2 2 2 2 0 0 1 0 1 9 15 10 13 13 9
NM_145256.2 LRRC25 23 18 19 2 5 3 6 7 4 12 8 15 1 3 2
NM_001972.2 ELA2 124 75 96 3 4 2 95 107 87 239 263 283 109 91 101
NM_000597.2 IGFBP2 4 7 7 23 24 22 13 16 9 115 95 106 319 350 341
NM_005413.1 SIX3 2 4 3 3 7 7 7 8 4 16 16 12 24 27 27
NM_006272.1 S100B 2 2 3 3 19 14 8 19 7 23 32 25 134 126 135
NM_003327.2 TNFRSF4 0 3 1 0 1 3 1 0 1 0 5 0 20 17 18
NM_004049.2 BCL2A1 78 78 83 35 50 35 37 35 28 13 16 10 9 8 11
NM_001911.2 CTSG 223 182 248 107 103 108 6 5 7 671 707 634 156 144 163
NM_001557.2 IL8RB 21 15 23 6 7 3 4 6 4 1 5 5 5 5 2
NM_001066.2 TNFRSF1B 90 60 93 11 18 11 20 12 13 14 11 7 5 4 6
NM_002046.3 GAPDH 2823 1890 2450 2778 3455 3297 2787 2900 1919 4007 4085 3661 3195 2812 2996
NM_006169.2 NNMT 1 1 2 2 1 1 0 1 1 10 5 4 13 19 15
NM_015381.3 FAM19A5 2 0 1 0 1 0 1 0 1 2 3 2 12 7 11
NM_015136.2 STAB1 73 52 65 47 83 70 11 12 7 529 611 518 245 195 255
NM_002029.3 FPR1 86 63 69 2 3 4 11 4 5 3 9 4 2 4 2
NM_003930.3 SCAP2 25 7 21 16 25 24 12 16 7 1 3 1 3 3 7
NM_006486.2 FBLN1 0 0 1 1 3 0 0 0 0 0 0 2 10 6 6
NM_153206.1 AMICA1 2 0 5 0 0 1 0 0 1 0 0 0 2 0 0
NM_002965.2 S100A9 1814 1322 1642 57 53 39 243 238 165 44 63 54 30 20 23
NM_021209.3 CARD12/NLRC4 9 8 12 2 3 3 4 3 4 1 3 2 5 3 2
NM_000433.2 NCF2 156 121 156 19 22 32 31 32 21 29 27 29 21 26 19
NM_003489.2 NRIP1 14 10 12 73 79 63 19 26 15 4 3 4 3 1 2
NM_001040084.1 LOC653107/ANXA8 2 0 2 1 3 0 1 4 0 60 55 72 33 39 62
NM_016582.1 SLC15A3 11 6 8 2 2 1 1 2 2 1 5 2 1 3 3
NM_000211.2 ITGB2 414 275 400 106 141 126 51 55 37 215 223 175 32 28 28
NM_000601.4 HGF 5 3 8 27 24 19 37 40 21 621 778 666 612 606 574
NM_182961.1 SYNE1 5 9 11 6 8 11 15 3 12 8 8 0 8 5 4
NM_001042729.1 FGR 331 267 310 39 35 35 17 12 14 67 54 48 12 7 5
NM_001614.2 ACTG1 2029 1559 1813 1849 2445 2162 2086 2190 1507 3295 3953 3430 1900 1984 1935
NM_138444.2 KCTD12 16 19 25 3 10 4 2 1 4 5 3 4 2 1 2
NM_002964.3 S100A8 3456 2593 3002 100 111 99 662 662 416 119 203 128 31 47 44
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 2 4 2 157 167 205 288 274 202 3 5 4 2 0 2
NM_000474.3 TWIST1 1 2 1 0 1 1 9 6 4 11 7 13 7 10 11
NM_015869.3 PPARG 4 8 5 2 0 2 1 2 2 17 16 12 24 30 30
NM_004666.1 VNN1 14 12 13 15 29 19 1 2 4 1 3 0 1 1 1
NM_005874.1 LILRB2 62 48 59 17 29 24 19 22 12 21 26 17 10 11 10
NM_001005463.1 EBF3 5 6 5 3 2 2 5 0 2 15 14 13 8 6 7
NM_152852.1 MS4A6A 10 5 5 6 3 3 2 3 2 1 1 2 0 5 3
NM_000954.5 PTGDS 3 2 4 0 0 0 1 0 0 114 119 116 12 11 13
NM_000222.1 KIT 12 6 9 43 59 60 70 76 49 28 38 39 28 24 29
NM_004961.3 GABRE 2 3 5 1 1 1 0 3 1 21 31 17 2 7 3
NM_007261.2 CD300A 7 7 5 5 5 6 4 2 0 4 3 5 3 4 2
NM_002115.1 HK3 17 8 6 0 3 1 4 5 1 4 8 6 2 2 5
NM_023914.2 P2RY13 74 49 63 5 3 6 31 25 21 4 4 6 2 6 3
NM_033642.1 FGF13 1 1 1 0 2 2 1 3 5 22 15 11 9 16 9
AF324996.2 Athal_Spike_S23 1897 1764 1772 1800 1810 1818 1792 1814 1808 1784 1759 1759 1820 1806 1800
AF325027.2 Athal_Spike_S14 729 749 785 760 783 776 794 754 757 782 812 803 729 753 782
AF325042.2 Athal_Spike_S19 493 579 513 530 516 504 512 507 524 512 484 490 533 517 512
AY058560.1 DrosSpike8 161 172 190 201 175 194 171 189 179 166 195 211 181 165 174
AF325027.2 Athal_Spike_S13 77 82 80 70 66 63 79 77 65 64 80 65 87 85 75
AF324998.2 Athal_Spike_S22 71 90 87 70 90 86 98 84 87 112 112 96 92 93 80
AY058658.1 DrosSpike7 37 27 32 28 26 23 22 31 39 34 30 32 25 32 27
AF325032.2 Athal_Spike_S17 19 22 25 29 26 23 21 32 32 38 24 29 22 35 33
DQ412624 SarsSpike3 8 12 8 7 4 7 9 9 4 3 1 10 6 9 11
AY058658.1 DrosSpike6 7 3 8 4 3 3 2 4 3 2 3 3 4 4 6
AY058560.1 DrosSpike10 1 0 2 1 0 2 1 1 1 0 1 6 1 0 2
AY058658.1 DrosSpike11 2 2 1 1 0 2 1 1 3 3 1 2 2 2 4
AF325014.2 Athal_Spike_S12 2 3 3 3 3 3 6 4 3 2 1 6 1 7 2
AF325016.2 Athal_Spike_S15 3 4 3 4 3 8 2 5 4 8 5 9 2 4 5
AF325016.2 Athal_Spike_S16 3 0 2 3 3 2 2 2 4 4 4 2 7 4 3
AF325032.2 Athal_Spike_S18 6 6 1 5 0 1 3 1 4 0 3 3 3 2 2
AF324998.2 Athal_Spike_S20 4 4 4 4 4 6 4 5 3 7 4 2 3 4 2
AF324998.2 Athal_Spike_S21 5 5 5 4 1 0 5 4 2 2 3 8 2 6 5
AF324998.2 Athal_Spike_S24 2 3 3 3 1 2 3 4 1 5 3 7 6 2 2
DQ412624 SarsSpike4 5 6 5 2 3 2 5 4 6 5 4 6 2 4 7
AY058560.1 DrosSpike9 5 2 1 2 2 1 1 1 1 1 0 3 2 0 0
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M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3
Accession No. Gene Name/Sample ID 6947 6947 6947 9062 9062 9062 15590 15590 15590 15591 15591 15591 15605 15605 15605
NM_002841.2 PTPRG 24 19 34 8 10 12 5 5 3 9 15 10 29 16 28
NM_145256.2 LRRC25 2 0 2 3 4 4 1 2 1 1 2 0 3 1 1
NM_001972.2 ELA2 325 245 353 438 351 372 388 408 352 183 192 186 213 215 319
NM_000597.2 IGFBP2 435 336 516 525 491 537 269 302 261 268 264 255 369 376 550
NM_005413.1 SIX3 4 4 9 21 22 18 34 22 18 15 14 13 78 71 133
NM_006272.1 S100B 43 26 43 196 165 213 108 113 122 44 36 39 86 86 116
NM_003327.2 TNFRSF4 16 12 16 16 11 8 16 18 23 11 6 3 73 50 87
NM_004049.2 BCL2A1 11 11 11 20 12 20 13 23 10 7 7 16 22 16 23
NM_001911.2 CTSG 534 434 617 2104 2089 2080 829 976 939 610 646 613 1207 1252 1899
NM_001557.2 IL8RB 2 0 2 1 4 8 5 3 4 2 1 2 6 4 7
NM_001066.2 TNFRSF1B 6 8 4 5 6 6 3 6 0 5 3 2 11 3 9
NM_002046.3 GAPDH 4026 3047 4763 5197 5040 5239 5816 6194 5803 2568 2787 2293 5517 5467 8500
NM_006169.2 NNMT 5 5 5 13 15 9 12 23 24 5 4 2 9 19 15
NM_015381.3 FAM19A5 2 5 5 17 17 17 17 23 21 21 20 15 29 42 65
NM_015136.2 STAB1 546 510 721 667 681 697 550 530 569 796 891 693 998 842 1295
NM_002029.3 FPR1 6 4 7 14 8 3 5 6 4 4 4 3 9 8 6
NM_003930.3 SCAP2 1 0 2 3 3 5 0 4 2 2 4 1 9 9 20
NM_006486.2 FBLN1 0 2 1 4 6 10 1 4 1 2 1 3 3 6 4
NM_153206.1 AMICA1 2 0 0 1 1 0 0 2 0 0 0 0 0 1 1
NM_002965.2 S100A9 28 28 48 96 84 107 16 25 20 9 4 10 5 5 4
NM_021209.3 CARD12/NLRC4 0 1 2 2 1 3 3 4 4 2 0 2 0 3 5
NM_000433.2 NCF2 28 20 43 38 27 37 26 22 23 18 26 14 31 17 20
NM_003489.2 NRIP1 2 3 1 4 6 4 16 6 8 3 3 2 6 7 14
NM_001040084.1 LOC653107/ANXA8 243 201 301 45 37 41 81 103 80 98 99 73 56 83 114
NM_016582.1 SLC15A3 1 1 2 8 2 1 1 5 4 2 2 1 1 2 6
NM_000211.2 ITGB2 21 13 21 33 33 41 16 21 23 11 7 22 29 27 54
NM_000601.4 HGF 962 719 1118 940 931 887 828 884 785 527 522 470 1096 1000 1504
NM_182961.1 SYNE1 7 2 14 9 13 15 8 5 8 3 7 5 13 11 13
NM_001042729.1 FGR 7 4 5 5 9 6 6 3 5 6 3 8 4 7 13
NM_001614.2 ACTG1 2937 2469 3799 4984 4897 4826 4636 4778 4599 2180 2432 2034 5431 4789 6845
NM_138444.2 KCTD12 5 0 1 5 5 4 5 2 6 2 0 1 5 3 4
NM_002964.3 S100A8 89 84 101 149 138 147 32 34 34 14 15 13 18 7 19
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 0 3 3 12 10 10 3 5 4 2 2 2 5 7 9
NM_000474.3 TWIST1 17 15 24 44 45 41 48 47 37 15 13 14 11 24 27
NM_015869.3 PPARG 33 20 32 28 27 23 53 48 41 19 15 13 26 23 24
NM_004666.1 VNN1 3 0 0 3 1 1 3 2 4 2 1 1 4 3 6
NM_005874.1 LILRB2 13 6 9 18 23 15 5 12 14 5 6 2 5 9 16
NM_001005463.1 EBF3 11 12 6 8 23 14 61 65 55 20 29 16 11 21 29
NM_152852.1 MS4A6A 4 2 1 2 2 0 3 6 4 0 3 1 1 1 3
NM_000954.5 PTGDS 70 42 78 66 39 45 32 29 21 49 50 59 36 36 66
NM_000222.1 KIT 49 30 45 43 39 43 68 81 72 37 46 35 57 66 69
NM_004961.3 GABRE 24 28 26 11 8 8 5 6 15 5 13 7 29 22 23
NM_007261.2 CD300A 3 4 3 9 10 19 1 6 8 4 6 5 9 4 9
NM_002115.1 HK3 1 7 4 5 5 8 3 10 9 2 3 3 4 6 4
NM_023914.2 P2RY13 5 6 3 7 7 8 12 9 10 2 5 0 6 6 9
NM_033642.1 FGF13 29 20 25 25 24 20 26 32 28 12 13 18 24 12 23
AF324996.2 Athal_Spike_S23 1861 1772 1760 1810 1851 1792 1816 1849 1821 1795 1877 1782 1808 1839 1795
AF325027.2 Athal_Spike_S14 741 803 801 757 744 748 754 755 802 799 758 757 796 789 787
AF325042.2 Athal_Spike_S19 502 547 507 525 481 486 542 501 491 519 475 542 505 464 518
AY058560.1 DrosSpike8 167 177 208 174 179 194 162 170 154 154 185 186 152 164 184
AF325027.2 Athal_Spike_S13 85 69 76 66 87 86 69 62 72 78 76 75 70 88 82
AF324998.2 Athal_Spike_S22 90 79 83 90 96 110 94 90 99 90 69 83 89 90 61
AY058658.1 DrosSpike7 21 24 29 37 26 36 27 30 23 28 28 37 28 30 27
AF325032.2 Athal_Spike_S17 23 16 27 29 28 33 27 31 25 25 25 25 29 26 27
DQ412624 SarsSpike3 5 9 7 8 3 10 4 6 11 9 4 8 15 3 10
AY058658.1 DrosSpike6 4 4 1 2 6 4 4 4 3 2 2 3 6 5 7
AY058560.1 DrosSpike10 2 2 1 1 1 1 1 4 0 2 0 3 4 0 2
AY058658.1 DrosSpike11 4 4 0 0 3 1 3 0 1 1 0 2 1 1 3
AF325014.2 Athal_Spike_S12 4 4 5 5 4 4 5 2 8 4 1 0 4 3 7
AF325016.2 Athal_Spike_S15 9 2 5 8 4 0 8 9 7 4 6 5 13 4 3
AF325016.2 Athal_Spike_S16 4 2 3 7 3 3 3 0 1 0 3 0 4 2 4
AF325032.2 Athal_Spike_S18 2 2 2 6 2 8 3 4 5 2 3 1 0 3 4
AF324998.2 Athal_Spike_S20 0 4 2 2 5 6 12 5 7 2 3 7 4 1 2
AF324998.2 Athal_Spike_S21 3 3 6 6 7 4 10 3 5 4 6 1 3 5 4
AF324998.2 Athal_Spike_S24 7 3 3 3 3 4 0 3 4 4 4 2 4 2 4
DQ412624 SarsSpike4 13 5 7 4 0 5 1 2 7 5 4 8 14 5 5
AY058560.1 DrosSpike9 2 2 0 2 2 1 1 0 1 0 1 1 0 1 2
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M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M3 M4 M4 M4
Accession No. Gene Name/Sample ID 16060 16060 16060 17932 17932 17932 20898 20898 20898 20899 20899 20899 6039 6039 6039
NM_002841.2 PTPRG 12 12 12 15 16 13 12 12 7 27 19 19 1 2 2
NM_145256.2 LRRC25 1 0 2 4 3 3 4 1 2 2 2 5 34 19 22
NM_001972.2 ELA2 219 164 124 175 131 174 816 760 761 380 423 365 39 32 33
NM_000597.2 IGFBP2 327 329 294 327 342 285 280 236 223 1167 1011 1171 12 13 9
NM_005413.1 SIX3 46 37 32 30 29 18 76 70 73 70 67 65 0 4 9
NM_006272.1 S100B 92 101 93 66 87 78 179 189 149 362 356 406 2 0 1
NM_003327.2 TNFRSF4 29 32 49 7 4 6 39 26 28 79 79 87 0 4 0
NM_004049.2 BCL2A1 28 18 18 11 21 21 17 19 20 23 8 23 28 25 19
NM_001911.2 CTSG 1650 1378 1236 448 447 370 3320 3186 2917 714 790 754 6 10 8
NM_001557.2 IL8RB 2 4 6 1 1 3 8 3 3 2 2 4 2 4 4
NM_001066.2 TNFRSF1B 3 2 0 27 24 19 7 16 5 14 14 23 153 142 143
NM_002046.3 GAPDH 6921 6006 5285 7955 8067 6548 7659 6995 6260 7903 7728 8005 3409 3494 3539
NM_006169.2 NNMT 51 51 49 11 18 15 138 95 102 42 59 53 4 4 3
NM_015381.3 FAM19A5 7 8 10 48 54 43 9 6 6 14 14 15 1 3 1
NM_015136.2 STAB1 886 879 832 977 933 766 571 531 453 710 591 690 57 58 53
NM_002029.3 FPR1 19 15 10 11 10 7 6 6 2 10 5 7 28 40 32
NM_003930.3 SCAP2 0 0 0 0 9 1 2 2 1 0 3 5 19 25 13
NM_006486.2 FBLN1 8 1 4 0 1 0 19 13 7 2 2 4 0 4 1
NM_153206.1 AMICA1 3 2 0 0 1 0 0 0 0 1 0 1 1 1 3
NM_002965.2 S100A9 46 55 35 194 219 179 21 23 16 53 46 44 1589 1610 1490
NM_021209.3 CARD12/NLRC4 3 1 0 6 7 9 5 0 5 8 2 8 24 19 28
NM_000433.2 NCF2 31 18 12 82 84 65 37 37 40 88 79 101 179 185 173
NM_003489.2 NRIP1 8 9 2 10 3 9 1 0 5 2 3 1 18 31 23
NM_001040084.1 LOC653107/ANXA8 195 189 209 18 24 21 19 19 10 203 212 218 7 4 6
NM_016582.1 SLC15A3 2 1 6 7 6 9 1 6 2 6 5 4 11 24 25
NM_000211.2 ITGB2 13 15 6 84 90 72 28 13 19 45 63 35 362 360 329
NM_000601.4 HGF 2554 2173 2297 896 873 723 2321 2146 1725 3477 3564 3492 68 62 71
NM_182961.1 SYNE1 10 9 4 17 18 16 15 12 15 8 11 12 6 4 12
NM_001042729.1 FGR 6 7 0 55 41 58 15 8 3 21 29 35 275 267 252
NM_001614.2 ACTG1 3736 3420 3430 6033 5898 4910 5367 4817 4064 7911 7974 7995 2761 2655 2513
NM_138444.2 KCTD12 1 5 8 11 4 15 4 5 7 4 6 12 58 64 67
NM_002964.3 S100A8 74 65 83 483 435 419 50 38 30 107 87 87 2883 2798 2649
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 0 2 4 4 1 3 5 8 7 14 14 11 6 12 18
NM_000474.3 TWIST1 18 18 20 46 31 38 31 19 24 18 11 18 4 3 2
NM_015869.3 PPARG 33 21 41 58 38 30 14 15 8 17 5 15 2 2 3
NM_004666.1 VNN1 3 4 2 1 6 3 4 2 1 1 3 3 23 19 23
NM_005874.1 LILRB2 10 16 10 39 25 25 9 5 3 16 25 27 100 112 118
NM_001005463.1 EBF3 70 69 49 92 103 69 11 18 12 45 59 49 1 2 2
NM_152852.1 MS4A6A 3 3 2 3 1 1 2 7 2 5 0 5 33 33 23
NM_000954.5 PTGDS 17 16 10 7 13 7 4 6 12 21 25 31 1 2 3
NM_000222.1 KIT 46 21 32 86 84 59 88 84 86 17 17 19 12 10 17
NM_004961.3 GABRE 27 25 20 24 25 19 0 1 2 12 10 11 2 2 4
NM_007261.2 CD300A 3 7 10 15 10 3 13 7 5 7 11 3 0 4 2
NM_002115.1 HK3 6 4 4 4 0 7 7 2 6 1 6 4 24 12 14
NM_023914.2 P2RY13 6 4 6 13 10 12 11 4 7 7 2 4 39 51 46
NM_033642.1 FGF13 25 20 16 34 22 19 37 40 27 28 32 18 2 2 1
AF324996.2 Athal_Spike_S23 1865 1797 1835 1801 1849 1889 1863 1832 1850 1875 1833 1819 1801 1816 1872
AF325027.2 Athal_Spike_S14 754 760 806 750 709 741 754 699 745 737 768 768 811 734 689
AF325042.2 Athal_Spike_S19 478 532 447 504 499 491 489 514 515 472 464 516 483 540 527
AY058560.1 DrosSpike8 161 191 203 197 194 167 155 201 168 174 208 195 190 183 183
AF325027.2 Athal_Spike_S13 97 68 55 66 79 65 67 92 71 60 62 60 66 69 66
AF324998.2 Athal_Spike_S22 85 85 87 103 97 100 79 91 89 97 79 76 84 88 93
AY058658.1 DrosSpike7 28 24 37 34 25 16 32 29 31 25 25 29 32 22 26
AF325032.2 Athal_Spike_S17 21 30 12 34 31 24 38 24 17 37 51 30 26 36 36
DQ412624 SarsSpike3 9 12 12 4 12 4 18 11 9 18 5 4 6 6 5
AY058658.1 DrosSpike6 1 0 6 6 3 1 5 6 5 4 5 3 2 5 2
AY058560.1 DrosSpike10 2 3 2 0 1 1 2 3 1 2 2 0 5 1 3
AY058658.1 DrosSpike11 2 2 2 0 1 4 2 0 6 2 0 1 1 3 0
AF325014.2 Athal_Spike_S12 4 4 6 1 3 4 5 6 6 5 8 7 2 6 5
AF325016.2 Athal_Spike_S15 2 5 8 4 6 3 5 6 5 4 2 5 1 1 1
AF325016.2 Athal_Spike_S16 0 10 2 6 1 4 2 3 8 4 0 5 2 3 4
AF325032.2 Athal_Spike_S18 3 2 10 4 4 6 5 3 3 5 10 3 7 3 2
AF324998.2 Athal_Spike_S20 0 2 2 6 0 1 6 4 3 4 3 5 2 1 4
AF324998.2 Athal_Spike_S21 4 5 2 0 6 3 1 3 7 0 5 5 2 4 3
AF324998.2 Athal_Spike_S24 3 5 0 3 1 1 6 2 1 2 5 1 5 3 3
DQ412624 SarsSpike4 3 5 4 3 6 6 1 7 0 7 2 10 4 7 3
AY058560.1 DrosSpike9 1 1 0 0 1 0 0 1 0 4 2 3 0 2 0
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M4 M4 M4 M4 M4 M4 M4 M4 M4 CD34 CD34 CD34 CD34 CD34 CD34
Accession No. Gene Name/Sample ID 15601 15601 15601 15602 15602 15602 20896 20896 20896 6 6 6 7 7 7
NM_002841.2 PTPRG 0 1 4 2 2 2 1 1 0 1 1 1 0 0 7
NM_145256.2 LRRC25 28 24 20 94 118 104 14 8 18 1 1 2 3 3 0
NM_001972.2 ELA2 78 78 68 7 9 15 28 15 12 12 39 28 13 18 18
NM_000597.2 IGFBP2 57 55 48 33 28 30 7 13 12 14 21 12 15 18 22
NM_005413.1 SIX3 6 5 1 3 5 3 1 0 2 1 0 3 4 1 0
NM_006272.1 S100B 8 16 11 6 9 8 25 19 15 3 5 3 0 0 4
NM_003327.2 TNFRSF4 4 0 1 7 2 4 1 0 1 2 0 0 0 1 0
NM_004049.2 BCL2A1 47 46 35 180 199 180 39 34 24 23 34 41 35 49 49
NM_001911.2 CTSG 9 14 12 155 183 164 222 220 205 100 90 97 48 43 60
NM_001557.2 IL8RB 6 5 4 8 12 17 6 13 11 2 2 6 6 5 0
NM_001066.2 TNFRSF1B 126 106 92 440 460 432 90 58 78 17 16 12 9 11 9
NM_002046.3 GAPDH 4175 4256 3942 4328 4325 4464 5168 5296 5129 3824 4716 4995 3221 3288 3670
NM_006169.2 NNMT 10 8 8 1 3 2 3 2 4 3 0 1 4 5 7
NM_015381.3 FAM19A5 0 3 4 1 4 2 1 1 0 15 12 19 3 4 0
NM_015136.2 STAB1 23 34 24 214 223 218 54 72 58 4 5 3 5 4 7
NM_002029.3 FPR1 27 35 20 64 81 57 21 28 21 8 9 7 6 4 4
NM_003930.3 SCAP2 24 21 12 30 34 42 20 26 18 17 12 13 14 5 4
NM_006486.2 FBLN1 0 0 0 2 1 1 0 1 0 2 0 1 1 0 0
NM_153206.1 AMICA1 1 1 0 2 0 3 0 0 3 1 1 1 1 0 0
NM_002965.2 S100A9 2243 2078 1948 1550 1667 1472 619 642 542 60 90 98 107 123 116
NM_021209.3 CARD12/NLRC4 14 13 23 39 46 33 6 3 8 4 2 4 3 0 2
NM_000433.2 NCF2 114 115 110 317 324 344 120 151 154 14 12 33 18 34 24
NM_003489.2 NRIP1 34 21 18 34 41 38 22 28 19 130 146 149 70 86 109
NM_001040084.1 LOC653107/ANXA8 6 5 3 3 1 2 4 4 1 0 4 1 1 4 0
NM_016582.1 SLC15A3 13 17 14 31 36 36 7 8 4 4 6 0 5 4 2
NM_000211.2 ITGB2 259 233 269 754 706 775 283 247 216 67 72 83 39 32 44
NM_000601.4 HGF 139 104 108 28 30 28 78 68 87 23 44 39 18 23 18
NM_182961.1 SYNE1 12 7 6 10 19 16 10 8 8 16 20 18 11 16 13
NM_001042729.1 FGR 176 164 200 591 602 611 259 233 216 11 13 15 8 12 9
NM_001614.2 ACTG1 3267 2964 2951 3764 3904 3747 3575 3698 3542 3295 3986 4302 2823 3171 3121
NM_138444.2 KCTD12 84 72 60 74 73 70 24 9 12 9 16 10 9 9 18
NM_002964.3 S100A8 4377 3984 3749 3220 3314 3276 1046 1055 967 169 195 228 301 339 371
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 55 68 76 8 8 5 39 23 29 112 118 149 54 61 62
NM_000474.3 TWIST1 3 2 2 8 2 4 4 1 3 4 5 10 1 4 4
NM_015869.3 PPARG 6 5 6 4 6 7 0 1 3 2 5 3 3 4 11
NM_004666.1 VNN1 3 3 3 54 56 47 17 18 15 3 2 3 3 5 0
NM_005874.1 LILRB2 75 69 74 487 473 440 39 54 48 35 34 33 42 31 42
NM_001005463.1 EBF3 10 5 4 3 3 2 6 4 4 2 8 3 3 3 7
NM_152852.1 MS4A6A 26 23 21 28 28 41 36 40 35 5 11 5 8 5 9
NM_000954.5 PTGDS 1 2 0 0 0 0 0 0 1 0 0 1 0 3 0
NM_000222.1 KIT 59 65 56 23 30 24 15 18 12 37 51 52 33 23 22
NM_004961.3 GABRE 2 7 3 4 4 2 0 2 4 1 4 3 0 0 2
NM_007261.2 CD300A 12 4 8 17 14 9 3 3 2 7 12 14 4 5 2
NM_002115.1 HK3 6 12 12 25 29 36 8 3 2 0 0 1 1 4 2
NM_023914.2 P2RY13 52 56 60 94 105 91 37 37 35 9 21 12 10 8 13
NM_033642.1 FGF13 2 0 3 2 1 1 1 1 0 4 0 3 3 0 2
AF324996.2 Athal_Spike_S23 1825 1866 1883 1858 1859 1909 1778 1871 1905 1838 1881 1839 1782 1827 1731
AF325027.2 Athal_Spike_S14 761 766 676 730 744 713 757 722 717 741 704 736 732 759 755
AF325042.2 Athal_Spike_S19 521 506 516 501 501 497 595 503 496 491 550 521 517 483 544
AY058560.1 DrosSpike8 166 165 196 190 187 173 155 170 165 190 145 178 187 167 202
AF325027.2 Athal_Spike_S13 76 69 77 84 74 61 69 69 79 72 64 85 89 77 73
AF324998.2 Athal_Spike_S22 90 65 81 84 81 89 85 100 87 82 90 81 117 101 98
AY058658.1 DrosSpike7 23 28 31 21 23 21 20 26 25 46 29 20 33 36 42
AF325032.2 Athal_Spike_S17 23 29 29 23 25 27 30 22 13 25 26 25 36 34 47
DQ412624 SarsSpike3 10 4 6 5 4 5 9 11 9 8 7 10 5 9 4
AY058658.1 DrosSpike6 5 3 4 4 0 4 1 4 3 6 4 3 0 4 2
AY058560.1 DrosSpike10 3 1 2 2 1 0 4 1 1 0 0 0 3 1 2
AY058658.1 DrosSpike11 2 0 3 2 0 2 8 1 4 1 1 0 0 0 0
AF325014.2 Athal_Spike_S12 2 5 3 5 3 3 2 2 4 5 2 5 0 5 0
AF325016.2 Athal_Spike_S15 6 5 10 2 0 5 2 6 1 3 6 3 0 4 0
AF325016.2 Athal_Spike_S16 1 5 3 3 2 5 4 3 2 1 2 3 1 3 0
AF325032.2 Athal_Spike_S18 2 5 8 2 5 4 0 2 3 2 4 4 3 0 0
AF324998.2 Athal_Spike_S20 4 3 6 1 5 5 4 3 0 1 1 4 1 1 0
AF324998.2 Athal_Spike_S21 5 4 3 3 5 4 4 1 2 1 2 5 3 4 4
AF324998.2 Athal_Spike_S24 3 2 4 3 6 2 6 2 5 3 2 5 0 3 0
DQ412624 SarsSpike4 3 4 6 6 7 3 4 2 3 5 2 4 3 4 4
AY058560.1 DrosSpike9 4 1 1 0 1 2 1 1 1 2 0 0 0 0 2
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Pros Pros Pros Pros Pros Pros Pros Pros Pros Pros Pros Pros Pros Pros Pros
Accession No. Gene Name/Sample ID 109055 109055 109055 109058 109058 109058 114099 114099 114099 114100 114100 114100 114101 114101 114101
NM_002841.2 PTPRG 8 13 9 10 9 17 8 5 8 8 2 10 9 13 9
NM_145256.2 LRRC25 17 15 10 28 25 28 6 11 5 9 2 7 13 15 13
NM_001972.2 ELA2 1199 1075 1244 868 789 867 216 247 272 354 259 317 310 324 323
NM_000597.2 IGFBP2 26 21 18 74 73 55 7 11 9 27 4 21 13 15 15
NM_005413.1 SIX3 57 44 55 55 63 64 48 52 60 77 4 67 104 86 80
NM_006272.1 S100B 10 10 11 4 0 6 1 2 5 4 0 2 6 6 2
NM_003327.2 TNFRSF4 3 5 2 2 2 5 3 2 4 4 0 2 5 5 4
NM_004049.2 BCL2A1 88 74 78 124 147 125 44 56 65 74 50 74 135 122 121
NM_001911.2 CTSG 2067 1769 1995 1946 1977 1973 431 433 445 556 167 553 729 703 668
NM_001557.2 IL8RB 16 18 10 21 27 32 21 20 23 22 0 15 31 36 28
NM_001066.2 TNFRSF1B 44 44 37 63 86 65 75 69 69 75 59 59 115 111 104
NM_002046.3 GAPDH 7616 6498 7234 6988 7429 7887 2952 3264 3296 3723 1530 3410 5675 5553 5591
NM_006169.2 NNMT 13 12 12 6 11 11 15 14 11 14 2 10 15 17 17
NM_015381.3 FAM19A5 9 7 6 7 14 10 4 6 7 5 1 4 14 11 10
NM_015136.2 STAB1 9 7 10 14 11 14 4 8 8 6 1 7 12 10 10
NM_002029.3 FPR1 22 27 9 27 25 45 19 22 19 29 16 30 96 96 85
NM_003930.3 SCAP2 32 18 15 41 16 30 11 11 12 18 8 9 22 22 25
NM_006486.2 FBLN1 1 2 2 2 2 3 2 3 1 1 0 0 1 1 1
NM_153206.1 AMICA1 12 1 5 10 2 4 11 14 12 11 6 15 20 20 20
NM_002965.2 S100A9 12420 11305 11278 13705 14343 14743 3636 4143 4066 4738 520 4224 6612 6592 6666
NM_021209.3 CARD12/NLRC4 67 74 72 70 102 75 82 91 85 79 31 74 113 118 100
NM_000433.2 NCF2 271 260 227 334 358 374 167 153 171 198 93 199 288 319 267
NM_003489.2 NRIP1 40 27 32 35 48 42 13 19 24 25 2 31 37 33 33
NM_001040084.1 LOC653107/ANXA8 14 4 9 22 41 31 9 7 7 18 4 19 14 18 15
NM_016582.1 SLC15A3 28 18 21 33 23 34 18 12 18 19 3 18 32 24 17
NM_000211.2 ITGB2 554 450 499 658 655 763 294 322 344 386 143 339 513 504 500
NM_000601.4 HGF 21 10 15 31 20 30 10 11 8 13 4 11 20 11 15
NM_182961.1 SYNE1 49 51 56 78 68 79 33 42 40 53 17 54 72 76 73
NM_001042729.1 FGR 948 829 888 1172 1043 1256 968 990 1036 1004 1322 1018 1616 1601 1554
NM_001614.2 ACTG1 4404 3904 3926 5081 5345 5497 1856 2023 2143 2709 1644 2497 3200 3382 3364
NM_138444.2 KCTD12 30 21 23 37 23 42 13 13 12 13 2 21 26 20 17
NM_002964.3 S100A8 39038 34512 34841 42709 46190 47216 16732 18504 18732 20596 5219 18606 28528 28884 28963
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 4 4 7 1 2 5 10 11 13 16 14 10 13 13 10
NM_000474.3 TWIST1 22 14 16 22 9 17 12 24 17 15 5 20 27 29 26
NM_015869.3 PPARG 41 30 28 51 50 49 27 34 33 41 2 26 40 43 51
NM_004666.1 VNN1 14 17 16 12 9 13 11 9 8 11 1 9 31 35 30
NM_005874.1 LILRB2 177 162 155 189 177 183 45 62 63 105 19 78 135 136 132
NM_001005463.1 EBF3 12 7 10 11 11 9 12 19 16 16 12 15 31 22 23
NM_152852.1 MS4A6A 6 5 4 7 11 11 4 2 1 3 1 2 5 6 4
NM_000954.5 PTGDS 2 1 0 2 0 3 2 1 1 1 1 0 2 2 1
NM_000222.1 KIT 7 4 5 4 14 6 5 1 5 4 1 2 6 9 3
NM_004961.3 GABRE 12 23 17 25 18 18 17 17 22 16 2 17 22 26 24
NM_007261.2 CD300A 12 4 7 6 5 10 3 5 5 5 2 5 10 10 9
NM_002115.1 HK3 40 42 37 51 70 57 22 28 27 23 3 22 34 40 36
NM_023914.2 P2RY13 157 125 161 190 224 189 159 167 176 156 60 147 262 233 241
NM_033642.1 FGF13 15 25 27 4 7 9 5 4 5 9 1 7 13 11 11
AF324996.2 Athal_Spike_S23 1797 1875 1830 1825 1907 1837 1794 1783 1850 1774 1961 1746 1837 1833 1798
AF325027.2 Athal_Spike_S14 669 659 703 753 621 674 377 411 407 424 327 388 381 400 396
AF325042.2 Athal_Spike_S19 580 538 525 530 510 555 620 658 644 637 547 671 634 648 639
AY058560.1 DrosSpike8 195 166 197 150 163 173 184 187 174 164 162 180 173 169 181
AF325027.2 Athal_Spike_S13 75 83 71 75 86 71 208 161 162 182 178 187 152 157 153
AF324998.2 Athal_Spike_S22 98 88 94 89 98 101 155 183 154 161 202 153 136 160 202
AY058658.1 DrosSpike7 41 35 38 32 34 35 22 34 23 33 21 27 35 35 33
AF325032.2 Athal_Spike_S17 26 38 28 25 68 35 116 55 55 91 82 119 98 62 61
DQ412624 SarsSpike3 12 8 6 12 7 11 11 13 15 20 12 14 20 16 15
AY058658.1 DrosSpike6 6 8 7 7 5 8 13 15 15 14 7 13 32 18 20
AY058560.1 DrosSpike10 3 4 4 4 2 5 8 8 9 12 2 9 8 10 14
AY058658.1 DrosSpike11 8 4 4 1 7 14 9 13 8 8 4 11 14 13 18
AF325014.2 Athal_Spike_S12 4 7 7 10 5 11 3 9 3 11 2 7 5 9 12
AF325016.2 Athal_Spike_S15 6 10 9 9 14 6 3 5 6 6 2 7 7 7 8
AF325016.2 Athal_Spike_S16 3 4 1 7 14 2 8 7 4 14 5 8 16 11 13
AF325032.2 Athal_Spike_S18 34 30 29 27 32 36 26 30 26 35 6 25 47 36 37
AF324998.2 Athal_Spike_S20 2 4 6 4 5 3 0 0 0 0 0 0 0 0 0
AF324998.2 Athal_Spike_S21 7 8 4 0 5 6 9 7 10 8 2 5 10 10 9
AF324998.2 Athal_Spike_S24 15 14 17 11 20 18 16 17 17 27 3 23 35 31 36
DQ412624 SarsSpike4 6 7 7 7 5 8 10 22 14 15 5 19 17 13 20
AY058560.1 DrosSpike9 5 1 4 5 0 8 5 11 9 10 1 6 15 6 12
 
 
 
 
 
 
 
 117
PMNs PMNs PMNs PMNs PMNs PMNs
Accession No. Gene Name/Sample ID 109057 109057 109057 109583 109583 109583 SpikeOnly SpikeOnly SpikeOnly
NM_002841.2 PTPRG 12 12 9 4 6 2 0 0 0
NM_145256.2 LRRC25 249 266 208 198 159 180 1 0 0
NM_001972.2 ELA2 47 35 38 19 21 7 3 1 2
NM_000597.2 IGFBP2 12 16 12 3 4 10 1 4 0
NM_005413.1 SIX3 61 43 40 26 35 22 0 0 1
NM_006272.1 S100B 5 8 6 1 6 0 1 2 1
NM_003327.2 TNFRSF4 5 9 5 3 2 8 1 0 1
NM_004049.2 BCL2A1 3264 2915 2420 1615 1554 1612 2 1 1
NM_001911.2 CTSG 73 65 49 46 38 35 0 0 0
NM_001557.2 IL8RB 2153 1982 1803 1273 1220 1311 1 1 1
NM_001066.2 TNFRSF1B 1273 1202 1257 768 788 720 3 5 1
NM_002046.3 GAPDH 3016 2697 2588 1269 1124 1213 1 1 0
NM_006169.2 NNMT 16 7 11 10 8 7 0 1 1
NM_015381.3 FAM19A5 12 3 4 6 4 3 0 1 0
NM_015136.2 STAB1 16 7 4 6 6 3 1 1 0
NM_002029.3 FPR1 2864 2610 2391 1342 1274 1345 0 2 1
NM_003930.3 SCAP2 56 60 43 82 43 66 0 0 0
NM_006486.2 FBLN1 2 0 2 4 2 0 0 0 0
NM_153206.1 AMICA1 17 14 20 7 5 20 1 1 1
NM_002965.2 S100A9 18402 16585 14408 10883 9845 10712 0 0 1
NM_021209.3 CARD12/NLRC4 21 43 37 22 19 22 1 0 1
NM_000433.2 NCF2 2950 2698 2364 1581 1531 1616 0 1 2
NM_003489.2 NRIP1 19 27 21 11 2 15 0 0 0
NM_001040084.1 LOC653107/ANXA8 12 15 12 8 7 5 1 0 0
NM_016582.1 SLC15A3 185 190 139 100 74 94 0 0 0
NM_000211.2 ITGB2 1534 1479 1466 753 687 670 1 1 0
NM_000601.4 HGF 16 18 14 8 12 19 0 0 1
NM_182961.1 SYNE1 66 65 60 35 46 32 0 0 0
NM_001042729.1 FGR 2959 2560 2483 1530 1615 1518 3 4 1
NM_001614.2 ACTG1 4005 3317 2889 1479 1383 1486 0 0 0
NM_138444.2 KCTD12 42 81 44 17 18 19 0 1 0
NM_002964.3 S100A8 38217 33320 29862 18679 17602 18700 1 0 0
NM_001034996.1 RPL14 0 0 0 0 0 0 0 0 0
NM_001025109.1 CD34 7 7 2 3 4 0 5 8 7
NM_000474.3 TWIST1 17 18 20 8 11 12 1 2 1
NM_015869.3 PPARG 33 31 31 11 11 17 0 0 0
NM_004666.1 VNN1 44 39 30 59 57 56 0 0 0
NM_005874.1 LILRB2 720 717 663 369 335 367 0 1 0
NM_001005463.1 EBF3 2 9 10 4 4 2 3 4 1
NM_152852.1 MS4A6A 0 4 2 6 8 3 1 0 0
NM_000954.5 PTGDS 2 1 0 0 1 0 0 0 0
NM_000222.1 KIT 5 4 1 0 0 0 1 1 0
NM_004961.3 GABRE 23 16 14 11 12 12 2 2 1
NM_007261.2 CD300A 21 19 23 46 34 62 0 1 0
NM_002115.1 HK3 44 43 41 46 33 22 0 0 1
NM_023914.2 P2RY13 887 726 736 488 437 456 3 4 3
NM_033642.1 FGF13 2 7 4 1 6 7 0 0 0
AF324996.2 Athal_Spike_S23 1881 1817 1874 1840 1847 1875 1815 1882 1863
AF325027.2 Athal_Spike_S14 657 688 694 707 694 677 380 428 405
AF325042.2 Athal_Spike_S19 528 535 500 513 522 518 653 650 683
AY058560.1 DrosSpike8 160 214 191 183 157 197 180 179 180
AF325027.2 Athal_Spike_S13 61 80 69 79 72 81 192 141 135
AF324998.2 Athal_Spike_S22 119 69 85 102 109 84 154 133 152
AY058658.1 DrosSpike7 31 35 37 24 47 20 26 19 22
AF325032.2 Athal_Spike_S17 47 46 33 26 33 37 85 56 48
DQ412624 SarsSpike3 9 14 11 18 13 8 9 7 9
AY058658.1 DrosSpike6 5 1 4 7 6 2 5 4 3
AY058560.1 DrosSpike10 2 4 7 0 2 3 2 2 2
AY058658.1 DrosSpike11 2 5 2 1 1 3 3 4 3
AF325014.2 Athal_Spike_S12 12 8 9 3 4 3 3 4 5
AF325016.2 Athal_Spike_S15 9 5 10 3 1 3 3 2 1
AF325016.2 Athal_Spike_S16 9 14 2 3 2 0 8 7 5
AF325032.2 Athal_Spike_S18 23 33 19 12 15 8 2 2 1
AF324998.2 Athal_Spike_S20 5 7 2 0 6 3 0 0 0
AF324998.2 Athal_Spike_S21 9 5 4 1 5 8 4 2 2
AF324998.2 Athal_Spike_S24 7 23 8 3 9 15 1 1 0
DQ412624 SarsSpike4 5 5 6 8 7 2 10 8 3
AY058560.1 DrosSpike9 2 3 3 1 2 2 1 3 2
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Table 2-6:  Detailed sequence information for nCounter CodeSet capture probes 
and reporter probes. 
Target-NSID Gene Symbol Reporter Probe Sequence
NM_001614.2:1615 ACTG1 CCACGGTGTTCTGGCCAAAGACATCAGCTAAGAAAGGAAACTGGGTCCTA
NM_153206.1:125 AMICA1 CTTTGCCATCAGCTTTCCAGCCTCTAGGTGCTTCACACAGG
NM_001040084.1:775 ANXA8 GCAATTTTCTCATACTCTTCAAACACTCTCAGCAGGTGAGTGGCACTGCG
NM_004049.2:80 BCL2A1 CTGGTGGAGAGCAAAGTCTTGAGCTGGCTCACCTTGAAGCTGTTGA
NM_007261.2:0 CD300A CTGCAGGTTCTTCGGCTATTTCTAGTGATGAGACCTCTCCC
NM_001025109.1:1580 CD34 AGCTTCTCCAGACCTTGGCTTTCCCCCGTCACACGTTTACCCAAAGAAGA
NM_001911.2:160 CTSG CAGGGTGACATTTATATTGCTTCCCCAGCAATGAGCTGCTGTCAGCACA
NM_001005463.1:640 EBF3 CCAGCACGTGGCCGTCCACGTTGACTGTTGTCGATACAACAACCTGGA
NM_001972.2:195 ELA2 ACCACCCGCACCGCGCGGACGTTTACATTCGCCACGCAGTG
NM_015381.3:320 FAM19A5 CTCCAGACACGGAAGCATGTCACACCACTGCTTGGTC
NM_006486.2:1260 FBLN1 GCTGGCACTCGTTGACATCGACACACATCCTGCTGATGCCGTCAAAATAG
NM_033642.1:620 FGF13 TTCAACAGCACCTGGAGGTAAGGTTCTGTTACAGAGCCCTTCTTTTGCCC
NM_001042729.1:440 FGR TATTGTTCAGGATGTGGAACTTCTCGCCCTTGGTGAAGGTGAGGTCATCC
NM_002029.3:350 FPR1 TGAGGGCGATCAGGAAGACACTTCCGAACAAGTTGATGTCCACTATGGTA
NM_004961.3:65 GABRE GACAACATCACGGGAAGAGGCTTCATTCTTTGATTCAGTCTGAGGTCCCT
NM_002046.3:245 GAPDH ATCTCGCTCCTGGAAGATGGTGATGGGATTTCCATTGATGACAAGCTTCC
NM_000601.4:550 HGF AAGCTGTGTTCGTGTGGTATCATGGAACTCCAGGGCTGACATTTGATGCC
NM_002115.1:495 HK3 GTCTGGTGACAAGGGAAAGAGAAGCTGAAGCCAAGCTGCAGACCCTGTTT
NM_000597.2:675 IGFBP2 CAAGGTGATGCTTGCCACCCTTGCCCATCTGCCGG
NM_001557.2:2050 IL8RB CTGAAGTTTTGAGGAAAGCTGCCATACTGTCTTCTGCAGTGGTCACACCA
NM_000211.2:520 ITGB2 CGGAGCAGGTCGCCACCTAGCTTCTTGACATTCCTGA
NM_138444.2:450 KCTD12 CTGCAAGTCCCGCAGGTAATCCAGGATGTAGCGGAAGAGGAA
NM_000222.1:5 KIT AGATGGTTGAGAAGAGCCTGTCTGGACGCGAAGCAGTAGGAGCAGAACGC
NM_005874.1:595 LILRB2 GGCTGGGAGTTCAGGCATTGTGGGTGTTCATCTTCTCCTTCCTTACACAG
NM_145256.2:115 LRRC25 TCTGGTTTGCAGTCCCTGCACAGGTGCAAGTTCTAGAG
NM_152852.1:65 MS4A6A TCTCAGTCCCATCAACGGTTTCTACTTACCTTCATCTTCTGAAAGTCATC
NM_000433.2:160 NCF2 AGGGACATGATTAGGTAGAAACTAGGAGGCCAAGAGAGCTGCCAGGAGAC
NM_021209.3:840 NLRC4 TGCCAGGTATATCCAGGAGTTGATCACAGAGGGTTTCAAAAAGTCCACCC
NM_006169.2:605 NNMT AAGCCAGGGAGTGACCCTGCAGAAGTTGTCTTCCTGA
NM_003489.2:335 NRIP1 CCTGATCCCCCTGCTGCCTGATGCATTAGTAATCCTTCTAGGTAAGTTAA
NM_023914.2:2385 P2RY13 AGGTAAGGCCAGAAAGGTAGGCAAGTTCTAGGGCCTTTGAGGCCATGGAA
NM_015869.3:1035 PPARG AAAACCAGGAATGCTTTTGGCATACTCTGTGATCTCCTGCACAGCCTCCA
NM_000954.5:180 PTGDS TGGACAACGCCGCCTTCTTCTCCCGGAGCCAGCTC
NM_002841.2:0 PTPRG CCTGAAAGTTGTGGCTCCGGCGCAGGCTGGGAAGGAAC
NM_002964.3:115 S100A8 AGACGTCTGCACCCTTTTTCCTGATATACTGAGGACACTCGGTCTCTAGC
NM_002965.2:75 S100A9 CTTTGAATTCCCCCTGGTTCAGGGTGTCTGGGTGC
NM_006272.1:40 S100B CCCTCCCTTCCAGAATATTGGTGGAAAACGTCGATGAGGGCCACCATGGC
NM_003930.3:1270 SCAP2 AATATCATACATCTCCATTATGTAGGCTTTAGGCACCAAGCCAATGGCTC
NM_005413.1:1305 SIX3 GCGGCCTTGGCTATCATACATCACATTCCGAGTCGCTGG
NM_016582.1:820 SLC15A3 CAGCAGGAAGCTGATGTTCTGCTGAATAAACGCCACCACCAGCAGCGA
NM_015136.2:95 STAB1 GAGTGACAAACGTGGTTTTCACATCACAGCCTTTGAACAGCACCTGCCCC
NM_001066.2:835 TNFRSF1B GACACAGTTCACCACTCCTATTATTAGTAGACCCAAGGCTGTCACACCCA
NM_003327.2:200 TNFRSF4 CACTCCCACTTCTGAGGTTACACCACGTGCAGGGC
NM_000474.3:35 TWIST1 AAAAAGAAAGCGCCCAACGGCTGGACGCACACCCCGCCAGGCC
NM_004666.1:195 VNN1 GGGTAGAGAGAGTCCCTGTTGAAGTTCCAGCCATAAATAGCATCTTCTGG
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Target-NSID Gene Symbol Capture Probe Sequence
NM_001614.2:1615 ACTG1 CGGCTTGGACTTTCCAACCCTGACAGACCCGCAAGACAAAACAACTGGTT
NM_153206.1:125 AMICA1 GACCCCTGCCCATTATCTCTATGTTGCTCAAGCAATTTCGAGCGGTCACT
NM_001040084.1:775 ANXA8 CGTGCACAGGATGGTGATGAATTTCATCTCATCAGTCCCACGAATCTTCT
NM_004049.2:80 BCL2A1 GGCAATGTGCTGAGAATGCTCACTGAGCTTGACTGAGTTATGACACATGA
NM_007261.2:0 CD300A TGTAGTGACTCCGTAGCTTGCAGGACTGATCCCCG
NM_001025109.1:1580 CD34 CCAGAGTCTGGCTCCAGGGAGCCGAATGTGTAAAGGACAGGAGTTTAC
NM_001911.2:160 CTSG AAGTCTTCTCGCACCAGGAACCCTCCACATCTGCT
NM_001005463.1:640 EBF3 ATCTCCGCATATCTCGAGGGTTGCCTGCATTCTTCAAACAGTTCTGATTG
NM_001972.2:195 ELA2 CGCGGCCGACATGACGAAGTTGGGCGCAATCAGGGTGGCG
NM_015381.3:320 FAM19A5 TTGATGATTCTTGCGTCCACACAGGCGGGCCGGGCT
NM_006486.2:1260 FBLN1 TAACCCGTCTTGCATTCGCAGCGGAAACTGCCGGGAGAGTTCACGCAGCG
NM_033642.1:620 FGF13 TCACTGGCTACGTTGATTCATTGTGGCTCATGGATTTGCCTCCGTTCAGC
NM_001042729.1:440 FGR TCAGTTCGAGCCTCATAGTCATACAGGGCAATGAACAGGGTCAC
NM_002029.3:350 FPR1 AAGACGAATTTGCACAGGAACCAGCCGAAAGGCCAATGTCCTCCCATGGC
NM_004961.3:65 GABRE CGACCCTCGACTGGAGGATCAATAAGATGCCTAGGAGGACTGGAAGAACT
NM_002046.3:245 GAPDH CGTTCTCAGCCTTGACGGTGCCATGGAATTTGCCATGGGTGGAATCATAT
NM_000601.4:550 HGF ACTCTTAGTGATAGATACTGTTCCCTTGTAGCTGCGTCCTTTACCAATGA
NM_002115.1:495 HK3 GTTCACAGGCTGCGCATCCAGGAACTCAGACAGGC
NM_000597.2:675 IGFBP2 TGCTGCTCAGTGACCTTCTCCCGGAACACGGCCAG
NM_001557.2:2050 IL8RB TTTTACAATCCCCCCCAGCAACGCTCGAGAGTTCCAGTTTCTCCTCTACA
NM_000211.2:520 ITGB2 GGTCATCAAGCATGGAGTAGGAGAGGTCCATCAGATAGTAC
NM_138444.2:450 KCTD12 GCCGTCCCGGTCCAGAAAGAAGCGGCCTTTGCTGT
NM_000222.1:5 KIT AGAGAAAATCCCAGGCGCCGCGAGCGCCTCTCATCG
NM_005874.1:595 LILRB2 AATGAAGCCGCCAAATGCCACCTGTGACTCACACTGGAGGGTCACCCTTC
NM_145256.2:115 LRRC25 CCTCAGTCCTACCTTTTGGGTCCCACTGCCACGCTTTTG
NM_152852.1:65 MS4A6A AGCCCTTCCTTATTCCAGTGTTTACAGCTATACAGGATGTGATACTCACA
NM_000433.2:160 NCF2 AGAGAGAAGACAGGTTGGAGCGTCTCCCCTAGCAG
NM_021209.3:840 NLRC4 TGGGCCCTGCTGAGACGGAGGAAGAAGACGAATTTGAACTTGGTCAGAGC
NM_006169.2:605 NNMT GTCTCAGGCTAACAGCATTCCTTCCATCAGTTCAGCCCTTCTTTTAGAAC
NM_003489.2:335 NRIP1 AACAATAGAATCCTGGTGCACATCAGAGCCAAGCTCTTCTCCATGAGTCA
NM_023914.2:2385 P2RY13 GAAAACGTGGGCTTCACCCTACGATGGTCGTGTTGGAGCTCGTGG
NM_015869.3:1035 PPARG CGGAGCGAAACTGGCAGCCCTGAAAGATGCGGATGGCCACCTCTTTG
NM_000954.5:180 PTGDS GAGTTGGAGGCGAGGCCCGCGCTGAACCAGCGCCC
NM_002841.2:0 PTPRG GAAGAGCGCGGCGCTGGAAACTGGCCATGCCTCCATACAGGAAGTAACAT
NM_002964.3:115 S100A8 AATTTCTTCAGGTCATCCCTGTAGACGGCATGGAAATTCCCCTTTATCAG
NM_002965.2:75 S100A9 CCCAGCTTCACAGAGTATTGGTGGAAGGTGTTGATGATGGTCTCTATGTT
NM_006272.1:40 S100B CTTCTCCAGCTCAGACATCCTCTTCCTTGTCTCAC
NM_003930.3:1270 SCAP2 CCTTCATTTCTCCTACCCACCAGCCATATCTATTGTATTCCTTGCTAAGA
NM_005413.1:1305 SIX3 AGGTTACCGAGAGGATGGAGGTGCCGGTGTCCGCG
NM_016582.1:820 SLC15A3 CAGCACAGCACCCAGGTTGATGCTCCAGTAAAACCAGTTGAAGAAGCGGC
NM_015136.2:95 STAB1 CTGACGAAGCTGAAGCCTGCCAGGCAGAAGGCCAG
NM_001066.2:835 TNFRSF1B CAATCAGTCCAACTGGAAGAGCGAAGTCGCCAGTGCTCCCTT
NM_003327.2:200 TNFRSF4 TTGCACGGCTTGGAGCTGACCACGTCGTTGTAGAAGCCCGG
NM_000474.3:35 TWIST1 TCCTGGAAACGGTGCCGGTGCTGCAGAGCCCGCGA
NM_004666.1:195 VNN1 AGTCACAATAATATGCGCACCCTGATCTGCTGCTGATGTGATCGCT
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Chapter 3 
 
Notch signaling has a role in leukemogenesis in a mouse model 
of acute promyelocytic leukemia (APL).
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Notch signaling has a role in leukemogenesis in a mouse model of acute 
promyelocytic leukemia (APL). 
 
3.1. Abstract 
The PML-RARA fusion protein is the initiating event in acute promyelocytic 
leukemia (APL), but the downstream pathways responsible for leukemogenesis are not 
yet completely understood.  In this report, we show that Notch signaling, which has 
known roles in proliferation and survival, plays a role in PML-RARA mediated 
leukemogenesis.  We demonstrate that human APL overexpresses the Notch ligand 
Jagged-1 (JAG1) compared to other AML subtypes, and normal promyelocytes. 
Overexpression of JAG1 is also found in human APL cell lines and in murine APL 
tumors derived from mCG-PML-RARA knockin animals.  Inhibition of Notch signaling 
by pharmacological and genetic approaches resulted in a loss of serial replating by 
marrow cells from young non-leukemic mCG-PML-RARA animals.  In contrast, colony 
formation by wildtype marrow is unaffected by Notch inhibition, suggesting that PML-
RARA expressing cells are uniquely dependent upon Notch signaling for increased self-
renewal.  Growth of primary murine APL cells in vitro was variably reduced by 
pharmacological inhibition of Notch signaling (6/9 samples), demonstrating that while 
Notch signaling is required for early events in leukemogenesis, in some cases it is 
dispensible for the fully transformed tumor.  In conclusion, we have demonstrated a 
previously unappreciated role for the Notch signaling pathway in the development of 
acute promyelocytic leukemia.   
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3.2. Introduction 
The t(15;17)(q22;q11.2) translocation, which is present in nearly 95% of acute 
promyelocytic leukemia (APL) cases, produces the PML-RARA fusion gene.  Multiple 
transgenic and knockin mouse models have demonstrated that PML-RARA has a 
causative role in leukemogenesis (1-3).  In all mouse models of APL, leukemogenesis 
proceeds slowly, presumably requiring secondary events for disease progression.  
However, there are subtle alterations in hematopoeisis that indicate that expression of 
PML-RARA per se alters hematopoeisis.  Marrow cells from young, non-leukemic mCG-
PR animals have increased colony forming ability, and will serially replate in 
methylcellulose cultures for up to one month, in contrast to wildtype cells, which do not 
form colonies after the second week in culture (4, 5).  Serial replating is similarly 
observed in a conditional PML-RARA knockin animal, upon Cre-mediated activation of 
PML-RARA (John Welch and Tim Ley, unpublished data).  In competitive repopulation 
assays with wildtype marrow, expansion of mCG-PR cells was observed not just in the 
Gr-1+ myeloid cells, but also in the CD19+ and CD3+ lymphoid lineage cells (John Welch 
and Tim Ley, unpublished data).  Collectively, these results suggest that PML-RARA 
acts in a multipotent progenitor cell to increase self renewal, and partially block myeloid 
differentiation.  The molecular pathways that are activated or repressed to create these 
phenomena remain largely unknown, but remain an active area of investigation. 
The Notch pathway is attractive candidate for further study.  Several groups, 
including our group, have demonstrated that primary human APL samples 
characteristically overexpress the Notch ligand JAG1 relative to other AML subtypes (6, 
7), promyelocytes (7, 8) or CD34+ stem and progenitor cells (9).  JAG1 expression is 
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also found in two common cell line models of APL.  When PML-RARA expression is 
induced in the PR-9 cell line, both JAG1 protein and mRNA increase (9).  In addition, 
JAG1 is highly expressed in NB-4 cells, and is rapidly downregulated upon ATRA 
treatment; similar results are observed in primary APL patient blasts (9, 10).  
Cotransfection of PML-RARA and a Hes1 promoter reporter construct resulted in 
increased luciferase expression, suggesting that PML-RARA expression leads to 
downstream activation of Notch signaling (9).  Despite these reports, to date there has 
been no in depth investigation of the role of JAG1 and Notch signaling in APL 
pathogenesis. 
Notch signaling is known to activate downstream targets involved in cellular 
survival, proliferation and self-renewal, as well as having major roles in the specification 
of several hematopoietic lineages (11).  While Notch signaling is not required for 
maintenance of steady-state hematopoeisis in adult mice (12), alterations in Notch 
signaling are common in hematopoietic diseases.  Most notably, Notch-1 itself is mutated 
in a majority of T-ALL cases (13) and in rare M0 AML cases (14), leading to 
constituitive activation of Notch signaling.  In other cases of T-ALL, Fbxw3, an E3 
ubiquitin ligase responsible for degradation of activated Notch, has inactivating 
mutations, allowing accumulation of intracellular Notch protein (15).  Two AML fusion 
proteins, OTT-MAL and AML-ETO, disrupt the normal repression of Notch target genes, 
allowing activation of transcription in the absence of ligand engagement (16, 17).  
Increased Notch signaling, as evidenced by increased expression of the Notch target 
gene, Hes1, is also associated with progression of chronic phase CML to blast crisis (18).  
Additionally, it has been reported that human AML leukemic initiating cells (LICs) 
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express high levels of the Notch ligand JAG2 and are susceptible to pharmacological 
inhibition of Notch signaling (19). 
Understanding the role of Notch signaling in disease has clinical relevance 
because the Notch pathway is a druggable target.  Multiples avenues of Notch inhibition 
are currently in pre-clinical development, including gamma secretase inhibitors (20), 
stapled peptide inhibitors (21), and Notch subtype specific antibodies (22).  Some of 
these agents are currently being tested in phase 1 clinical trials (23).     
In this report, we describe an in depth study of the functional role of Notch 
signaling in APL.  In agreement with previous studies, we found that JAG1 is highly 
expressed in APL cells.  Furthermore, we demonstrate that the essential components of 
Notch signaling are expressed in human APL cells, and we provide bioinformatic 
evidence for activation of a known Notch signature in APL.  Similar to the human 
disease, Jag1 mRNA and protein are present in primary murine APL cells, allowing us to 
use the PML-RARA knockin mouse to model the role of Notch signaling in 
leukemogenesis.  Using both pharmacologic and genetic approaches, we show that Notch 
signaling is a component of the increased self-renewal observed in preleukemic cells.  In 
most fully transformed tumors, dependence on Notch signaling is retained in vitro.  These 
findings suggest that Notch signaling is a key downstream effector of PML-RARA, with 
roles in both early leukemogenesis and the fully transformed state. 
 
3.3. Results 
3.3.1. Jagged-1 is dysregulated in acute promyelocytic leukemia. 
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We previously reported a signature of genes with altered expression specifically 
in APL; the Notch ligand Jagged-1 (JAG1) was among this set (7).  Using gene 
expression profiling, we examined the expression of JAG1  in bone marrow samples 
collected from a larger set of 180 de novo AML patients (see Table 3-1 for clinical 
characteristics of AML patients) and in sorted normal myeloid populations (CD34+ cells, 
promyelocytes and neutrophils) from 5 normal human bone marrow samples.  JAG1 was 
expressed at significantly higher levels in APL samples compared to all other FAB 
subtypes in 4/5 probesets on the Affymetrix 133+2 platform (see Figure 3-1A for 2 
selected probesets).  JAG1 expression in APL was also significantly higher than in any 
normal myeloid population (Figure 3-1A).  While JAG1 expression in some other AML 
samples was similar to that seen in APL, it was consistently expressed at high levels only 
in APL.  We validated the expression pattern of JAG1 by comparing these results to those 
found in a second set of 93 de novo AML samples (M0-M4) obtained from the Cancer 
and Leukemia Group B (CALGB) Cooperative group.  In this independent validation set, 
JAG1 was also most highly expressed in APL samples (Figure 3-1B).  We additionally 
performed quantitative RT-PCR for JAG1 on 11 APL, 16 other AML and 4 normal 
promyelocyte RNA samples (Figure 3-1C) and confirmed that JAG1 mRNA is present at 
significantly higher levels in APL compared to both other AML and normal 
promyeolocytes.  These results are similar to several other AML gene expression 
profiling studies including our own, and strongly suggest that overexpression of JAG1 is 
characteristic of APL.  Because JAG1 is a Notch ligand, we then decided to investigate 
the role of Notch signaling in APL. 
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3.3.2. Components of the Notch signaling pathway are expressed in APL. 
 We examined the expression of Notch pathway components in APL and normal 
promyelocytes.  The NOTCH1 and NOTCH2 genes are expressed in APL cells at levels 
that do not differ significantly from normal promyelocytes, while NOTCH3 and NOTCH4 
are not expressed in either group (Figure 3-2A).  Of the Notch ligands, JAG1, as 
described above, and DLL1 are overexpressed in APL samples relative to normal 
promyelocytes (Figure 3-2A).  To determine whether APL cells express the necessary 
machinery for intact Notch signaling, we examined the expression of components of the 
gamma secretase complex (Figure 3-2B), enzymes involved in the S1 and S2 Notch 
cleavage events (Figure 3-2C), transcriptional cofactors of Notch (Figure 3-2D), Notch 
modifying enzymes (Figure 3-2E), and the Mindbomb and Fbxw7 E3 ubiquitin ligases 
involved in Notch endocytosis and degradation (Figure 3-2F).  These genes were 
expressed at moderate to high levels in APL samples and promyelocytes, indicating that 
the essential components of Notch signaling are present in APL cells.  For the majority of 
Notch pathway genes, expression did not differ significantly between APL and normal 
promyelocytes.  However, 5 of these genes were previously reported as part of a 
signature of genes specifically dysregulated in APL relative to other AML and normal 
promyelocytes (7).  MIB1 and MAML3 are expressed at higher levels in APL, while CSL, 
PSEN1, and LFNG were expressed at lower levels. 
 
3.3.3. Bioinformatic evidence of Notch signaling in APL 
Increased Notch signaling is a major component of T-ALL, due to activating 
mutations in NOTCH1 (13).  Several studies have reported signatures of genes whose 
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expression is controlled by Notch signaling in T-ALL cells.  We used gene set 
enrichment analysis (GSEA) to determine whether these same pathways might be 
activated in APL.  We selected two signatures, ‘GSI-Notch’, comprised of genes whose 
expression changes in T-ALL cells upon treatment with gamma secretase inhibitors (21) 
and ‘Notch-Targets’, comprised of genes previously reported to be transcriptional targets 
of NOTCH1, as defined by both ChIP-on-chip and microarrays (24).  We then used 
GSEA to determine whether these signatures are enriched in APL compared to normal 
promyelocytes, and found that both the Notch-Targets (Figure 3-3A) and GSI-Notch 
(Figure 3-3B) gene sets are significantly enriched in human APL samples (FDR=0.00 for 
both comparisons).  We then performed GSEA with a third signature derived from 
culturing murine KLS cells on OP9 stroma expressing Dll1 (25).  This signature, termed 
KLS-Notch, was also enriched in human APL samples (Figure 3-3C, FDR=0.013).  
These results provide bioinformatic evidence that Notch signaling is activated in APL 
cells. 
 
3.3.4. Notch signaling is present in APL cell lines. 
The PR-9 cell line, which contains a zinc inducible PML-RARA cassette, is 
frequently used as a model of APL and PML-RARA activities.  As previously reported 
(9), JAG1 mRNA and protein increase upon addition of ZnSO4 to the culture media 
(Figure 3-4A-B).  Both the mRNA and protein levels begin to rise at 8 hours post 
induction, peak at 16 hours, and remain elevated at 24 hours.  JAG1 protein can also be 
detected in induced PR9 cells by intracellular flow cytometry (Figure 3-5).  While 
staining non-permeabilized cells resulted in staining levels only slightly above the isotype 
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control background, incubating the antibody with fixed, permeabilized PR9 cells 
produced robust intracellular staining, indicating that the bulk of JAG1 protein is located 
within an intracellular compartment (Figure 3-5).  Similarly, abundant intracellular JAG1 
was detected in the NB-4 APL cell line, which possesses t(15;17) and expresses PML-
RARA (Figure 3-6). 
When PML-RARA expression is induced in PR-9 cells, cleaved Notch-1 protein 
also increases (Figure 3-4B) with the same kinetics as JAG1 protein.  In addition, cleaved 
Notch-1 can be detected in NB4 cells by flow cytometry (Figure 3-6).  These results 
demonstrate that JAG1 expression and activation of Notch signaling are a common 
feature of two widely used cell line models of APL. 
 
3.3.5. Jag1 and Notch signaling are found in a murine model of APL. 
We next examined Notch signaling in a previously described murine model of 
APL, the mCG-PML-RARA knockin mouse (3), which develops AML with 
differentiation.  Murine mCG-PR leukemia cells are morphologically promyelocytes and 
respond to ATRA both in vitro and in vivo.  In addition, we have previously reported that 
a bona fide, validated human APL gene expression signature is present in the murine 
tumors (26).  We examined the expression of Jag1 using previously published gene 
expression profiles of 21 murine APL samples and wildtype Lin-Sca+ (LS) progenitor 
cells undergoing 7 days of G-CSF induced myeloid differentiation (Figure 3-7A).  Jag1 
expression was detectable in a majority of tumors and was higher than that of either LS 
cells (d0) or promyelocytes (d2).  We then used flow cytometry to assess the presence of 
Jag1 protein and cleaved Notch-1 in murine APL.  Jag1 protein was readily detected by 
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intracellular staining but not by surface staining (see Figure 3-8 for 3 example tumors), 
similar to the results observed with PR-9 and NB-4 cells.  We then examined Jag1 and 
cleaved Notch1 protein in 10 independent primary APL samples (see Table 3-2 for 
characteristics of murine APLs, Figure 3-7B for summarized results, Figure 3-7C for 
representative flow plots).  Jag1 was detectable in all tumors assayed, with expression 
levels ranging from 19% to greater than 90% of the cells.  Cleaved Notch-1 protein was 
detected in 6/10 tumors (range 0.32-71%).  Notably, the abundance of intracellular 
Notch1 was significantly correlated with the level of Jag1 protein present (Pearson 
R=0.9447, p<0.0001).  Therefore, like human APL and APL cell lines, murine APL cells 
both overexpress Jag1 and have activated Notch signaling, providing a rationale for 
utilizing the mCG-PR mouse as a model system in which to investigate the role of Notch 
signaling in leukemogenesis. 
 
3.3.6. Inhibition of Notch signaling reduces colony formation by mCG-PR marrow. 
Marrow cells from mCG-PR animals have increased colony forming ability and 
will serially replate in methylcellulose cultures for up to one month, in contrast to 
wildtype cells, which do not form colonies after a single round of replating.  To examine 
the role of Notch signaling in early leukemogenesis, we cultured marrow cells from 
young (6-8 weeks) non-leukemic mCG-PR mice (or wildtype B6 mice) in 
methylcellulose media, and assessed colony formation in the presence of GSIs 
(compound E or compound IX) or DMSO control (Figure 3-9).  Colony formation by 
marrow derived from young wildtype B6 animals was not affected by either compound 
(Figure 3-9A), as expected (12).  In contrast, after 1 week in culture, colony formation by 
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PR+ marrow was significantly reduced (Figure 3-9B).  After 2 rounds of replating, 
vehicle treated control cells had colony formation activity similar to that observed in the 
first week.  In contrast, at weeks 2 and 3, GSI treated cells had significantly reduced 
colony forming activity.  In some marrow samples, colony formation in GSI treated 
cultures was nearly abrogated by the third week of continuous drug exposure (Figure 3-
9C).  These data suggest that Notch signaling may be partially responsible for the 
replating phenotype observed in mCG-PR progenitor cells. 
 To further validate the role of Notch signaling in serial replating of mCG-PR 
marrow, we used a genetic approach to inactivate Notch signaling.  We used a retrovirus 
containing a dominant-negative fragment of MAML1 fused to GFP (DNMAML-GFP) 
(27).  DNMAML contains the domains necessary to interact with cleaved Notch, but 
lacks the domains needed to recruit transcriptional machinery.  DNMAML therefore 
blocks Notch signaling at a transcriptional level, downstream of gamma secretase-
mediated cleavage of Notch.  We transduced wildtype B6 and mCG-PR marrow with 
either DNMAML-GFP or GFP control virus, sorted GFP+ cells to >95% purity, and 
plated them in methylcellulose media (Figure 3-10).  As expected, genetic inhibition of 
Notch signaling did not impair colony formation by wildtype cells (Figure 3-10A).  In 
contrast, DNMAML transduced mCG-PR marrow had significantly reduced colony 
forming activity at weeks 1, 2 and 3 (Figure 3-10B-C), similar to that observed with 
pharmacological inhibition of Notch signaling.   
 
3.3.7. Inhibition of Notch signaling reduces colony formation in primary murine APL 
cells. 
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In order to investigate the role of Notch signaling in fully transformed tumors, we 
developed an assay to measure the effect of Notch inhibition on colony formation by 
murine APL cells (Figure 3-11A).  Cryopreserved primary APL cells isolated from the 
spleens of moribund 129/B6 F1 mCG-PR mice were thawed, grown in liquid culture 
media supplemented with IL-6, IL-3 and SCF in the presence of ATRA, GSI (compound 
E or compound IX) or DMSO vehicle control for 48 hours, and then plated in 
methylcellulose without inhibitors.  Colony formation was then scored after 7 days in 
methylcellulose.  Both the liquid and methylcellulose cultures were conducted under 
hypoxic (3%) conditions, since a majority of primary APL tumors have poor colony 
formation under standard growth conditions (20% 02) (data not shown).  As a control, 
129/B6 F1 marrow was subjected to the same assay.  Neither compound E nor compound 
IX significantly alters colony formation by wildtype marrow cells (Figure 3-11B).  Of 13 
tumors evaluated, 9 formed colonies under vehicle control conditions (Table 3-2), which 
allowed us to assess responses to drugs.  As expected, ATRA exposure resulted in the 
formation of significantly fewer colonies in 9/9 tumors (Figure 3-11C), demonstrating 
that this assay is viable for testing drug activity.  Six of the 9 assayed tumors formed 
significantly fewer colonies after exposure to GSIs (Table 3-2 and Figure 3-11C).  In 
many of the GSI responsive tumors, the reduction in colony formation was similar to that 
observed with ATRA treatment.  On average, exposure to compound E or compound IX 
resulted in colony formation that was 62.2% (SD 35.0%) and 45.2% (SD 24.4%) of the 
DMSO controls, respectively (Figure 3-11C).  In addition, the degree of inhibition of 
colony formation was generally similar between compound E and compound IX treated 
plates for the same tumor.  These results were statistically significant (p<0.01 for 
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compound E, and p<0.001 for compound IX), and suggest that Notch signaling plays a 
role in the survival or self-renewal of some fully transformed leukemic cells. 
 
3.3.8. In vivo inhibition of Notch signaling in murine APL 
To determine whether inhibition of Notch signaling reduces tumor growth in vivo, 
we utilized 2 indpendent murine APL cell lines derived from mCG-PR mice which 
express click beetle red luciferase (28).  Both APLluc cell lines express the myeloid 
marker Gr-1 and high levels of intracellular Jag1 protein (Figure 3-12).  We injected 
500,000 cells intraperitoneally into 129/B6 recipient animals.  Animals received either no 
treatment, subcutaneous ATRA (20 mg as a sustained release pellet) or daily injections of 
6 mg/kg compound E, and were imaged biweekly until clinical illness developed.  As 
expected, ATRA treatment reduced tumor burden for both cell lines (Figure 3-13A and 
B).  In contrast, the bioluminescence in GSI treated animals was not significantly 
different than that of untreated control animals (Figure 3-13). 
Hypothesizing that immortalized cell lines may not retain the dependence on 
Notch signaling seen in primary APL, we transplanted two tumors that responded to GSIs 
in vitro (numbers 2894 and 3149) into sublethally irradiated syngeneic recipient animals 
and treated with the GSI compound E.  Treated animals received intraperitoneal 
injections (3mg/kg) on a 5 days on, 2 days off dosing schedule, while control animals 
received no treatment.  The lower dose and altered dosing schedule was selected in order 
to avoid the GI toxicity associated with continuous GSI exposure (29).  At 4 weeks post-
transplant, mice in both treated and control groups were anemic, thrombocytopenic and 
some animals had elevated WBCs (Figure 3-14A, B and C).  There was no significant 
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difference in blood counts between GSI treated and control groups for either tumor.  In 
addition, there was no decrease in spleen size or percentage of immature myeloid (Gr1+, 
c-Kit+) cells in the spleens with GSI treatment (Figure 3-14D).  To determine whether 
drug treatment resulted in inhibition of gamma secretase-mediated cleavage of Notch, we 
examined protein extracts from the spleens of 3 treated and 3 untreated moribund 
animals.  There was no decrease in cleaved Notch-1 in the GSI treated spleens, 
suggesting that the dose or delivery was not adequate to inhibit Notch cleavage (Figure 3-
14E).  Therefore whether Notch inhibition results in decreased disease burden in vivo 
remains an open question. 
 
3.4. Discussion 
 In this report, we have shown that overexpression of JAG1 and downstream 
activation of Notch signaling is important for the pathogenesis of APL.  JAG1 
overexpression is found in human APL samples compared to other AML subtypes and to 
normal myeloid cells.  Several groups, including our own, have previously reported that 
JAG1 overexpression is associated with APL (6-8, 30).  We extended these observations 
to a functional study of the role of Notch signaling in APL.  APL cells express core 
components of the Notch pathway and are expected to be capable of transducing Notch 
signals.  We have also provided bioinformatic data that two known Notch signatures are 
enriched in APL cells, suggesting that Notch signaling is activated.  Like human APL 
samples, murine APL cells express abundant Jag1 mRNA and protein, and have activated 
Notch signaling.  This fact allowed us to use the mCG-PML-RARA knockin mouse as a 
model of Notch signaling in vivo.  Pharmacological and genetic inhibition of Notch 
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signaling resulted in a loss of serial replating by mCG-PR progenitor cells, demonstrating 
that the Notch pathway is necessary for self-renewal.  Most murine APL samples retain 
sensitivity to Notch inhibition in vitro, suggesting that Notch signaling is also relevant for 
fully transformed tumors. 
 JAG1 overexpression appears to be characteristic of APL, since nearly every APL 
sample has abundant JAG1 mRNA.  However, JAG1 expression is not restricted to only 
the M3 subtype of AML.  Interestingly, in an unsupervised analysis of 285 AML patients, 
Valk et al. reported that high JAG1 expression was associated with a cluster of patients in 
which the majority had either FLT3-ITD or FLT3-TKD mutations, and not with APL 
patients (31).  Similarly, Verhaak et al. assigned JAG1 to a signature associated with 
overexpression in FLT3-ITD or TKD mutated AML (32).  We also observed 30 other 
AML subtype samples with high JAG1 expression in our dataset, as defined by having 
signal intensity equal or greater to the APL sample with the lowest signal intensity for 
that probeset (see Table 3-3).  While 12 cases did have either FLT3-ITD or FLT3-TKD 
mutations, we found that NPMc, IDH1, IDH2 and DNMT3A mutations were also 
present, either alone or in combination with FLT3 mutations.  In addition, 4/9 patients 
with inv(16) alone had high JAG1 expression.  It may be that there are multiple distinct 
pathways that lead to high JAG1 expression, and that Notch signaling has roles in 
pathogenesis for other AML subtypes as well. 
While JAG1 expression is induced upon PML-RARA expression in the PR-9 cell 
line, and is abrogated with ATRA treatment of NB-4 cells (9, 10),  it is not clear how 
PML-RARA regulates JAG1.  The proximal JAG1 promoter has an everted repeat (10) 
and combined direct repeat-PU.1 motif sites similar to ones that PML-RARA has been 
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shown to bind (33).  However, three independent whole genome chromatin 
immunoprecipitation studies failed to find evidence of PML-RARA binding in the JAG1 
promoter in either cell lines or primary APL cells (33-35).  In addition, cotransfection of 
a JAG1 promoter reporter construct (1.5  kb of 5’ flanking sequence) with PML-RARA 
did not result in JAG1 promoter activation (data not shown).  These data suggest that 
JAG1 is not a direct transcriptional target of PML-RARA.   
 In both cell lines and primary murine APL samples, Jag1 protein exists primarily 
within an intracellular compartment, since it can only be detected by flow cytometry if 
cells are fixed and permeabilized.  While we cannot formally exclude the possibility that 
some Jag1 protein (below the limit of antibody detection) resides on the cell surface, this 
would be a minor portion compared to the intracellular fraction.  If Jag1 is not present on 
the cell surface, how then is Notch signaling activated?  One possible explanation is that 
autocrine activation of Notch signaling may occur intracellularly, within a membrane 
compartment shared by Jag1 and Notch.  While Notch signals are generally thought to be 
transmitted from a ligand-bearing cell to an adjacent receptor-expressing cell, autocrine 
signaling has clearly been reported in primary human eosinophils (36).  It is also possible 
that Jag1 reaches the cell surface, but is immediately encounters receptors and is 
endocytosed, so that under steady-state conditions, little surface Jag1 is present.  Further 
studies are needed to distinguish between these mechanisms.  Knowledge of the 
molecular details of Jag1 mediated signaling has clinical ramifications.  For example, if 
Jag1 does not reach the cell surface, then antibodies targeting it are unlikely to be 
efficacious therapies. 
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 Several groups have reported Notch independent effects of Jag1 mediated via 
binding of the cytoplasmic tail to PDZ-domain containing proteins, or via cleavage of 
Jag1 to release an intracellular fragment with transcriptional activation properties (37, 
38).  While we cannot exclude Notch independent activities of JAG1 in APL, we think 
that Notch-independent mechanisms are unlikely to be the primary mechanism for 
several reasons.  First, Notch signaling is correlated with Jag1 expression in both cell 
lines and primary murine APL, suggesting that Notch cleavage is activated as a 
consequence of Jag1 expression.  Second, pharmacologic inhibition of Notch signaling 
decreases colony formation by both preleukemic and leukemic cells.  Similarly, genetic 
inhibition of Notch signaling through dominant negative mastermind-like (DNMAML) 
resulted in decreased colony formation by mCG-PR marrow.  Neither GSIS nor 
DNMAML would be expected to affect expression of Jag1 or its potential interactions 
with cytoplasmic proteins.  If these mechanisms were important components of Jag1 
activity, GSIs and DNMAML would not be expected to decrease colony formation. .  
Finally, these Notch independent properties of Jag1 have primarily been studied in non-
myeloid cell lines.  No reports have yet demonstrated that these mechanisms have 
relevance in vivo or in primary myeloid cells. 
 We were unable to achieve inhibition of Notch signaling in vivo using a standing 
dosing protocol (39).  Therefore, we do not yet know whether Notch inhibition will 
reduce tumor growth in this setting.  Compound E is hydrophobic, and has been reported 
to have poor absorption when delivered intraperitoneally (40).  Milano et al reported that 
increased doses resulted in a less than proportional increase in plasma concentration (40).  
In addition, the IC50 doses for compound E and other GSI used in vivo are commonly 
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reported as the dose necessary to reduce serum Aβ40, a cleavage product of amyloid 
precursor protein (APP) by 50% (40).  There is evidence that gamma secretase cleavage 
of Notch is less susceptible to GSI mediated inhibition in vitro, requiring higher doses to 
achieve the same decrease in cleave as APP (41),  and this may be true in vivo as well.  
We are currently considering other GSIs and dosing strategies, as well as alternative ways 
of demonstrating the role of Notch signaling in vivo, including determining whether APL 
cells treated with GSIs ex vivo are still capable of inducing disease in secondary 
recipients. 
 In summary, we have demonstrated a previously unappreciated role for Notch 
signaling in the pathogenesis of acute promyelocytic leukemia.  The expression of JAG1 
and activation of Notch signaling is a common event in the development of both murine 
and human APL.  Collectively, our results demonstrate that Notch signaling allowing for 
increased self-renewal is an early event in PML-RARA mediated leukemogenesis, and 
that dependence on Notch signaling is retained by some tumors in vitro.  These results 
suggest that the Notch pathway is an attractive target for drug development, which may 
have clinical utility in treating some patients with relapsed or refractory APL. 
  
3.5. Methods 
3.5.1 AML and Normal Marrow Samples 
One hundred eighty de novo adult AML bone marrow samples, including 22 APL 
samples, were collected as part of a study at Washington University to identify genetic 
factors associated with leukemogenesis.  The study was approved by the Human 
Research Protection Office at Washington University School of Medicine and all patients 
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provided informed consent in accordance with the Declaration of Helsinki.  Criteria for 
study inclusion were age greater than 18, more than 30% myeloblasts (or promyelocytes 
for M3 cases) in bone marrow aspirates.  Patients with a history of myelodysplastic 
syndrome or prior chemotherapy or radiation therapy treatments were excluded.  Patient 
characteristics are summarized in Table 3-1.  An additional 93 de novo AML bone 
marrow samples were obtained from the Cancer and Leukemia Group B Tumor Bank and 
were processed using the same methods as the Washington University samples.  Bone 
marrow aspirates from normal donors were also collected.  The fractionation of normal 
marrow samples into CD34+ stem/progenitor cells, promyelocytes and neutrophils has 
been previously described (7).   
 
3.5.2. RNA Processing, Microarray Hybridization and Data Analysis 
The processing of RNA samples has been previously described (7) .  In brief, RNA was 
isolated from unfractionated snap-frozen cell pellets using the Trizol reagent (Invitrogen).  
RNA was quantified using UV spectroscopy (Nanodrop Technologies) and assessed 
using a BioAnalyzer 2100 and RNA NanoChip assay (Agilent Technologies).  RNA 
samples were labeled and hybridized to Affymetrix Human Genome 133 Plus 2.0 Array 
Gene Chip microarrays using standard protocols at the Laboratory for Clinical Genomics 
at Washington University (details availalable at 
http://www.pathology.wustl.edu/research/lcgoverview.php).  Raw scan data was scaled to 
a target intensity of 1,500 using the Affymetrix GCOS 1.2 (MAS 5) statistical algorithm 
and then merged with current probeset annotations.  Profiling data for all samples will be 
deposited online at the Gene Expression Omnibus. 
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3.5.3. Quantitative RT-PCR 
One-step quantitative RT-PCR was performed with 20 ng RNA using the QuantiTect 
SYBR Green RT-PCR kit and QuantiTect Primer assays (Qiagen) on a Prism 7300 real-
time PCR system (Applied Biosystems) according to the manufacturer’s instructions. All 
reactions were performed in triplicate.  Expression was normalized to GAPDH using the 
∆Ct method. 
 
3.5.4. Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) was performed using gene set permutation analysis 
with ratio-of-classes gene ranking (http://www.broad.mit.edu/gsea).  Array data were pre-
processed to remove probesets with average signal intensity < 500 in both comparison 
groups (APL and promyelocytes). 
 
3.5.5. Cell lines 
The PR-9 cell line was a kind gift of P. Pellicci of the European Institute of Oncology, 
Milan, Italy.  NB-4 cells were obtained from the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ).  Cell lines were grown in RPMI 
supplemented with 10% fetal calf serum.  PML-RARA expression was induced in PR9 
cells using 100 µM ZnSO4 diluted in media. 
 
3.5.6. Western blots and antibodies 
Prior to lysis, 2 × 106 cells were incubated in the presence of 100 µM diisopropyl-
fluorophosphate (Sigma-Aldrich), then lysed in 100 µl 2% SDS/PBS.  Total protein was 
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electrophoresed and transferred to Hybond-C membranes (Amersham) as described (3).  
Antibodies used include Rara (C-20, Santa Cruz), Jag1 (H-114, Santa Cruz), cleaved-
Notch1 Val1744 (Cell Signal Technologies) and actin (C-4, Milipore).  Blots were 
developed using the ECL Plus chemiluminescence system (Amersham). 
 
3.5.7. Flow Cytometry 
Cells were washed, RBC-lysed if necessary and pre-incubated with unlabeled anti-mouse 
CD16 (eBioscience) before surface staining against the following antigens:  Jag1, Gr-1, 
and c-Kit (eBioscience).  For intracellular staining, cells were fixed and permeabilized 
following surface staining using the FoxP3 Intracellular Staining Buffer Set 
(eBioscience) according to the manufacturer’s recommendations.  In experiments 
comparing the presence of Jag1 on the cell surface versus with intracellular 
compartments, equal amounts of antibody were used for surface and intracellular 
staining.  Intracellular cleaved Notch-1 was detected using the mN1A Notch antibody 
(eBioscience).  Data were collected on a FacSCAN (BD) and analyzed using FlowJo 
(Treestar). 
 
3.5.8. Mice 
The mCG-PML-RARA mice have been previously described (3), and have been fully 
back-crossed to the C57/B6 strain (Jackson Laboratory) for at least 10 generations.  
129SvJ/B6 F1 hybrid animals were generated by mating 129SvJ males with C57/B6 
females (both parental strains obtained from Jackson Laboratory).  Animal care and 
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experimental protocols were approved by the Animal Studies Committee of Washington 
University School of Medicine.  
 
3.5.9. Drugs 
The gamma secretase inhibitors (GSIs) compound E and compound IX (Calbiochem) 
were dissolved in DMSO at concentrations of 2mM and 25mM, respectively.  These 
solutions were used as 1000X stocks in liquid and semi-solid culture experiments.  All-
trans retinoic acid (ATRA, Sigma) was dissolved in 100% ethanol to make a 10mM stock 
solution.  This stock was then diluted in DMSO to make a 1mM 1000X working stock 
solution for liquid and methylcellulose culture experiments.  For in vivo experiments 
compound E (Axon Med Chem) was diluted in DMSO to make a 6 mg/mL stock 
solution.  DMSO stock was diluted into a 1:1 mixture of PBS and propylene glycol 
(Sigma) immediately prior to intraperitoneal injections. 
 
3.5.10. Methylcellulose assays 
Marrow was harvested from the tibias and femurs of 6-8 week mCG-PR or C57/B6 
animals and subjected to a 10 minute incubation in ammonium chloride lysis buffer on 
ice.  After washing, 35,000 cells were added to 3.5 mL of methylcellulose media 
containing IL-3, IL-6 and stem cell factor (M3534 media, Stem Cell Technologies).  
Following thorough mixing to evenly distribute cells into the media, 1 mL was plated in 3 
replicate dishes.  After 1 week, colony formation was scored using the 40X objective on a 
light microscope.  For replating experiments, cells were harvested from methylcellulose 
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cultures by dissolving in 37°C RPMI, and were then replated in fresh methylcellulose 
media as described above. 
 
3.5.11. Retroviral transductions 
The MSCV-DNMAML-GFP plasmid has been previously described (27) and was a kind 
gift of Rafael Kopan.  Retrovirus production was performed as described (42).  Viral 
stocks were titered based upon GFP expression in 3T3 cells.  Viral transductions were 
done as follows:  after harvest and red cell lysis, marrow cells were grown in 6 well 
plates overnight in 3mL RPMI media supplemented with 10% FBS, 6 ng/mL IL-3, 10 
ng/mL IL-6 and 100 ng/mL SCF.  On day 1, 0.5-1mL of viral supernatant, 3 µg/mL 
polybrene, and 100 mM Hepes buffer were added to the culture media.  Plates were spun 
for 90 minutes at 1,500 rpm.  After 3 hours, the cells were transferred to fresh media.  
The transduction was repeated on day 2.  On day 3, GFP+ cells were sorted into media 
using an iCyte Reflection sorter at the High Speed Cell Sorting Core of the Siteman 
Cancer Center, Washington University.  Cells were plated in methylcellulose media as 
described above. 
 
3.5.12. Cryopreserved murine APL samples 
Cryopreserved murine APL samples were collected and frozen as described previously 
(43).  Vials containing 1 mL of cells were rapidly thawed in a 37°C water bath.  An equal 
volume of fetal calf serum was added to the cryovial, and the 2mL of cells/FBS were 
immediately diluted in 8mL of cold recovery media (30%FBS in RPMI), which was then 
further diluted in 40 mL of recovery media.  After centrifugation, the cell pellet was 
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resuspended in 20 mL recovery media and incubated at 37°C for 1-2 hours.  APL cells 
were then centrifuged and resuspended in 10 mL RPMI media supplemented with 10% 
FBS, 6 ng/mL IL-3 (Peprotech), 10 ng/mL IL-6 (Peprotech) and 100 ng/mL SCF 
(Peprotech).  Viable cell counts were performed using trypan blue exclusion.  Viability 
typically exceeded 75%.  Two mL of media containing approximately 200,000 live cells 
were plated into each well of a 12 well plate.  Inhibitors were added to the wells at 
concentrations as described above and the plate was incubated at 37°C at 3% O2 for 48 
hours.  After 2 days in liquid culture, cells were plated in methylcellulose media as 
described above and grown in 3% O2 for 7 days.  Colony formation was scored as 
described above. 
 
3.5.13. Secondary transplantation of primary murine APL 
Murine APL cells were thawed as described above, washed and resuspended in PBS.  
5x105 cells were injected retro-orbitally into sub-lethally irradiated (300cGy) 129/B6 F1 
recipient animals.  Treated animals received IP injections of 3 mg/kg compound E on a 5 
days on/2 days off dosing schedule beginning the day immediately after transplant.  
Disease progression was assessed with weekly CBCs performed on retro-orbital eye 
bleeds beginning 3 weeks post injection.  Upon the appearance of clinical illness, animals 
were humanely sacrificed and spleen cells were harvested and banked as described. 
 
3.5.14. Murine APL Cell Lines and Bioluminescent Imaging 
Click beetle red labeled APLluc cell lines derived from mCG-PR mice on a 129/B6 F1 
background have been described previously (28).  Two independent clones, 42c5 and 
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62c5, were used in our experiments.  129/B6 recipient animals were injected 
intraperitoneally with 500,000 cells diluted in PBS.  Some animals received two 21-day 
release 10 mg subcutaneous ATRA pellets (Innovative Research of America).  
Compound E treated animals were injected daily with 6mg/kg compound E.  
Bioluminescent imaging was performed using an IVIS 50 CCD camera (Xenogen).  Mice 
were shaved ventrally to reduce signal attenuation, and injected intraperitoneally with D-
luciferin (150 µg/g in PBS) and anesthetized using isoflurane.  Images were collected 10 
minutes after D-luciferin injection.  Photons/second were measured using a rectangular 
region of interest drawn around the head, thorax, abdomen and hind limbs of the animal.  
Imaging was performed biweekly until animals exhibited clinical signs of illness. 
 
3.5.15. Statistics 
Data shown are mean +/- standard deviation.  P-values were calculated using a Student’s 
two tailed t-test and were considered significant when P < 0.05.  Statistical analysis and 
graphing were performed using Prism5 (GraphPad). 
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3.7. Figure Legends 
 Figure 3-1:  JAG1 is overexpressed in human APL. 
A).  Gene expression profile data for Jagged-1 (JAG1) in a set of 180 de novo AML and 
sorted normal CD34+ cells, promyelocytes, and neutrophils.  Two probesets, 209099 and 
216286, are shown.  B).  JAG1 expression in the CALGB set of 93 de novo AML 
samples, showing the same probesets as in A.  Each data point in A and B represents one 
patient sample or one normal sample.  C). Validation of JAG1 expression by qRT-PCR in 
11 APL, 12 other AML (4 samples each of M0, M1, M2, and M4 FAB subtypes) and 4 
flow-sorted normal promyelocyte samples.  Data are normalized to GAPDH expression. 
 
Figure 3-2:  Human APL cells express the necessary components of Notch signaling. 
A). Expression of Notch receptors and ligands in APL (closed bars) and normal 
promeylocytes (open bars).  Data shown are the mean +/- standard deviation of the 
probeset with the highest average signal intensity for 22 APL and 5 normal promyelocyte 
samples present in the Washington University de novo AML set.  B). Expression of 
gamma secretase components in APL cells and promyelocytes  C). Expression of 
enzymes involved in the S1 and S2 cleavage of Notch.  D). Expression of transcriptional 
cofactors of cleaved Notch.  E). Expression of enzymes that modify Notch receptors.  F). 
Expression of E3 ubiquitin ligases involved in Notch signaling.  Genes present in the 
APL dysregulome are marked with an asterisk. 
 
Figure 3-3:  Notch target gene signatures are enriched in human APL cells 
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A). GSEA plot (top) and heat map (bottom) of 22 APL samples compared to 5 normal 
promyelocyte samples demonstrates significant enrichment in APL of a previously 
described set of Notch transcriptional targets in T-ALL (21).  B). GSEA plot (top) and 
heat map (bottom) of the same APL and promyelocyte samples as in A, showing 
significant enrichment in APL of a previously published set of genes downregulated in T-
ALL by gamma secretase inhibitor treatment (24).   
 
Figure 3-4: Increased JAG1 expression and activation of Notch signaling are found 
in induced PR-9 cells. 
A). Microarray expression data for JAG1 in PR-9 cells after Zn2+ induction of PML-
RARA expression.  Each data point represents a single sample.  B). Western blots 
showing protein levels of PML-RARA, JAG1, cleaved Notch-1 and actin in PR-9 cells at 
4, 8, 16 and 24 hours after Zn2+ induction.    
 
Figure 3-5:  JAG1 protein is found in an intracellular compartment in PR-9 cells. 
Flow cytometry plots showing: A). staining of PR-9 cells with an isotype control 
antibody,   B) detection of JAG1 protein by flow cytometry in PR-9 cells by surface 
staining or C) intracellular staining following fixation and permeabilization. 
 
Figure 3-6:  NB-4 cells express JAG1 protein and have activated Notch signaling. 
Flow cytometry plots showing:  A). staining of NB-4 cells with an isotype control 
antibody,   B). intracellular staining of NB-4 cells with a PE conjugated anti-JAG1 
antibody or C) intracellular staining of NB-4 cells with a PE conjugated anti-Notch1 
 161
antibody.  This antibody recognizes only cleaved isoforms of Notch1 and not uncleaved 
surface Notch1. 
 
Figure 3-7:  Jag1 and activated Notch signaling are found in murine APL samples. 
A). Microarray expression data for Jag1 from in vitro differentiation of LS cells with G-
CSF and 22 murine APL samples.  B). Summarized data showing percent of Jag1 and 
intracellular Notch-1 (ICN1) positive cells present in 10 independent murine APL 
tumors.  C). Intracellular flow cytometry detection of Jag1 and ICN1 in a representative 
murine APL (tumor number 13355).   
 
Figure 3-8:  Comparison of extracellular and intracellular Jag1 in murine APL 
samples. 
Flow cytometry staining of 3 murine APL tumors (numbers 13441, 13843 and 3430 from 
top row to bottom row) stained with either isotype control (left column), extracellular 
staining for Jag1 and Gr-1 (center column), or extracellular staining for Gr-1 and 
intracellular staining for Jag1 (right column). 
 
Figure 3-9:  Pharmacological inhibition of Notch signaling in mCG-PR marrow 
A). Relative colony formation for 3 wildtype marrow samples plated in Methocult (3534) 
containing DMSO, 2 µM compound E, or 25 µM compound IX.  Data shown are mean 
value +/- standard deviation.  Data are normalized to the week 1 DMSO treated control 
colony counts.  Cells from each animal were plated in triplicate for all treatment 
conditions.  B). Relative colony formation for 5 independent mCG-PR marrow samples 
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plated in Methocult (3534) under the same conditions and normalized as described in A.  
C). Representative data from a single mCG-PR animal.  Each data point is mean +/- SD 
of 3 replicate platings.  In all graphs, one asterisk (*) indicates p<0.05, two asterisks (**) 
indicates p<0.01 and three asterisks (***) indicates p<0.001. 
 
Figure 3-10:  Genetic inhibition of Notch signaling via DNMAML in mCG-PR 
marrow 
A). Relative colony formation for 3 wildtype B6 marrow samples transduced with either 
MSCV-GFP-DNMAML or GFP control, sorted for GFP+ cells and plated in Methocult 
(3534).  Data shown are mean +/- standard deviation.  Data are normalized to the GFP 
control.  Cells from each animal were plated in triplicate for all treatment conditions.  B).  
Relative colony formation for 2 independent mCG-PR marrow samples plated in 
Methocult (3534) under the same conditions and normalized as in A.  C). Representative 
data from a single PR+ animal.  Each data point is mean +/- SD of 3 replicate platings.  In 
all graphs, one asterisk (*) indicates p<0.05, two asterisks (**) indicates p<0.01 and three 
asterisks (***) indicates p<0.001.   
 
Figure 3-11:  Pharmacological inhibition of Notch signaling in murine APL cells in 
vitro 
A).  Schematic diagram of experimental setup.  B). Summarized data for 3 wildtype 
marrow samples treated for 48 hours with 1 µM ATRA, 2 µM compound E, 25 µM 
compound IX or DMSO control, and then plated in Methocult in triplicate, as described 
in A.  Each data point represents the average of 3 plates for a single animal.  Data were 
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normalized to the average colony formation for DMSO controls for each tumor.  C).  
Summarized data for 9 independent tumors treated for 48 hours with 1 µM ATRA, 2 µM 
compound E, 25 µM compound IX or DMSO control and then plated in Methocult in 
triplicate.  Each data point represents the average of three plates for a single tumor.  Data 
were normalized to the average colony formation for DMSO controls for each tumor.  
Tumor numbers 2894 and 3149 are highlighted in red and blue, respectively. D.  
Representative data from 3 tumors.  In all graphs, one asterisk (*) indicates p<0.05, two 
asterisks (**) indicates p<0.01 and three asterisks (***) indicates p<0.001. 
 
Figure 3-12:  Detection of Jag1 protein in murine APLluc cell lines 
A)  Staining of murine APL cell lines with an isotype control antibody.  B). Intracellular 
staining of murine APL cell line 42c5 with a PE conjugated anti-Jag1 antibody.  C). 
Intracellular staining of murine APL cell line 62c5 with a PE conjugated anti-Jag1 
antibody.  Both cell lines were surface stained with an APC-conjugated anti-Gr1 
antibody.   
 
Figure 3-13: In vivo treatment of APLluc cell lines with compound E 
A). Bioluminescence (photons/sec) detected in mice injected intraperitoneally with 
500,000 42c5 cells, and then treated with no drug, 20 mg subcutaneous ATRA or daily IP 
injections of 6mg/kg compound E.  Mice were imaged on post-injection days 1, 4, 7 and 
11.  B). As in A, except the 62c5 cell line was used.  C). Representative images from 
mice in B. 
 
 164
Figure 3-14:  In vivo treatment of primary murine APL with compound E 
Sub-lethally irradiated 129/B6 mice were injected retro-orbitally with 500,000 tumor 
cells, either tumor 2894 or 3149, and received either no treatment or IP injections of 3 
mg/kg compound E on a “5 days on, 2 days off” dosing schedule.  A) WBC counts 4 
weeks after injections with tumor 2894 or 3149.  Compound E treated animals are 
indicated in red.  B). Platelet counts for animals in A.  C). RBC counts for animals in A.  
D). Spleen weights for animals in A.  E)  Percentage of Gr-1+, c-Kit+ cells in the spleens.  
F)  Western blot showing the presence of cleaved Notch-1 in spleen cell lysates from 3 
untreated (left) or 3 compound E treated (right) animals.    
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Table 3-1:  Clinical characteristics of patients and de novo AML samples 
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Table 3-2:  Characteristics of mCG-PR mice and murine APL samples 
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Table 3-3:  Characteristics of other AML samples with high JAG1 expression 
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Figure 3-3A and 3-3B 
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Figure 3-3C 
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Chapter 4 
 
Summary and Future Directions 
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4.1. Summary 
In this thesis, we present an analysis of factors involved in the pathogenesis of 
acute promyelocytic leukemia.  In Chapter 2, we described a signature of genes with 
expression specifically altered in APL compared to other subtypes of AML and normal 
myeloid cells.  This signature is not retained in two common cell line models of APL, 
PR-9 and NB-4 cells, suggesting that the presence of PML-RARA alone is insufficient to 
produce most of the gene expression changes seen in APL, and that most dysregulome 
genes are not immediate targets of PML-RARA.  In contrast, the APL specific signature 
is enriched in a murine model of APL, demonstrating that common pathways for APL 
development exist in humans and mice.  In Chapter 3, we focused on the Notch ligand 
JAG1, an APL signature gene that is expressed in APL cell lines and is also found in 
murine APL cells.  We then showed that activated Notch signaling is found in human 
APL, APL cell lines and murine APL.  We then demonstrated that Notch signaling is 
required for the serial replating phenotype of hematopoietic progenitor cells derived from 
young mCG-PR mice, and that most murine APL tumors retain dependence on Notch 
signaling for growth in vitro.  In Chapter 4, we will examine the unresolved issues raised 
by these results, and how future experiments might be designed to further elucidate the 
role of Notch signaling in APL. 
 
4.2. Regulation of JAG1 in APL 
Although JAG1 expression is induced upon PML-RARA expression in cells lines 
and abrogated with ATRA treatment, it is not clear how PML-RARA regulates JAG1.  
The proximal JAG1 promoter has an everted repeat (1) and combined direct repeat-PU.1 
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motif sites that PML-RARA is known to bind (2).  However, three independent whole 
genome chromatin immunoprecipitation studies failed to find evidence of PML-RARA 
binding in the JAG1 promoter in either cell lines or primary APL cells (2-4).  In addition, 
cotransfection of a JAG1 promoter (1.5 kb of upstream sequences) reporter construct with 
PML-RARA did not result in promoter activation (data not shown).  These data suggest 
that JAG1 is not a direct transcriptional target of PML-RARA.  How, then, is JAG1 
expression such a reproducible characteristic of PML-RARA expressing cells?  Clearly, 
some intermediary is required.  JAG1 is a known target of the Wnt/β−Catenin (5) and 
TGF-βpathways (6).  While PML-RARA is thought to inhibit TGF-β signaling (7), it is 
known to activate expression of γ−catenin/plakoglobin (8).  It is possible that plakoglobin 
is the unknown intermediary.  This hypothesis could be tested via examining whether 
overexpression of plakoglobin in either myeloid cell lines or primary hematopoetic cells 
results in increased expression of JAG1. 
In addition, JAG1 mRNA translation is repressed by several microRNAs, 
including mir34a and mir21 (9) in addition to mir335 and mir153 (10).  PML-RARA 
represses several miR genes, though not any associated with JAG1 regulation (11).  JAG1 
mRNA has a 3’ UTR over 1.5 kb in length.  It is possible that PML-RARA represses a 
microRNA, relieving JAG1 repression.  Alternatively, PML-RARA may drive the 
expression of a microRNA which downregulates a repressor of JAG1 expression.  A 
comprehensive screen of microRNAs with altered expression upon PML-RARA 
induction in PR-9 cells using microRNA arrays could be employed.  First tier candidate 
mIRs selected for further study would include those with decreased expression upon 
PML-RARA induction, predicted binding to the JAG1 3’UTR, and either altered 
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expression in APL or known regulation by PML-RARA.  These mIRs would then be 
validated by cotransfection with luciferase-JAG1 3’UTR reporters.  Any mIR that 
represses the luciferase JAG1 3’ UTR reporter would be further confirmed via repeating 
the experiment using a reporter with a mutated mIR binding site.  Second tier mIRs 
would include those that increase upon PML-RARA induction and repress transcription 
factors thought to repress JAG1 expression.  These candidates would be assessed in a 
similar manner to tier1 mIRs, except that the 3’ UTR assessed in the reporter assay would 
be a JAG1 repressor.   
 
4.3. Cellular location of JAG1 and the mechanism of signaling 
In both cell lines and primary murine APL samples, Jag1 protein exists primarily 
within an intracellular compartment, since it can be detected by flow cytometry only if 
cells are fixed and permeabilized.  While we cannot formally exclude the possibility that 
some Jag1 protein below the limit of antibody detection resides on the cell surface, this 
would be a minor portion compared to the intracellular fraction.  If Jag1 is not present on 
the cell surface, how then is Notch signaling activated?  One possible explanation is that 
autocrine activation of Notch signaling may occur intracellularly, within a membrane 
compartment shared by Jag1 and Notch.  While Notch signals are generally thought to be 
transmitted from a ligand-bearing cell to an adjacent receptor-expressing cell, autocrine 
signaling has been reported in primary human eosinophils (12).  It is also possible that 
Jag1 reaches the cell surface, but is immediately encounters receptors and is endocytosed, 
so that under steady-state conditions, little surface Jag1 is present.   
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Further studies are needed to distinguish between these mechanisms.  
Immunoelectron microscopy could demonstrate the specific subcellular localization of 
Jag1.  The question of whether JAG1 reaches the cell surface could be answered by 
treating of NB-4 cells with pharmacological inhibitors of endocytosis.  If Jag1 
concentration on the cell surface is kept low by endocytosis, inhibition should result in an 
increase in surface Jag1, so that it could be detected by surface staining and flow 
cytometry.  Knowledge of the molecular details of Jag1-mediated signaling has clinical 
ramifications.  For example, if Jag1 does not reach the cell surface, then antibodies 
targeting it are unlikely to be efficacious therapies. 
 
4.4. Consequences of JAG1 overexpression in hematopoietic cells 
The consequences of JAG1 overexpression in hematopoietic cells are not yet 
known.  Retroviral mediated expression of Dll4 result in lymphoproliferation with 
progression to T cell leukemia/lymphoma in mice (13).  There is reason to believe that 
overexpression of Jagged would result in myeloproliferation or myeloid leukemia, not 
lymphoid lineage alterations.  Secondary Jag1 overexpression results in 
myeloproliferation in several mouse models, and none of these mice exhibit 
lymphoproliferation (14-17).  In Ikba -/- mice, overexpression of Jag1 in the fetal liver 
and bone marrow stroma results in myeloproliferation not lymphoid alterations (16).  In 
the Lck-Jag1 KI mouse, Jag1 is overexpressed in the T cell precursors, resulting in loss of 
thymic epithelial cells without cell autonomous effects on the T cell lineages themselves 
(14).  Transgenic mice expressing activated parathyroid hormone receptor on osteoblasts 
have increased stem cells due to secondary to PTHR/adenylate cyclase-activated 
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overexpression of JAG1 on osteoblasts (15, 17).  It should be noted that in the Ikba -/- 
and Pthr transgenic animals, the Notch ligand is expressed on a stromal cell, not the 
hematopoietic cell, and in the Lck-Jag1 mice, the cells affected by Jag1 overexpression 
are stromal cells.   
Because Jag1 overexpression is found in many non-M3 AML cases, 
understanding its effects have importance for the understanding of AML pathogenesis in 
general.  We have obtained Dll1 and Jag1 retroviruses from Raphael Kopan and are 
currently examining whether transduction with Jag1 results in serial replating of wildtype 
marrow progenitors or the development of leukemia/MPD after transplantation into 
syngeneic hosts.  In addition, it is possible that Jag1 may cooperate with PML-RARA, 
and that Jag1 overexpression in the context of PML-RARA expression may result in a 
different phenotype than Jag1 overexpression alone.  Repeating the experiments 
described above with marrow from mCG-PR mice will allow us to answer these 
questions.  Finally, the target genes of Jag1-mediated Notch signaling in hematopoetic 
stem and progenitor cells are currently unknown.  In contrast, the target genes of Dll1 
mediated Notch signaling in KLS cells are known from experiments in which KLS cells 
were grown on OP9 stroma expressing either Dll1 or GFP control (18).  Evidence 
suggests that different Notch ligands have differing biologic activities, and that activation 
of Notch signaling by different ligands may result in differential activation of target 
genes (19, 20).  We plan to repeat these experiments using OP9-Jag1 cells to determine 
the gene expression changes activated by Jag1-mediated Notch signaling in 
hematopoietic precursor cells, and to learn whether they are different than those induced 
by Dll1.   
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 A transgenic mouse could also be developed to model the role of Jag1 in AML; 
for example, Jag1 could be expressed under the control of cathepsin G regulatory 
sequences (21).  It is possible that these animals would have a different phenotype than 
that observed with retroviral overexpression of Jag1.  In addition to characterizing the 
hematopoietic phenotype of Jag1 overexpression by itself, hCG-Jag1 mice could be 
useful in examining the broader role of Jag1 in AML pathogenesis.  The marrow from 
these animals could be transduced with other AML-associated oncogenes such as FLT3-
ITD, DNMT3A, IDH1, and/or NPMc to examine possible cooperation between Jag1 and 
other AML associated oncogenes.  Since increased JAG1 expression is found in non-M3 
AML, particularly those with FLT3 mutations (22, 23), these mice could provide insights 
into the role of Notch signaling in AML. 
 
4.5. In vivo targeting of Notch signaling in APL 
As described in Chapter 3, we were unable to achieve inhibition of Notch 
signaling in vivo using a standing dosing protocol (24).  Therefore, we do not yet know 
whether Notch inhibition will reduce tumor growth in this setting, something that is 
important to know for clinical translation.  Why were we unable to achieve inhibition of 
Notch cleavage?  There are several possible reasons.  Compound E is hydrophobic, and 
has been reported to have poor absorption when delivered intraperitoneally (25).  Milano 
et al reported that increased doses resulted in a less than proportional increase in plasma 
concentration.  In addition, the IC50 doses for compound E and other GSI used in vivo 
are commonly reported as the dose necessary to reduce serum Aβ40, a cleavage product 
of amyloid precursor protein (APP) by 50%.  There is evidence that gamma secretase 
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cleavage of Notch is less susceptible to GSI mediated inhibition in vitro, requiring higher 
doses to achieve the same decrease in cleave as APP (26), and this may be true in vivo as 
well.   
It may be possible to alter our current dose or delivery method of compound E to 
produce Notch inhibition in vivo.  There are several aspects of our system that could be 
altered besides simply increasing the dose.  For example, compound E can be given by 
oral gavage and is effective against breast cancer xenografts in nude mice when 
administered in this manner (Loren Michel, personal communication).  Furthermore, we 
dissolved compound E in a 1:1 mix of PBS and propylene glycol, while other groups 
have used 0.5% (w/v) hydroxypropyl methylcellulose and 0.1% (w/v) Tween 80 in water 
or 6% (v/v) ethanol/94% (v/v) Labrafil M 1944 CS (25).  Labrafil M 1944 CS is an 
emulsifier known to increase bioavailability.  It is possible that the differences in the 
diluent used altered the absorption of the drug, and that a different method of dissolving 
compound E would yield improved results.  To test these approaches, wildtype mice 
would be dosed daily for 2 weeks, and assessed for signs of Notch inhibition, including 
development of GI toxicity and reduction in the CD4/CD8 double positive thymocyte 
population (27).  Upon finding a dose and delivery system that produces consistent Notch 
inhibition, the in vivo experiments described in Chapter 3 could be repeated. 
 In addition, there are other pharmacological means to inhibit Notch signaling 
which have been used in in vivo mouse models, including the GSI compound IX (28), the 
experimental GSI MRK003 (29), MK0752, a GSI produced by Merck that is currently in 
phase I clinical trials (30), and stapled peptide inhibitors of the Notch/Csl/Maml complex 
(31).  It is possible that these drugs may prove superior to compound E; they could be 
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tested as described above.  Finally, we are currently determining whether APL cells 
treated with GSIs ex vivo are still capable of inducing disease in secondary recipients.  
While these experiments still do not directly address the question of whether Notch 
inhibition has clinical efficacy in vivo, they will serve as a useful proof of principle as 
well as helping to determine if GSI treatment reduces the leukemia initiating cell (LIC) 
population. 
 
4.6. Leukemia development in PML-RARA knockin x transgenic Notch Reporter 
mice. 
The true extent of Notch signaling in leukemic and preleukemic mCG-PR mice 
cannot be ascertained using currently available methodology.  Measurement of Notch 
signaling by flow cytometry detects only Notch-1 signaling due to limitations in available 
antibodies.  Some of the murine APLs have little detectable cleaved Notch-1, yet respond 
to GSIs.  Transgenic Notch Reporter (TNR) mice have a GFP transgene under the control 
of 4 tandem copies of the Notch/CSL consensus site, so GFP expression is known to be a 
faithful reporter of Notch signaling (32).  Furthermore, the GFP expression in TNR mice 
integrates signals from all four Notch receptors, and will allow for a more accurate 
readout of the presence of Notch signaling.  Do the TNR+PR+ mice develop leukemia, 
and if so, are their tumors inevitably GFP+, indicating active Notch signaling?  How does 
the number of GFP+ cells in the marrow and spleen change over time as mice progress 
from a preleukemic state to frank leukemia?  The establishment of a tumor watch using 
TNRxPR mice and collection of resulting APL tumors will allow for these questions to 
be answered.  This reagent will allow us to determine at what point in leukemogenesis 
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Notch signaling is most active.  In addition, TNR+/PR+ tumors could be a valuable tool 
for screening drugs and drug dosages that inhibit Notch signaling in vivo, since GFP 
expression would be a convenient read out of efficacy.   
One potential caveat is that the TNR mice are currently on a mixed B6/SJL 
background.  SJL mice are considered to be a tumor-prone strain; they develop AML 
after radiation exposure (33), and lymphoma after ENU exposure (34).  Without exposure 
to carcinogenic agents, SJL mice develop a B cell lymphoma resembling Hodgkin’s 
lymphoma with 90% penetrance by 1 year of age (35), and 40% of B6/SJL F2 animals 
retain this phenotype (36).  It is possible that strain related B cell neoplasms will 
complicate our analysis of APL in TNR+PR+ mice, and any tumors resulting in these 
animals will have to be carefully screened for myeloid lineage markers and PML-RARA 
expression.  If our analysis of APL is hampered by lymphoma development, we could 
backcross the TNR mice to the B6 strain and repeat the TNRxPR cross. 
 
4.7. The requirement for Notch signaling in leukemia development 
Are Jag1 expression and Notch signaling required for leukemogenesis in mCG-
PR mice?  These questions are addressable using knockout and conditional knockout 
mice that have already been reported in the literature.  Because of the complexity of the 
Notch pathway (4 receptors and 5 ligands), fully dissecting the requirement for Jag1 and 
Notch signaling in leukemogenesis would necessitate breeding our mCG-PR mice with 
animals carrying multiple other targeted mutations.  
Mice with conditional alleles of Jag1 (37) and CSL (38) are available, as are mice 
with a conditional DNMAML transgene (38).  Jag1 conditional knockout mice have no 
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detectable hematopoietic phenotype (37), while Csl conditional knockout and conditional 
DNMAML expression (both of which inhibit all Notch signaling) results in phenotypes in 
the lymphoid lineages only (38).  These mice could be intercrossed with mCG-PR mice 
and Mx-Cre animals (39) to generate mCGPR/+Jag1f/fMx-Cre, mCGPR/+Cslf/fMx-Cre and 
mCGPR/+DNMAMLf/fMx-Cre, and the corresponding controls that have either 1 or no 
floxed alleles.  Young animals would be treated with pIpC to induce Cre-mediated 
excision, and the mice would be followed for the development of leukemia.  If Jag1 or 
Notch signaling are necessary for leukemogenesis, we would expect to see decreased 
penetrance or increased latency in the conditional knockout mice.  It would be 
particularly interesting to see whether there is a unique requirement for Jag1, or if it has 
redundant functions with the other Notch ligands in the setting of PML-RARA-mediated 
leukemogenesis.  In the second scenario, conditional loss of Jag1 would have no effect on 
the development of APL, but CSL loss or DNMAML expression (both of which would 
block all Notch signaling) would result in impaired leukemogenesis.  Any leukemias 
resulting from conditional ablation of Jag1 or Notch signaling would then be fully 
characterized using lineage marker analysis, secondary transplantation, and gene 
expression profiling, with results compared to tumors derived from mCG-PR controls. 
These mice could also be used to investigate the requirement for Jag1 and Notch 
signaling in early stages of leukemia development.  Marrow from pIpC treated 
mCGPR/+Jag1f/fMx-Cre, mCGPR/+Cslf/fMx-Cre and mCGPR/+DNMAMLf/fMx-Cre mice or 
untreated controls would be subjected to the serial replating assay as described in 
Chapter 3.  We would expect that conditional loss of Csl or expression of DNMAML 
would result in loss of serial replating.  If conditional loss of Jag1 abrogated replating, 
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those results would indicate that Jag1 is non-redundantly required for the replating 
phenotype of mCG-PR progenitor cells.  However, if conditional Jag1 knockout mCG-
PR marrow replates, this would indicate that other Notch ligands may have redundant 
functions with Jag1. 
In addition, the marrow from the conditional knockout animals could be used for 
competitive repopulation experiments.  While inhibition of Notch signaling decreases 
colony formation and serial replating in vitro, the role of Notch signaling in the early 
events of leukemogenesis in vivo is not known.  In competitive repopulation assays with 
wildtype marrow, expansion of mCG-PR cells was observed not just in the Gr-1+ myeloid 
cells, but also in the CD19+ and CD3+ lymphoid lineage cells (John Welch and Timothy 
Ley, unpublished observation).  Collectively, these results suggest that PML-RARA acts 
in a multipotent progenitor cell to increase self renewal, and partially block myeloid 
differentiation.  To determine whether Jag1 and Notch signaling are necessary for 
competitive expansion in vivo, marrow from pIpC treated mCGPR/+Jag1f/fMx-Cre, 
mCGPR/+Cslf/fMx-Cre and mCGPR/+DNMAMLf/fMx-Cre mice (or controls with 1 or no 
floxed alleles) would be transplanted into lethally irradiated syngeneic CD45.1/45.2 hosts 
with WT CD45.1 competitor marrow at WT:PR ratios of 1:9, 1:1, and 9:1.  Expansion 
would be followed by flow cytometry of CD45.2+Gr-1+ and CD45.2+CD19+ cells.  
Note that CD3+ T cells cannot be used to follow expansion, because the presence of 
DNMAML by itself results in the loss of T cells.   
These experiments would be very time and labor intensive.  A shorter approach 
would be to utilize haploinsufficent Jag1 and CSL animals, which are viable and fertile 
(40,41), to generate mCGPR/+Jag1+/- and mCGPR/+CSL+/- animals, and determine whether 
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a reduction in gene dosage affects the penetrance of leukemia, serial replating or 
competitive repopulation.  This approach should be performed in parallel with the 
conditional knockouts, since it is possible that a phenotype exists only with loss of both 
Jag1 or Csl alleles.   
Finally, in the short term, the requirement for Notch signaling in vivo could be 
tested via use of the DNMAML-GFP retrovirus (42), concurrent with breeding mCG-PR 
mice to the conditional knockouts.  Marrow from mCG-PR animals would be transduced 
with DNMAML-GFP or GFP control, and GFP+ cells would be transplanted into 
recipient animals; we would determine whether DNMAML expression reduces 
penetrance or extends APL latency, compared to GFP controls.  It is possible that the 
retroviral construct could undergo silencing, allowing Notch signaling to resume.  
Measurement of GFP expression by flow cytometry would allow us to determine whether 
leukemias arising in DNMAML-GFP/PR animals are derived from cells that developed 
alternate pathways to compensate for inhibited Notch signaling (GFP+ tumors), or from 
cells in which DNMAML-GFP was silenced (GFP-), allowing for re-activation of the 
normal Notch-mediated pathway.  In addition, to determine whether Notch signaling is 
necessary for competitive expansion in vivo, competitive repopulation experiments with 
DNMAML-GFP or GFP-transduced mCG-PR marrow could be performed as described 
above, except that expansion would be followed GFP expression instead of CD45.2.   
 
4.8. Roles of Notch1 versus Notch2 in leukemogenesis 
If Notch signaling is necessary for leukemogenesis, which specific Notch genes 
are necessary?  Both human and murine APL cells express Notch1 and Notch2 (with little 
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or no expression of Notch3 and Notch4) but it is not known whether there is a unique 
requirement for Notch1 or Notch2.  This question has important clinical ramifications.  
Inhibition of signaling by both Notch1 and Notch2 results in gastrointestinal toxicity in 
mice, causing significant mortality (43, 44).  However, inhibiting only Notch1 in T-ALL 
models spares the GI tract while preserving anti-leukemic effects (44).  Notch subtype 
antibodies are currently in development, and the stapled peptide inhibitor reported by 
Moellering et al appears to be specific for the Notch1/CSL/MAML complex without 
affecting Notch2/CSL/MAML (31).  Knowing whether Notch1 or Notch2 are most 
important for APL pathogenesis could guide drug development and influence the design 
of clinical trials.  Conditional alleles of Notch1 and Notch2 are available (37, 45), as are 
haploinsufficient animals (46, 47).  These could be crossed with mCG-PR mice and 
analyzed for development of leukemia, serial replating, and competitive repopulation, as 
described above.   
It is possible that neither Notch1 nor Notch2 alone are sufficient for 
leukemogenesis, and acquisition of leukemia will be unaffected by conditional loss of 
either Notch1 or Notch2.  In this case, we could investigate the outcome when both 
Notch1 and Notch2 are deleted.  Notch2 haploinsufficient mice are viable and fertile but 
Notch2 null animals die during the perinatal period (48).  It would be possible to generate 
mCG-PR+/-Notch2-/-Notch1f/f animals and harvest marrow from neonatal pups.  Marrow 
from these mice could be transduced with Cre-expressing retrovirus or adenovirus ex 
vivo, and transplanted into recipient animals to determine whether loss of both Notch1 
and Notch2 affects leukemia development or competitive repopulation. 
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4.9. Target genes of Notch signaling in APL and their roles in leukemogenesis 
The transcriptional target genes of Notch are highly dependent upon the cellular 
context.  Indeed, one study found significant differences between the genes activated by 
Notch signaling in embryonic stem cells, ectoderm, and mesoderm (49).  The targets of 
Notch1 in T-ALL include genes such as cold shock domain protein A (CSDA), c-myc, 
cyclin D2 and Taspase-1 (50).  While these genes are overexpressed in APL compared to 
normal promyelocytes, it is not known whether they are directly activated by Notch 
signaling.  Identification of Notch target genes in APL would help to identify the 
mechanism of Notch signaling in leukemogenesis.  ChIP grade antibodies against Notch1 
and Notch2 are available (50, 51) and ChIP on chip studies could be performed in order 
to define the promoters that are bound by Notch1 and Notch2.  Correlation of ChIP 
results with gene expression profiles of APL cells and normal promyelocytes would then 
be used to filter genes without detectable changes in gene expression resulting from 
intracellular Notch binding.  Notch binding to the promoters of candidate target genes 
would then be validated by ChIP-QPCR.  These experiments would be useful for 
determining the mechanism(s) by which Notch signaling promotes the growth and 
survival of APL cells, and how it compares to the mechanism of Notch signaling in other 
malignancies. 
Several putative target genes of Notch are currently being investigated.  The role 
of cold shock domain proteins (including Ybx1 and CSDA/Msy4) in leukemogenesis is 
currently under active investigation in the Ley laboratory.  Myc and Taspase-1 
haploinsufficient mice have been generated by other groups (52, 53) and could 
potentially be intercrossed with mCG-PR animals to assess their roles in APL.  Assuming 
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that these genes are in fact targets of Notch signaling in APL, these studies would shed 
further light on the downstream effectors of Notch signaling and their roles in 
leukemogenesis. 
 
4.10. Roles of other Notch pathway components in leukemogenesis 
In Chapter 3, we demonstrated that expression of several other components of 
the Notch pathway besides JAG1 are altered in APL.  These include the fringe family 
glycosylase lunatic fringe (LFNG), which is repressed in APL, and Mindbomb-1 (MIB1) 
and Mastermindlike-3 (MAML3), which have increased expression in APL.  The role of 
these genes in leukemogenesis is not known, nor is it understood how they interact with 
JAG1 overexpression in APL.  It is possible that any MPD or leukemia resulting from 
Jag1 overexpression requires cooperation with other Notch pathway members. 
PML-RARA downregulates the fringe family glycosylase lunatic fringe (LFNG) 
(54).  Fringe modified Notch receptors preferentially bind delta-like family ligands at the 
expense of Jagged ligands (55).  Therefore, downregulation of LFNG would be expected 
to increase JAG1 mediated signaling.  The role of LFNG in leukemogenesis has not yet 
been investigated.  LFNG null mice have been generated and while there is some 
embryonic lethality, some mice do survive to adulthood (56, 57).  LFNG null mice could 
be crossed with mCG-PR mice to generate mCGPR/+Lfng+/- and mCGPR/+Lfng-/- animals.  
We predict that due to increased Jag1 mediated signaling, Lfng loss would cooperate with 
PML-RARA, and that mCGPR/+Lfng+/- and mCGPR/+Lfng-/- mice will have shorter 
latencies than mCGPR/+Lfng+/+ controls.  In addition, we hypothesize that Lfng+/- and 
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Lfng-/- marrow would be more susceptible to the effects of Jag1 overexpression than 
wildtype marrow. 
MIB1 and MAML3 are overexpressed in human APL samples compared to normal 
promyelocytes.  The effect of overexpression of these genes in hematopoietic cells has 
not yet been reported.  This could be investigated by creating MSCV-MIB1 and MSCV-
MAML3 retroviruses to transduce WT marrow.  MIB1 and MAML3 transduced marrow 
would be assessed for increased colony formation, acquisition of replating, and ability to 
cause leukemia after transplantation.  In addition, possible cooperation of MIB1 and 
MAML3 with PML-RARA would be investigated by repeating the above experiments 
using marrow from mCG-PR mice.  Finally, cooperation of MIB1 and MAML3 with 
Jag1 could be assessed using three different approaches.  The Ley laboratory is currently 
generating MSCV-based retroviruses that express mCherry or YFP in place of the typical 
Ires-EGFP marker, and these additional markers would be critical for implementation of 
these experiments.  Wildtype marrow would be co-transduced with Jag1-Ires-GFP and 
either Mib1-Ires-mCherry or Maml3-Ires-mCherry, and GFP+mCherry- and 
GFP+mCherry+ cells sorted and transplanted into secondary recipients.  If there is 
cooperation between Jag1 and either Mib1 or Maml3, the double positive marrow would 
be expected to have accelerated disease progression or a more severe disease phenotype 
(for example, AML instead of a non-transplantable MPD) than marrow transduced with 
Jag1 alone.  In the second approach, marrow from hCG-Jag1 animals would be 
transduced with Mib1, Maml3 or vector control, transplanted into secondary hosts and 
followed for leukemia development, with similar results to the co-transduction 
experiments described above.  In the third approach, conditional Mib1 and Maml3 
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animals could be crossed with Mx-Cre and hCG-Jag1 mice to generate hCG-Jag1, Mx-
Cre, Mib1f/f and hCG-Jag1, Mx-Cre, Maml3f/f mice.  Mib1 conditional knockout animals 
have previously been reported (58), but Maml3 conditional knockout mice would have to 
be generated using gene targeting and homologous recombination.  After pIpC-induced 
Cre-mediated excision, the mice would be followed to determine if Mib1 or Maml3 loss 
alters the hematopoietic phenotype of hCG-Jag1 mice. 
 
4.11. Final remarks 
In conclusion, we have described a set of genes whose expression is specifically 
altered in APL and demonstrated a previously unappreciated role for Notch signaling in 
the development of APL.  These results underscore the complexity involved in 
leukemogenesis.  Oncogenes may have indirect effects that are nonetheless important in 
disease development.  Overexpression of JAG1 and activation of Notch signaling are 
indirect consequences of PML-RARA expression, yet they appear to have an important 
role in leukemogenesis.  In addition, pathways may be necessary for early events in 
tumorigenesis, but dispensible for later stages.  Notch signaling was necessary for serial 
replating in every young mCG-PR animal tested, yet not all fully transformed tumors 
retain dependence on Notch signaling.  While our results have clinical relevance for the 
treatment of relapsed or refractory APL, it is clear that there is still much to learn about 
the role of Notch signaling in myeloid leukemogenesis. 
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